Unnamed: 0,RowID,Outcome,Intervention,Comparator,Answer,Reasoning,XML
1,2425,venous ulcer healing,two-layer bandage,compression stocking,no significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).",3298351
2,2425,venous ulcer healing,four-layer bandage,compression stocking,no significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).",3298351
3,2425,venous ulcer healing,compression therapy,no treatment,significantly increased,We compared the dynamics of ulcer healing of patients treated with different types of compression therapy. The changes of ulceration area were statistically significant regardless of the type of compression therapy.,3298351
4,2425,venous ulcer healing,four-layer bandage,two-layer bandage,no significant difference,"What is more, no statistically significant advantage of any of the applied types of compression therapy was found (Table II).",3298351
5,2425,CEAP scores,four-layer bandage,two-layer bandage,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
6,2425,CEAP scores,four-layer bandage,compression stocking,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
7,2425,CEAP scores,two-layer bandage,compression stocking,no significant difference,"The statistical analysis did not reveal any statistically significant intra-group differences (Kruskal-Wallis test H = 3.102, p > 0.05).",3298351
8,2425,venous ulcer healing,ProGuide system,Profore compression,no significant difference,"In our own research, the comparison of two pre-prepared Profore and ProGuide compression systems as well as elastic compression, that is to say, compression stockings, did not show statistically significant differences.",3298351
9,2425,faster healing dynamics,layer compression,Compression stocking,significantly increased,"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.",3298351
10,2425,higher percentage of healed area,layer compression,Compression stocking,significantly increased,"However, in layer compression, faster healing dynamics and a higher percentage of healed area than in the case of using stockings were observed.",3298351
11,2286,interval to delivery,tocolysis,antibiotic therapy and tocolysis,no significant difference,"no significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
12,2286,birth weight,tocolysis,antibiotic therapy and tocolysis,no significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
13,2286,neonatal outcomes,tocolysis,antibiotic therapy and tocolysis,no significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.",2366143
14,2286,infection,antibiotic therapy,placebo,significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group.,2366143
15,2270,gestational age,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
16,2270,frequency of contractions,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
17,2270,cervical Bishop's score,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
18,2270,white blood cell count,antibiotic therapy,placebo,no significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",2366143
19,51310,pregnancy,twice weekly single iron tablet,weekly supplements of two iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
20,51310,pregnancy,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
21,51310,pregnancy,daily single iron tablets,twice weekly single iron tablet,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
22,51310,birth outcome,twice weekly single iron tablet,weekly supplements of two iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
23,51310,birth outcome,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
24,51310,birth outcome,daily single iron tablets,twice weekly single iron tablet,no significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups.,3233526
25,51310,side effects,weekly supplements of two iron tablets,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
26,51310,side effects,daily single iron tablets,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
27,51310,side effects,twice weekly single iron tablet,no treatment,no significant difference,Adherence to the regime was 100% according to data provided in the forms for the participants. No side effects were reported throughout the duration of the study.,3233526
28,51310,hemoglobin levels at week 28,weekly supplements of two iron tablets,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
29,51310,hemoglobin levels at week 28,daily single iron tablets,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
30,51310,hemoglobin levels at week 28,twice weekly single iron tablet,no treatment,no significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,3233526
31,51310,hemoglobin levels at week 38,weekly supplements of two iron tablets,twice weekly single iron tablet,significantly decreased,"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 μg/L in Group B).",3233526
32,51310,hemoglobin levels at week 38,daily single iron tablets,twice weekly single iron tablet,significantly decreased,"When comparing the final levels at 38 weeks, a significant difference was observed between Group B and the other two groups in this iron status indicator (P = 0.035). This difference was also of marginal clinical significance (19.9 μg/L in Group B).",3233526
33,51310,ferritin levels at week 28,daily single iron tablets,weekly supplements of two iron tablets,significantly increased,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
34,51310,ferritin levels at week 28,daily single iron tablets,twice weekly single iron tablet,significantly increased,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
35,51310,ferritin levels at week 38,weekly supplements of two iron tablets,twice weekly single iron tablet,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
36,51310,ferritin levels at week 38,weekly supplements of two iron tablets,daily single iron tablets,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
37,51310,ferritin levels at week 38,daily single iron tablets,twice weekly single iron tablet,no significant difference,"A similar trend was observed for the difference in ferritin levels, in that although daily supplementation led to a significant increase in ferritin at 28 weeks (P = 0.03), this difference was not maintained towards 38 weeks in comparison with the other two regimes.",3233526
38,46206,symptoms of RA,golimumab and methotrexate,methotrexate,significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.,2674549
39,46206,physical function,golimumab and methotrexate,methotrexate,significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.,2674549
40,46206,ACR20 ,placebo and methotrexate,Golimumab 100 mg and placebo,no significant difference,,2674549
41,46206,Median HAQ-DI score,placebo and methotrexate,Golimumab 100 mg and placebo,no significant difference,"No difference in the improvement in median HAQ-DI score was observed between group 2 and group 1 (−0.13; p = 0.240). Overall, 38.6% of patients in group 1, 45.3% of patients in group 2 (p = 0.276), 68.2% of patients in group 3 (p<0.001) and 72.1% of patients in group 4 (p<0.001) achieved a reduction in HAQ-DI score of 0.25 or greater.",2674549
42,46206,HAQ-DI score,50mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (−0.44, p<0.001) compared with group 1 (−0.13), with improvements of −0.38 (p = 0.001) in group 3 and −0.50 (p<0.001) in group 4 (table 2).",2674549
43,46206,HAQ-DI score,100mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"At week 24, patients in the combined groups 3 and 4 also showed significantly greater improvement in the median HAQ-DI score (−0.44, p<0.001) compared with group 1 (−0.13), with improvements of −0.38 (p = 0.001) in group 3 and −0.50 (p<0.001) in group 4 (table 2).",2674549
44,46206,serious adverse events,100mg of Golimumab and methotrexate,placebo and methotrexate,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
45,46206,serious adverse events,100mg of Golimumab and methotrexate,Golimumab 100 mg and placebo,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
46,46206,serious adverse events,100mg of Golimumab and methotrexate,50mg of Golimumab and methotrexate,significantly increased,"The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3; however, the 95% CI were wide and overlapping.",2674549
47,4505,induction-delivery interval,misoprostol,dinoprostone,significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).",524504
48,4505,number of women who deliver within 12 hours,misoprostol,dinoprostone,significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05)",524504
49,4505,number of women who deliver within 24 hours,misoprostol,dinoprostone,significantly increased,,524504
50,4505,spontaneous rupture of membranes,misoprostol,dinoprostone,significantly increased,"spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)",524504
51,4505,administration of oxytocin augmentation,misoprostol,dinoprostone,significantly decreased,"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05)",524504
52,4505,Caesarean section rate,dinoprostone,misoprostol,no significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).",524504
53,4505,abnormal fetal heart rate,dinoprostone,misoprostol,no significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).",524504
54,4505,uterine tachysystole,misoprostol,dinoprostone,significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05)",524504
55,4505,Uterine Hyperstimulation,misoprostol,dinoprostone,no significant difference,Uterine Hyperstimulation 2 (2.5%) 1 (1.2%) NS,524504
56,4505,Meconium stained AF,dinoprostone,misoprostol,no significant difference,Meconium stained AF 15 (18.8%) 7 (9.6%) NS,524504
57,4505,perinatal death,dinoprostone,misoprostol,no significant difference,Perinatal death 0 1(1.2%) NS,524504
58,4505,Neonatal resuscitation,dinoprostone,misoprostol,no significant difference,Neonatal resuscitation 9 (11.3%) 9 (10.8%) NS,524504
59,4505,Core blood pH,dinoprostone,misoprostol,no significant difference,Cord blood pH (arterial)1 7.28 ± 0.05 7.27 ± 0.05 NS,524504
60,4505,Hyperbilirubinemia,dinoprostone,misoprostol,no significant difference,Hyperbilirubinemia 2 9 (11.3%) 5 (6.0%) NS,524504
61,4505,Birth trauma,dinoprostone,misoprostol,no significant difference,Birth trauma 3 0 2 (2.5%) NS,524504
62,2680,rates of vacuum-assisted delivery rate,Meperidine analgesia,epidural analgesia,no significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate.,1764008
63,2680,c-section,Meperidine analgesia,epidural analgesia,no significant difference,"Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.",1764008
64,2680,duration of labor stages,Meperidine analgesia,epidural analgesia,no significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant.,1764008
65,2680,oxytocin augmentation,Meperidine analgesia,epidural analgesia,no significant difference,"Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",1764008
66,2680,preanalgesic visual analog pain,Meperidine analgesia,epidural analgesia,no significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09)",1764008
67,2680,pain levels during first stage labor,epidural analgesia,Meperidine analgesia,significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor",1764008
68,2680,pain levels during second stage labor,epidural analgesia,Meperidine analgesia,significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor",1764008
69,2680,hypotension,epidural analgesia,Meperidine analgesia,significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001),1764008
70,2680,nausea and vomiting,Meperidine analgesia,epidural analgesia,no significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%),1764008
71,2680,obstetric outcome,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
72,2680,obstetric intervention,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
73,2680,neonatal outcome,Meperidine analgesia,epidural analgesia,no significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",1764008
74,35535,continuous abstienence at week 12,varenicline,placebo,significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)",3281242
75,35535,continuous abstienence at 24 week follow up,varenicline,placebo,significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001)",3281242
76,35535,frequency of quit events by day 35,varenicline,placebo,no significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062). ",3281242
77,35535,time to make first quit attempt,varenicline,placebo,significantly decreased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).",3281242
78,36775,improved A1C,detemir,glargine,no significant difference,Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149),2875419
79,36775,number of patients with A1C <7%,detemir,glargine,no significant difference,with similar proportions of patients achieving A1C <7% (P = 0.254),2875419
80,36775,number of patients with A1C <6.5%,detemir,glargine,significantly increased,more detemir-treated patients reaching A1C <6.5% (P = 0.017),2875419
81,36775,Hypoglycemia,detemir,glargine,no significant difference,Hypoglycemia risk was similar.,2875419
82,36775,Weight Gain,glargine,detemir,significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).",2875419
83,36775,frequency of insulin doses,glargine,detemir,significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001) (Fig. 1B)",2875419
84,36775,drop-out rate,detemir,glargine,significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",2875419
85,43880,IVD comlication rates,routine replacement,staff inclination replacement,no significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).",2944158
86,43880,time until first complication,routine replacement,staff inclination replacement,no significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).",2944158
87,43880,infections,routine replacement,staff inclination replacement,no significant difference,There were no local infections or IVD-related bloodstream infections in either group. ,2944158
88,43880,therapy duration,routine replacement,staff inclination replacement,no significant difference,IV therapy duration did not differ between groups (P = 0.22),2944158
89,43880,frequency of replacements,routine replacement,staff inclination replacement,significantly increased,"but more (P = 0.004) IVDs were placed per patient in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5)",2944158
90,43880,cost per patient,routine replacement,staff inclination replacement,significantly increased,with significantly higher hospital costs per patient (P < 0.001).,2944158
91,43880,IVD complications per person,routine replacement,staff inclination replacement,no significant difference,,2944158
92,43880,phlebitis,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
93,43880,infiltration,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
94,43880,occlusion,routine replacement,staff inclination replacement,no significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43)",2944158
95,43880,IVD dwell times,staff inclination replacement,routine replacement,significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).",2944158
96,24976,frequency of healed index ucler after 1 year,HBOT ,placebo,significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03),2858204
97,24976,hypoglycemia occuring after treatment,HBOT ,placebo,no significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",2858204
98,24976,downsizing of ucler area 2 weeks after treatment,HBOT ,placebo,significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037)",2858204
99,2871176,HbA1c level at 26 weeks,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)",2871176
100,2871176,HbA1c level at 26 weeks,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.",2871176
101,2871176,Fasting plasma glucose at week 26,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l)",2871176
102,2871176,Fasting plasma glucose at week 26,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).",2871176
103,2871176,Postprandial plasma glucose,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)",2871176
104,2871176,Postprandial plasma glucose,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.,2871176
105,2871176,HbA1c level at 26 weeks,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.",2871176
106,2871176,HbA1c level at 26 weeks,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,All liraglutide doses were superior to placebo (P < 0.0001),2871176
107,2871176,HbA1c level at 26 weeks,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.",2871176
108,2871176,HbA1c level at 26 weeks,Liraglutide (0.6 mg) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,Liraglutide 0.6 mg was non-inferior to rosiglitazone,2871176
109,2871176,HbA1c level at 26 weeks,Rosiglitazone plus glimepiride,Placebo plus glimepiride,Significantly decreased,Rosiglitazone also was superior to placebo (P < 0.0001),2871176
110,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001),2871176
111,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001),2871176
112,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),2871176
113,2871176,Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),2871176
114,2871176,Patients reaching HbA1c goals less than 7.0% ,Liraglutide (1.8 mg) plus glimepiride,Liraglutide (1.2 mg) plus glimepiride,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",2871176
115,2871176,Fasting plasma glucose at week 26,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l)",2871176
116,2871176,Fasting plasma glucose at week 26,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)",2871176
117,2871176,Fasting plasma glucose at week 26,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).",2871176
118,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,2871176
119,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,2871176
120,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,2871176
121,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).",2871176
122,2871176,ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).",2871176
123,2871176,Postprandial plasma glucose,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)",2871176
124,2871176,Postprandial plasma glucose,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001),2871176
125,2871176,Postprandial plasma glucose,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.,2871176
126,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (0.6 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone",2871176
127,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone",2871176
128,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (1.8 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone",2871176
129,2871176,ADA postprandial plasma glucose goals less than 10.0 mmol/l,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.",2871176
130,2871176,Weight gain,Rosiglitazone plus glimepiride,Liraglutide plus glimepiride,Significantly increased,"Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (−2.3 to −1.4 kg; P < 0.0001)",2871176
131,2871176,Proinsulin : insulin ratio,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
132,2871176,Proinsulin : insulin ratio,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
133,2871176,Proinsulin : insulin ratio,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
134,2871176,Proinsulin : insulin ratio,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02),2871176
135,2871176,HOMA-B,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly increased,HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),2871176
136,2871176,HOMA-B,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,Significantly increased,HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),2871176
137,2871176,HOMA-B,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)",2871176
138,2871176,HOMA-B,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)",2871176
139,2871176,HOMA-IR,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,There were no significant differences between treatments for HOMA-IR.,2871176
140,2871176,HOMA-IR,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,There were no significant differences between treatments for HOMA-IR.,2871176
141,2871176,Reductions in systolic blood pressure,Liraglutide (1.2 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)",2871176
142,2871176,Reductions in systolic blood pressure,Liraglutide (1.8 mg) plus glimepiride ,Placebo plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)",2871176
143,2871176,Reductions in systolic blood pressure,Liraglutide (1.2 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",2871176
144,2871176,Reductions in systolic blood pressure,Liraglutide (1.8 mg) plus glimepiride ,Rosiglitazone plus glimepiride ,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",2871176
145,2871176,Decreases in diastolic blood pressure,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.",2871176
146,2871176,Decreases in diastolic blood pressure,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.",2871176
147,2871176,Pulse variations,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).,2871176
148,2871176,Pulse variations,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).,2871176
149,2871176,Pulse variations,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).,2871176
150,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.2 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
151,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.8 mg) plus glimepiride,Rosiglitazone plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
152,2871176,Incidence of minor hypoglycaemia,Liraglutide (1.2 mg) plus glimepiride,Placebo plus glimepiride,Significantly increased,"The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.",2871176
153,2871176,Changes in calcitonin at week 26,Liraglutide (all doses) plus glimepiride,Rosiglitazone plus glimepiride,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.,2871176
154,2871176,Changes in calcitonin at week 26,Liraglutide (all doses) plus glimepiride,Placebo plus glimepiride,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.,2871176
155,2708184,Self-selected overground walk velocity,Body-weight supported treadmill training combined with Lokomat,Manually-assisted body-weight supported treadmill training,No significant difference,No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.,2708184
156,2708184,Paretic step length ratio,Body-weight supported treadmill training combined with Lokomat,Manually-assisted body-weight supported treadmill training,No significant difference,No significant differences in primary outcomes were revealed between Lokomat and manual groups as a result of training.,2708184
157,2708184,Locomotor-training effects,Fast treadmill speed,Slow treadmill speed,No significant difference,"Our second aim was to assess locomotor-training effects at faster vs. slower treadmill speeds. As anticipated, independent of whether training occurred in the Lokomat or manual-BWSTT mode, average weekly training speeds within the fast and slow groups were similar, p ≥ 0.29",2708184
158,2708184,Self-selected overground walk velocity,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Although an equal number of participants (n = 7) produced a training related increase in self-selected overground walking speed in each group, a significant difference, p = 0.04, was revealed only in the Lokomat group with a pre-post intervention difference of 0.10 m/s and an effect size of 0.32",2708184
159,2708184,6-minute walk test,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),No significant difference,"With the exception of the 6-minute walk test and LLFDI, p ≥ 0.16, all secondary measures revealed significant improvements within the Lokomat group",2708184
160,2708184,Late Life Function and Disability Instrument,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),No significant difference,"With the exception of the 6-minute walk test and LLFDI, p ≥ 0.16, all secondary measures revealed significant improvements within the Lokomat group",2708184
161,2708184,Improvement in lower extremity Fugl-Meyer score ,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Fast overground walk speed improved from pre- to post-training in 6 of 8 Lokomat participants, p = 0.05, with a small effect size of 0.15 (Figure 2A). Lower extremity Fugl-Meyer score improvements were also noted, p = 0.04, with an effect size of 0.60 and higher scores in 5 of 8 Lokomat group participants",2708184
162,2708184,Physical performance battery scores,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Similarly, short physical performance battery scores were improved in the Lokomat group, p = 0.04, with an effect size of 0.29 and improvements in 5 of 8 participants.",2708184
163,2708184,Berg Balance Scale score,Body-weight supported treadmill training combined with Lokomat (Post-test),Body-weight supported treadmill training combined with Lokomat (Pre-test),Significantly increased,"Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved)",2708184
164,2708184,Berg Balance Scale score,Manually-assisted body-weight supported treadmill training (post-test),Manually-assisted body-weight supported treadmill training (pre-test),Significantly increased,"Berg Balance Scale scores significantly improved in both the Lokomat group, p = 0.04, effect size 0.19 (5 participants improved), and manual group, p = 0.02, effect size 0.57 (7 participants improved)",2708184
165,3001156,Care-seeking from qualified providers for ill newborns  ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly increased,there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8).,3001156
166,3001156,Care-seeking from the Kumudini Hospital for ill newborns ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly increased,"care-seeking for sick newborns specifically from the Kumudini Hospital increased significantly in both intervention and comparison arms, but the increase was of a much greater magnitude in the intervention arm",3001156
167,3001156,Care-seeking from unqualified providers (such as village doctors) for ill newborns  ,Promotion by CHWs of maternal and newborn-care interventions ,Comparison arm ,Significantly decreased,"the proportion of families who sought care from unqualified providers, such as unlicensed village doctors, remained unchanged in the comparison arm, but declined significantly in the intervention arm",3001156
168,2864284,Parasite clearance at day 1,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"Initial parasitological responses were faster with dihydroartemisinin-piperaquine (Figure 4); in the dihydroartemisinin-piperaquine group 241/264 (91.3%) of patients cleared their parasitaemia at day 1 compared to 209/265 (78.9%) in the chloroquine group (p < 0.001, relative risk of clearance in chloroquine group = 0.87, 95% CI 0.81-0.93).",2864284
169,2864284,Parasite clearance at day 2,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"At day 2, the groups were no longer significantly different with 259/265 (97.8%) of the dihydroartemisinin-piperaquine group and 257/265 (97.0%) in the chloroquine group having cleared their parasitaemia (p = 0.59).",2864284
170,2864284,Recurrent infections at day 56,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"By the end of the 56-day follow-up period, there were 23 recurrences (parasitological failures) in the chloroquine group and 7 in the dihydroartemisinin-piperaquine group, giving a day 56 failure rate of 8.9% (95% CI 6.0 - 13.1%) in the chloroquine group and 2.8% (1.4 - 5.8%) in the dihydroartemisinin-piperaquine group (Figure 2).",2864284
171,2864284,Superiority of treatment given by survival curves,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,The log-rank test comparing the survival curves confirmed the superiority of dihydroartemisinin-piperaquine over chloroquine (p = 0.003).,2864284
172,2864284,Serious adverse events,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,Both regimens were well tolerated and no serious adverse events were reported.,2864284
173,2864284,Baseline white blood cell count,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"Patient characteristics at baseline were broadly similar between the two treatment groups (Table 1) except that the median white blood cell count was lower in the chloroquine group compared with dihydroartemisinin-piperaquine (median 6.0 vs. 6.6 × 109/l respectively, p = 0.02).",2864284
174,2864284,Fever resolution by day 1,Dihydroartemisinin-piperaquine,Chloroquine,Significantly increased,"In terms of resolution of fever (defined as axillary temperature >37.0°C) dihydroartemisinin-piperaquine was again superior (Figure 4), with 29/266 (10.9%) of the dihydroartemisinin-piperaquine group febrile on day 1 compared to 45/268 (16.8%) in the chloroquine group (p = 0.049).",2864284
175,2864284,Fever resolution by day 2,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"By day 2 there was no longer a significant difference in the proportion with fever (3/265 (1.1%) for dihydroartemisinin-piperaquine, 9/264 (3.4%) for chloroquine, p = 0.08).",2864284
176,2864284,Headache,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"At day 1, headache was less frequent in the dihydroartemisinin-piperaquine arm (105/265 (39.6%)) compared to the chloroquine arm (145/266 (54.5%), p = 0.001)",2864284
177,2864284,Cure rate at day 28,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,The day 28 cure rate was 100% in both arms,2864284
178,2864284,Parasitaemias associated with gametocytaemia,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,"Twenty-one of 30 (70%) recurrent parasitaemias were associated with gametocytaemia, with no significant difference between treatment arms in terms of proportion of recurrent patients with gametocytaemia (16/23 and 5/7 for chloroquine and dihydroartemisinin-piperaquine respectively, p = 1.0).",2864284
179,2864284,Pruritus,Dihydroartemisinin-piperaquine,Chloroquine,Significantly decreased,"There was a significant increase in the proportion of patients with pruritus in the chloroquine arm compared to dihydroartemisinin-piperaquine on days 1, 2 and 3; on day 1, 15/268 subjects in the chloroquine arm had pruritus compared to 2/266 in the dihydroartemisinin-piperaquine arm (p = 0.002, relative risk 7.44, 95% CI 1.71-32.3), consistent with the known side-effects of chloroquine.",2864284
180,2864284,Haemoglobin concentration,Dihydroartemisinin-piperaquine,Chloroquine,No significant difference,There were no significant differences between the two arms in haemoglobin concentration or occurrence of anaemia (haemoglobin < 10 g/dl) at any stage during follow-up (all p > 0.5).,2864284
181,2517154,Severity of pain,Infliximab,Placebo,No significant difference,Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001).,2517154
182,2517154,Nodules diameters,Infliximab,Placebo,No significant difference,"No effect of treatment was found upon the mean diameters of the nodules as measured by TVU. For the placebo group (n = 7) and the infliximab group (n = 13), the diameters were 15.2 ± 4.6 and 13.6 ± 3.2 mm, during Visit 3, 15.1 ± 5.12 and 14.25 ± 3.5 mm, during Visit 5, 13.5 ± 4.9 and 15.6 ± 3.5 mm and during Visit 6, 13.2 + 3.4 and 15.1 + 2.38 mm.",2517154
183,2517154,Endometrial thickness,Infliximab,Placebo,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3–18) and 7.8 (1.9–11) mm and for the placebo group 7.7 (1.8–23) and 8.2 (3–15) mm, respectively.",2517154
184,2517154,Extend of the disease as visualized during surgery,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.",2517154
185,2517154,Macroscopic aspect of the tissue,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.",2517154
186,2517154,Surgery duration,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates",2517154
187,2517154,Bleeding during surgery,Infliximab,Placebo,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates",2517154
188,2517154,Tissue examination by routine pathology,Infliximab,Placebo,No significant difference,Routine pathology (FC) also showed no obvious differences between the two groups.,2517154
189,2517154,Pain estimates after surgery,Infliximab,Placebo,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs 1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",2517154
190,2517154,Pain killers intake,Infliximab,Placebo,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01)",2517154
191,2517154,Dysmenorrhea scores,Infliximab,Placebo,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).",2517154
192,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
193,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
194,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
195,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
196,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
197,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
198,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
199,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
200,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
201,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
202,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
203,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
204,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
205,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
206,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
207,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
208,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
209,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
210,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
211,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l) Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	<0.001† Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	<0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
212,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							 Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			<0.001† Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			<0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
213,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							 Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949† Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
214,1475568,Hospitalization or death,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"61% of patients in the control group had at least one hospitalization or died, and 42% of patients in the intervention group had at least 1 hospitalization or died (p = 0.13).",1475568
215,1475568,Daily weight monitoring at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"At 12 months, more patients in the intervention group reported monitoring weights daily (79% vs. 29%, p < 0.0001).",1475568
216,1475568,Heart failure-related quality of life at the end of treatment,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.",1475568
217,1475568,Baseline hypertension,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
218,1475568,Baseline diabetes,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
219,1475568,Baseline systolic dysfunction,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
220,1475568,Baseline beta-blockers intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
221,1475568,Baseline angiotensin-converting enzyme (ACE) inhibitors intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
222,1475568,Baseline digoxin intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
223,1475568,Baseline angiotensin II receptor blockers (ARBs) intake,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking β-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.",1475568
224,1475568,Minnesota living with heart failure (MLHF) questionnaire baseline scores,Follow-up and thorough education on self-care,Standard information about self-care,Significantly decreased,The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,1475568
225,1475568,Cardiac-related hospitalization,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"39% of patients in the control group and 34% of patients in the intervention group had at least one hospitalization for cardiac causes (p = 0.55). The unadjusted IRR was 0.79 (95% CI 0.42, 1.5). After adjusting for baseline differences, the IRR was 0.85 (95% CI 0.44, 1.7).",1475568
226,1475568,Knowledge about heart failure,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).",1475568
227,1475568,Self-efficacy,Follow-up and thorough education on self-care,Standard information about self-care,Significantly increased,"Heart failure self-efficacy improved more in the intervention group than in the control group. Mean difference in score improvement was 2 points (95% CI 0.7, 3.1; p = 0.0026).",1475568
228,1475568,Baseline life-quality score,Follow-up and thorough education on self-care,Standard information about self-care,No significant difference,"Twenty-four patients in each group had inadequate literacy based on the S-TOFHLA (Table 2). Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81). For the combined outcome of hospitalization or death, the unadjusted IRR was 0.77 (95% CI 0.30, 1.94). After adjusting for baseline differences, the IRR was 0.39 (95% CI 0.16, 0.91).Seventy-five patients had marginal or adequate literacy based on the S-TOFHLA. We found no difference in quality of life score in unadjusted and adjusted analyses (difference = -4.2; 95% CI -14, 6; p = 0.40). Among patients in the higher literacy group, the unadjusted IRR for hospitalization or death was 0.65 (95% CI 0.33, 1.3). After adjusting for baseline differences, the IRR was 0.56 (95% CI 0.30, 1.04). We did not find a statistically significant effect modification between literacy and the intervention.",1475568
229,3090298,Uncorrected distance visual acuity at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
230,3090298,Uncorrected distance visual acuity at 3 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
231,3090298,Uncorrected distance visual acuity at 1 month,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA. Visual acuities were not statistically different between the groups at 3 or 6 months.",3090298
232,3090298,Corrected distance visual acuity at 1 month,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),Significantly decreased,"CDVA was statistically different between groups at 1 month, with 24% of the PRK group losing a line or more from preoperative values, while 9% of eyes in the thin-flap LASIK group lost only 1 line at 1 month. No eyes in the thin-flap LASIK group lost more than 1 line. Also, 39% of eyes in the thin-flap group gained a line by 1 month compared with only 12% of eyes in the PRK group.",3090298
233,3090298,Corrected distance visual acuity at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,Significant differences were not found between treatment groups in contrast sensitivity (P ≥ 0.156) or CDVA (P = 0.800) at postoperative 6 months.,3090298
234,3090298,1 line or more of CDVA at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"At 6 months 64% and 56% of eyes had gained a line or more of CDVA in the PRK and thin-flap LASIK groups, respectively (P = 0.462).",3090298
235,3090298,Contrast sensitivity,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"Contrast sensitivity measurements at 3, 6, 12, and 18 cycles per degree (cpd) in each group are shown in Figure 1. There were no differences between groups at any cpd at any time in the study (P ≥ 0.156).",3090298
236,3090298,Contrast sensitivity,Thin-flap laser in situ keratomileusis (LASIK) ,Pre-surgery baseline,No significant difference,The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131),3090298
237,3090298,Contrast sensitivity at 1 month seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively.",3090298
238,3090298,Contrast sensitivity at 3 months seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).",3090298
239,3090298,Contrast sensitivity at 1 month seen at 12 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively.",3090298
240,3090298,Contrast sensitivity at 6 months seen at 3 cpd,Photo-refractive keratectomy (PRK),Pre-surgery baseline,Significantly decreased,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).",3090298
241,3090298,Higher-order aberrations during the study,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"There were no significant differences between groups in any HOAs throughout the study (P ≥ 0.101), with all P values at 6 months ≥0.63.",3090298
242,3090298,Higher-order aberrations at 6 months,Photo-refractive keratectomy (PRK),Thin-flap laser in situ keratomileusis (LASIK),No significant difference,"There were no significant differences between groups in any HOAs throughout the study (P ≥ 0.101), with all P values at 6 months ≥0.63.",3090298
243,2922723,Sputum expectoration during a single session,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual ACTs than with HFCWO (p<0.001).",2922723
244,2922723,FEV1%,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline.,2922723
245,2922723,O2 saturation,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline.,2922723
246,2922723,Sputum expectoration over a 24-hour period,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24 h period (mean difference 4.4 g and 6.9 g, respectively) with usual ACTs than with HFCWO (p<0.001).",2922723
247,2922723,Sputum expectoration between treatments in a 24-hour period,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No statistically significant difference was observed in the amount of sputum expectorated when using HFCWO or usual ACT between treatments in a 24 h period.,2922723
248,2922723,Visual analogue scale scores for comfort,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT.,2922723
249,2922723,Visual analogue scale scores for urinary leakage,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT.,2922723
250,2922723,Visual analogue scale scores for efficacy,High frequency chest wall oscillation,Usual airway clearance techniques,Significantly decreased,Patients scored the efficacy of their usual ACT significantly higher than for HFCWO (mean difference 14 mm; p=0.002).,2922723
251,2922723,Adverse events,High frequency chest wall oscillation,Usual airway clearance techniques,No significant difference,Neither HFCWO nor any of the usual ACTs were associated with any adverse clinical events,2922723
252,1831737,HIV-1 incidence,Communities that received additional education and preventive measures,Communities that received standard Government services,No significant difference,"Integrated peer education, condom distribution, and syndromic STI management did not reduce population-level HIV-1 incidence in a declining epidemic, despite reducing HIV-1 incidence in the immediate male target group.",1831737
253,1831737,HIV-1 prevalence,Communities that received additional education and preventive measures,Communities that received standard Government services,Significantly increased,"HIV-1 prevalence was higher in the intervention communities than in the control communities (24% versus 21%, risk ratio 1.13 [95% CI 1.05–1.22], p = 0.001)",1831737
254,1831737,Patients infected with T. vaginalis,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
255,1831737,Secondary school education,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
256,1831737,Spatial mobility,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
257,1831737,Genital discharge history,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
258,1831737,Intake of STI treatment,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.",1831737
259,1831737,Self-reported STI symptoms,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,self-reported STI symptoms were similar in both sets of communities,1831737
260,1831737,HIV/AIDS meeting attendance,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33–1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52–5.17], p < 0.001)",1831737
261,1831737,Programme meeting attendance,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33–1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52–5.17], p < 0.001)",1831737
262,1831737,High-risk sexual behaviour,Baseline communities that received additional education and preventive measures,Baseline communities that received standard Government services,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities.,1831737
263,2691927,Surgery duration,Laparoscopic surgery,Conventional open approach,Significantly increased,Operating time in the laparoscopy group was significantly longer than in the open group (75 min versus 50 min).,2691927
264,2691927,Visual analog scale pain score at day 1,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
265,2691927,Visual analog scale pain score at day 3,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
266,2691927,Visual analog scale pain score at day 7,Laparoscopic surgery,Conventional open approach,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.",2691927
267,2691927,Postoperative complications,Laparoscopic surgery,Conventional open approach,No significant difference,Complications were equally distributed.,2691927
268,2691927,Need for opiates,Laparoscopic surgery,Conventional open approach,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure.,2691927
269,2691927,Hospital permanence,Laparoscopic surgery,Conventional open approach,No significant difference,Hospital stay was also comparable: 6.5 days in the laparoscopic group versus 8.0 days in the open group (P = 0.235).,2691927
270,2691927,Ulcer mean diameter,Laparoscopic surgery,Conventional open approach,No significant difference,"The discovered ulcer perforations were found to have a mean diameter of 10 mm, which did not differ between groups",2691927
271,2691927,Ulcer location ,Laparoscopic surgery,Conventional open approach,No significant difference,Location of the perforated ulcers was distributed equally between groups,2691927
272,2691927,Median loss of blood,Laparoscopic surgery,Conventional open approach,No significant difference,Median blood loss did not differ between groups.,2691927
273,2691927,Time to nasogastric decompression,Laparoscopic surgery,Conventional open approach,No significant difference,Nasogastric decompression could be stopped after 2–3 days in both groups,2691927
274,2691927,Better scar appearance score as measured by visual analog scale,Laparoscopic surgery,Conventional open approach,Significantly increased,"The VAS score for appearance of the scar left by the respective procedures (subjectively recorded in the same way as pain) differed by 2.3 points, favoring the laparoscopic procedure (7.7 vs. 5.4; P = 0.033)",2691927
275,2375236,Prognosis enquiry,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls,2375236
276,2375236,Prognosis information given,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients.,2375236
277,2375236,Consult duration,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
278,2375236,Anxiety,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
279,2375236,Information recall,Patients who received a question prompt sheet,Patients who didn't receive a question prompt sheet,Significantly increased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.",2375236
280,2361806,Clinical response rates at 14 weeks,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"The objective clinical response rates after 14 weeks treatment (primary end point) were 30% for ILF and 17% for ELF (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.29–1.13, P=0.0766).",2361806
281,2361806,Overall response rates,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),Significantly increased,"Overall response rates over the entire treatment period for ILF and ELF were 43 and 24%, respectively (RR 0.56, 95% CI 0.33–0.97; P=0.0467).",2361806
282,2361806,Time to treatment failure,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542)",2361806
283,2361806,Overall survival,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).",2361806
284,2361806,Progression-free survival,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),No significant difference,"Compared with ELF, the ILF regimen extended median progression-free survival, median time to treatment failure and median overall survival (Table 4). However, when the treatment groups were compared by log-rank test, there was no significant difference between the two treatments for any of these parameters",2361806
285,2361806,Grade 3/4 digestive system toxic events,Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF),Etoposide with 5-fluorouracil plus leucovorin (ELF),Significantly increased,"There were more grade 3/4 gastrointestinal toxic events with ILF, notably diarrhoea, which was reported by 18% of patients compared with no reports with ELF.",2361806
286,1871574,Quit attempt of 1 week or longer reported at 3 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"With regards to quit attempts, at 3 months, there was a statistically significantly higher proportion of participants who reported a sustained quit attempt of one week or longer in the intervention group (16/43; 37%) compared to the control group (8/44; 18%) (p-value = 0.043, 95% CI (I-C) = (1, 37)%).",1871574
287,1871574,Gender,Smoking cessation advice and NRT offered,Usual care,No significant difference,"With respect to the baseline characteristics (Table 1), there was no significant difference between intervention and control groups with respect to gender or socio-economic status as measured by DEPCAT.",1871574
288,1871574,Socio-economic position,Smoking cessation advice and NRT offered,Usual care,No significant difference,"With respect to the baseline characteristics (Table 1), there was no significant difference between intervention and control groups with respect to gender or socio-economic status as measured by DEPCAT.",1871574
289,1871574,Baseline smoking habits,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
290,1871574,Baseline nicotine dependence variables,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
291,1871574,Baseline quit motivation,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There was no statistically significant difference between intervention and control groups with respect to any of the smoking behaviours or nicotine dependence variables, nor was there a significant association between the allocated group and motivation to quit as measured by 'Stage of Change'.",1871574
292,1871574,Baseline cotinine level,Smoking cessation advice and NRT offered,Usual care,No significant difference,There was no significant difference between the mean baseline biochemical values in the two groups,1871574
293,1871574,Baseline CO level,Smoking cessation advice and NRT offered,Usual care,No significant difference,There was no significant difference between the mean baseline biochemical values in the two groups,1871574
294,1871574,Smoking cessation at 3 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"the 9 intervention and 5 control participants determined as having quit smoking, represented quit rates of 15.3% and 8.8% respectively. However, the difference between intervention and control groups, in terms of the proportion of participants classified as quitters, did not reach statistical significance (p = 0.449, 95% CI (I-C) = (-8.4, 25.6)%).",1871574
295,1871574,Smoking reduction at 3 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"There was also a statistically significantly higher proportion of participants who reported reducing their smoking behaviour in the intervention group (35/43; 81%) compared to the control group (20/44; 45%) (p-value < 0.001, 95% CI (I-C) = (17, 55)%).",1871574
296,1871574,"Inhaling less smoke, measured at 3 months",Smoking cessation advice and NRT offered,Usual care,No significant difference,"With regards to other self-reported potential changes, such as inhaling less, or smoking less of a cigarette, there was no statistically significant difference between the groups at this timepoint.",1871574
297,1871574,"Smoking less of a cigarette, measured at 3 months",Smoking cessation advice and NRT offered,Usual care,No significant difference,"With regards to other self-reported potential changes, such as inhaling less, or smoking less of a cigarette, there was no statistically significant difference between the groups at this timepoint.",1871574
298,1871574,Smoking cessation at 6 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"there was no statistically significant difference between the intervention and control groups in terms of the proportion of participants classified as having quit (p-value = 0.530, 95% CI (I-C) =(-8.5, 23.6)%). With regards to repeated point prevalence, there were 5/59 (8.5%) in the intervention group, compared to 3/57 (5.3%) in the control group (p-value = 0.671, 95% CI (I-C) =(-9.9, 21.8)%).",1871574
299,1871574,Quit attempt of 1 week or longer reported at 6 months,Smoking cessation advice and NRT offered,Usual care,Significantly increased,"At 6 months, with regards to quit attempts, a greater proportion in the intervention group reported a quit attempt of 1 week or more (14/30; 47%), compared to the control group (5/32; 16%). This result was of statistical significance (p-value = 0.018, 95% CI (I-C) = (6, 56)%).",1871574
300,1871574,Smoking habits at 6 months,Smoking cessation advice and NRT offered,Usual care,No significant difference,"There were no statistically significant differences between the groups, at 6 months, in terms of any other changes in smoking behaviour.",1871574
301,2817867,Duration of surgery,Radiofrequency ablation,Hepatic resection,Significantly decreased,The operative time was significantly longer for the resection group compared to the RFA group (median of 269 minutes (range 118 to 452) versus 204 minutes (range 113 to 316); P < .0005).,2817867
302,2817867,Blood loss during surgery,Radiofrequency ablation,Hepatic resection,Significantly decreased,Operative blood loss (median 1400 mL (range 100 to 9000) versus 150 mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA.,2817867
303,2817867,Transfusion requirements,Radiofrequency ablation,Hepatic resection,Significantly decreased,Operative blood loss (median 1400 mL (range 100 to 9000) versus 150 mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA.,2817867
304,2817867,Need for ICU ,Radiofrequency ablation,Hepatic resection,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.",2817867
305,2817867,Hospital stay,Radiofrequency ablation,Hepatic resection,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.",2817867
306,2817867,Rate of complications,Radiofrequency ablation,Hepatic resection,No significant difference,"More patients developed complications with resection compared to RFA (59% compared to 43%), but the difference was not statistically significant.",2817867
307,2817867,Overall survival rate at 5 years,Radiofrequency ablation,Hepatic resection,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).",2817867
308,2817867,Disease-free survival rate at 5 years,Radiofrequency ablation,Hepatic resection,No significant difference,"The 5-year disease-free survival (DFS) for patients who underwent hepatic resection was 17% (95% CI = 7 to 29%), compared to 15% (95% CI = 6 to 28%) for patients who underwent RFA alone (P = .06).",2817867
309,2817867,Local recurrence rate through the study,Radiofrequency ablation,Hepatic resection,Significantly increased,"Over the course of the study (mean follow-up of 46 months for patients undergoing RFA), 60% of patients who had only open RFA suffered local recurrences compared to 7% of patients who underwent hepatic resection (P < .0005).",2817867
310,3580134,Time to discontinuation,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Time to discontinuation was significantly (p ≤ 0.004) prolonged in both budesonide/formoterol groups versus placebo.,3580134
311,3580134,Time to discontinuation,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Time to discontinuation was significantly (p ≤ 0.004) prolonged in both budesonide/formoterol groups versus placebo.,3580134
312,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
313,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
314,3580134,Pre-dose FEV1 improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 μg compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a].,3580134
315,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
316,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
317,3580134,1-hour post-dose FEV1 improvements,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 μg also resulted in significantly greater improvements compared with formoterol (p = 0.023)",3580134
318,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012),3580134
319,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012),3580134
320,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012) and for both budesonide/formoterol dosages compared with formoterol (p ≤ 0.017),3580134
321,3580134,Peak expiratory flow in the morning and evening ,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ≤ 0.012) and for both budesonide/formoterol dosages compared with formoterol (p ≤ 0.017),3580134
322,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
323,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
324,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
325,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
326,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
327,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
328,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
329,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ≤ 0.002),3580134
330,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
331,3580134,Mean FEV1 at 12 hours on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
332,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
333,3580134,Baseline-adjusted average 12-hour FEV1 on the day of randomization,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
334,3580134,Baseline-adjusted average 12-hour FEV1 at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
335,3580134,Mean FEV1 at 12 hours at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ≤ 0.029), only budesonide/formoterol 320/9 μg demonstrated this effect at the end of treatment (p ≤ 0.004) [table II]. Fig. 4",3580134
336,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
337,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
338,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 160/9 μg,Placebo,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
339,3580134,Pre-dose inspiratory capacity,Budesonide/formoterol pMDI 320/9 μg,Placebo,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups,3580134
340,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
341,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
342,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
343,3580134,1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period ,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ≤ 0.018),3580134
344,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
345,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
346,3580134,Time to first COPD exacerbation,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ≤ 0.004) and with budesonide/formoterol 320/9 μg compared with formoterol (p = 0.026) [figure 6].,3580134
347,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
348,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
349,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
350,3580134,Amount of exacerbations per patient-treatment year,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 μg and 160/9 μg versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ≤ 0.004)",3580134
351,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
352,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
353,3580134,Improvements in St. George's Respiratory Questionnaire overall score,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ≤ 0.006) and for budesonide/formoterol 160/9 μg compared with formoterol (p = 0.006; table III).,3580134
354,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
355,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
356,3580134,Cough score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
357,3580134,Sputum score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
358,3580134,Sleep score improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
359,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
360,3580134,Overall use of daily rescue medication improvement,Budesonide/formoterol pMDI 160/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
361,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
362,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
363,3580134,Cough score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
364,3580134,Sputum score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
365,3580134,Sleep score improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
366,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
367,3580134,Overall use of daily rescue medication improvement,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ≤ 0.003].",3580134
368,3580134,Dyspnoea score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,",3580134
369,3580134,Breathlessness Cough and Sputum Scale improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,",3580134
370,3580134,Cough score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
371,3580134,Sleep score improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
372,3580134,Overall use of daily rescue medication  improvement,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights",3580134
373,3580134,Cough score improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
374,3580134,Sleep score improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
375,3580134,Overall use of daily rescue medication  improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
376,3580134,Awakening-free nights percentage improvement,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 μg (p ≤ 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 μg (p ≤ 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score",3580134
377,3580134,24-hour urinary cortisol at 6 months,Budesonide/formoterol pMDI 320/9 μg,Placebo,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 μg and placebo groups (p = 0.035) at month 6,3580134
378,3580134,24-hour urinary cortisol at end of treatment,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 μg and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 μg and formoterol groups (p = 0.044) at end of treatment.,3580134
379,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 320/9 μg,Formoterol DPI 9 μg,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
380,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 160/9 μg,Formoterol DPI 9 μg,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
381,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 320/9 μg,Placebo,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
382,3580134,Incidence of pneumonia,Budesonide/formoterol pMDI 160/9 μg,Placebo,No significant difference,No differences in pneumonia incidence were observed among treatment groups in this study,3580134
383,2721929,Micturition frequency,Bladder training plus tolterodine (Co),Bladder training only (BT),Significantly decreased,The decrease in frequency was significantly greater in the Co group than in the BT group (p<0.05).,2721929
384,2721929,Urgency score improvement,Tolterodine only (To),Bladder training only (BT),Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).",2721929
385,2721929,Urgency score improvement,Bladder training plus tolterodine (Co),Bladder training only (BT),Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).",2721929
386,2721929,Micturition frequency,Bladder training plus tolterodine (Co),Tolterodine only (To),No significant difference,"When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively). No difference was observed between the To and Co groups.",2721929
387,2721929,Urgency score improvement,Bladder training plus tolterodine (Co),Tolterodine only (To),No significant difference,"When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively). No difference was observed between the To and Co groups.",2721929
388,2690844,Incisional hernia apparition at follow-up,Transverse incision,Midline incision,Significantly decreased,Two percent (1/60) of patients that had undergone the procedure through a transverse incision presented with an incisional hernia as opposed to 14% (9/63) of patients from the midline incision group (P = 0.017).,2690844
389,2690844,Smaller incision ,Transverse incision,Midline incision,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance.,2690844
390,2690844,Better cosmetic appearance of the incision as subjectively assessed by surgeons,Transverse incision,Midline incision,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (P < 0.0001 and P = 0.03, respectively, Table 5).",2690844
391,2690844,Pain on day one after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3).",2690844
392,2690844,Pain on day two after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3).",2690844
393,2690844,Pain on day three after surgery,Transverse incision,Midline incision,Significantly decreased,"Significantly more patients, having undergone a midline incision, reported pain on day one, two and three postoperatively (P < 0.0001, Table 3)",2690844
394,2690844,Analgesics use,Transverse incision,Midline incision,No significant difference,No significant difference in the use of analgesics was found between the groups (P = 0.69).,2690844
395,2690844,Average patient's weight,Transverse incision,Midline incision,No significant difference,no differences were found in the body mass and average length between the two groups,2690844
396,2690844,Average patient's lenght,Transverse incision,Midline incision,No significant difference,no differences were found in the body mass and average length between the two groups,2690844
397,2690844,Procedure performed directly by the staff surgeon,Transverse incision,Midline incision,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65).,2690844
398,2690844,Surgery duration,Transverse incision,Midline incision,No significant difference,"The total duration of the procedures until extubation (in min) did not differ between the midline and transverse incisions (71.0 ± 30.5 and 67.0 ± 27.3, respectively, P = 0.34).",2690844
399,2690844,Skin-to-skin time,Transverse incision,Midline incision,No significant difference,"No significant difference was noted in the skin-to-skin time (in min) for the two different incisions (Table 2). Surgery utilising midline and transverse incision took 56.9 ± 29.3 and 53.2 ± 26.8 min, respectively (P = 0.35).",2690844
400,2690844,Complications after surgery,Transverse incision,Midline incision,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30).,2690844
401,2690844,Cardiac complications,Transverse incision,Midline incision,No significant difference,"Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30). Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).",2690844
402,2690844,Urinary retention,Transverse incision,Midline incision,No significant difference,"Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30). Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).",2690844
403,2690844,Infection of the surgical site,Transverse incision,Midline incision,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).",2690844
404,2690844,Hospital stay,Transverse incision,Midline incision,No significant difference,The duration of hospital admission did not differ between the two types of incision (P = 0.74),2690844
405,2690844,Scar length,Transverse incision,Midline incision,Significantly decreased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).",2690844
406,2690844,Scar width,Transverse incision,Midline incision,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001).,2690844
407,2690844,Better cosmetic appearance of the incision as subjectively assessed by patients,Transverse incision,Midline incision,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (P < 0.0001 and P = 0.03, respectively, Table 5).",2690844
408,2575601,Refractory intracranial pressure,Thiopental,Pentobarbital,Significantly decreased,Uncontrollable intracranial pressure occurred in 11 patients (50%) in the thiopental treatment group and in 18 patients (82%) in the pentobarbital group (P = 0.03).,2575601
409,2575601,Intracranial pressure control,Thiopental,Pentobarbital,Significantly increased,"thiopental was more effective than pentobarbital in terms of controlling intracranial pressure (odds ratio = 5.1, 95% confidence interval 1.2 to 21.9; P = 0.027).",2575601
410,2575601,Infection,Thiopental,Pentobarbital,No significant difference,There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.,2575601
411,2575601,Hypotension,Thiopental,Pentobarbital,No significant difference,There were no significant differences between the two groups with respect to the incidence of arterial hypotension or infection.,2575601
412,2575601,Administration of hyperosmolar treatments,Thiopental,Pentobarbital,No significant difference,The number of hyperosmolar treatments administered (manitol and/or hypertonic saline) during the barbiturate coma was similar in both groups: 16.5 (8.0 to 24.2) in the thiopental group and 16.5 (3.0 to 21.5) in the pentobarbital group (P = 0.9).,2575601
413,2575601,Mean barbiturate coma length,Thiopental,Pentobarbital,No significant difference,The mean ± SD duration of the barbiturate coma was 156 ± 60 hours for thiopental and 108 ± 100 hours for pentobarbital (P = 0.06).,2575601
414,2575601,Intracranial pressure recurrence after treatment withdrawal,Thiopental,Pentobarbital,No significant difference,Seven (31.8%) patients presented an ICP rebound with thiopental and six (27.3%) with pentobarbital (P = 0.74) during treatment withdrawal.,2575601
415,2575601,Sepsis related Organ-Failure Assessment (SOFA) baseline scores,Thiopental,Pentobarbital,No significant difference,"There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment,",2575601
416,2575601,Sepsis related Organ-Failure Assessment (SOFA) maximum score during treatment,Thiopental,Pentobarbital,No significant difference,"There were no differences between groups with respect to the incidence of infections, Sepsis related Organ-Failure Assessment (SOFA) scores before initiation of treatment, or the maximum SOFA value [17] during the entire period of barbiturate coma.",2575601
417,1784771,Changes in Bishop score after 6 hours,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,Significantly increased,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007)",1784771
418,1784771,Baseline demographic differences,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,No significant difference,No demographic differences were noted between the groups.,1784771
419,1784771,Induction time,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,No significant difference,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007) and tended to have a shorter induction time (21.7 vs. 26.4 hours, P = 0.085).",1784771
420,1784771,Infection,Prostaglandin gel plus hygroscopic cervical dilators ,Prostaglandin gel,Significantly increased,"The combined therapy group had a higher infection rate than the prostaglandin-only group (59% vs. 12%, P = 0.003).",1784771
421,1187893,Knee injury and Osteoarthritis Outcome Score,Exercise,No exercise,No significant difference,"No significant differences in the KOOS subscales assessing pain, other symptoms, or function in daily life or in sport and recreation were seen at any time point between exercisers and controls.",1187893
422,1187893,Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 weeks,Exercise,No exercise,No significant difference,"In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05).",1187893
423,1187893,Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months,Exercise,No exercise,Significantly increased,"In the exercise group, an improvement was seen at 6 weeks in the KOOS subscale quality of life compared to the control group (mean change 4.0 vs. -0.7, p = 0.05). The difference between groups was still persistent at 6 months (p = 0.02).",1187893
424,1187893,Baseline characteristics,Exercise,No exercise,No significant difference,There were no clinically significant differences in baseline characteristics between the groups.,1187893
425,1187893,SF-36 Mental Component Summary scale at 6 weeks,Exercise,No exercise,Significantly increased,"A significant improvement was found in the exercise group compared to the control group at six weeks with regard to the SF-36 Mental Component Summary scale (MCS) (2.1 vs -1.6, p = 0.04",1187893
426,1187893,SF-36 Mental Component Summary scale at 6 months,Exercise,No exercise,No significant difference,"A significant improvement was found in the exercise group compared to the control group at six weeks with regard to the SF-36 Mental Component Summary scale (MCS) (2.1 vs -1.6, p = 0.04). At six months follow-up this difference was no longer persistent",1187893
427,1187893,Functional performance improvement,Exercise,No exercise,No significant difference,Improvements in functional performance of 0–20 % were seen in both groups at six weeks and six months. There was no difference in improvement between exercisers and controls (p = 0.08–0.9),1187893
428,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
429,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
430,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
431,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
432,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
433,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
434,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
435,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
436,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
437,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
438,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
439,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
440,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
441,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
442,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
443,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
444,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
445,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
446,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
447,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
448,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
449,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
450,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
451,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
452,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
453,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
454,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
455,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
456,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
457,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
458,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
459,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
460,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
461,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
462,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
463,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
464,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
465,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
466,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
467,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
468,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
469,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p = 0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p = 0.005).",2430614
470,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p = 0.4)",2430614
471,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
472,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
473,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
474,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
475,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
476,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
477,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
478,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
479,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
480,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
481,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
482,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
483,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
484,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
485,2806484,Virological failure,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,Rates of detection of plasma viral loads of more than 500 copies per mL after a 6-month visit were much the same in both groups.,2806484
486,2806484,Mortality rates,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"Mortality rates were much the same in the two groups during the study (figure 2). Combined mortality rates per 100 person-years were 16·47 (95% CI 13·69–19·82) during the first 5 months after treatment started, 6·69 (4·94–9·05) for 6–11 months, 2·71 (1·92–3·84) for 12–23 months, and 0·97 (0·54–1·76) for 24 months and after.",2806484
487,2806484,Costs for the health service,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"The home-based strategy did not result in higher costs for the health service. Moreover, home-based care was slightly cheaper than facility-based care by about $45 per patient per year, or 6% of the total cost.",2806484
488,2806484,Admission diagnoses,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"Admission diagnoses were similar in both groups (table 3). 20 (13%) patients who were admitted died (15 on home and five on facility care) and eight (5%) worsened and requested discharge (six on home and two on facility care)—seven died subsequently. Table 4 shows frequency of outpatient attendance at clinic, number of presentations in which a new diagnosis was made, and new diagnoses by number and type. Distribution of diagnoses was similar between groups and more than half were infectious and parasitic disease.",2806484
489,2806484,Increase in CD4-cell counts,Home-based HIV-care strategy,Facility-based HIV-care strategy,No significant difference,"CD4-cell counts increased rapidly in both groups (figure 3). 748 (87%) participants in home care and 521 (88%) in facility care were tested for CD4-cell count at least once after starting treatment, with median intervals between baseline and final tests of 32 months (IQR 25–39) for home and 29 months (23–35) for facility. 608 (81%) in home and 419 (80%) in facility had CD4-cell counts of greater than 200 cells per μL at the final visit. Counts at this visit were lower than baseline in 32 (4%) of those in home compared with 29 (6%) in facility care.",2806484
490,2363351,Progression-free survival after 3 years,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,Significantly increased,"Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (P = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82).",2363351
491,2363351,Overall survival at 3 years,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,No significant difference,"Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).",2363351
492,2363351,Full clinical responses,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,No significant difference,Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.).,2363351
493,2363351,Toxicity,"Cisplatin and Cyclophosphamide, plus subcutaneous IFN-γ ",Cisplatin and Cyclophosphamide,No significant difference,"Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ.",2363351
494,2253708,24-hour point prevalence abstinence,Tailored letters,Practitioner-delivered brief advice,Significantly increased,"the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (OR) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (OR = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.",2253708
495,2253708,7-day point prevalence abstinence,Tailored letters,Practitioner-delivered brief advice,No significant difference,"the tailored letters intervention was significantly more effective than brief advice for 24-hour [odds ratio (OR) = 1.4; P = 0.047] but not for 7-day point prevalence abstinence (OR = 1.4; P = 0.068) for prolonged abstinence, or for alternative assumptions about participants lost to follow-up.",2253708
496,2253708,6-month prolonged abstinence,Tailored letters,Practitioner-delivered brief advice,No significant difference,"With regard to prolonged abstinence, numerical differences were even lower and vanished completely for some of the analyses, taking into account the alternative assumptions about lost for follow-up. None were statistically significant.",2253708
497,2364533,Low birth weight ,Erythromycin,Placebo,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4)",2364533
498,2364533,Preterm delivery,Erythromycin,Placebo,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7)",2364533
499,2956883,HIV-1 incidence,0·5% PRO2000 gel,Placebo gel,No significant difference,"In the primary efficacy analysis, incidence of HIV-1 did not differ between groups at discontinuation of 2% PRO2000 or study end (table 2). Equally, incidence of HIV-1 did not differ between groups in the second analysis that did not censor for pregnancy",2956883
500,2956883,Gel efficacy in consistent gel users,0·5% PRO2000 gel,Placebo gel,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 for interaction).",2956883
501,2956883,Gel efficacy in inconsistent gel users,0·5% PRO2000 gel,Placebo gel,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0·19 for interaction), or between consistent (HR 0·97, 95% CI 0·87–1·35, p=0·87) and inconsistent (1·17, 0·42–1·72, p=0·42) gel users (p=0·47 for interaction).",2956883
502,2956883,Adverse events,PRO2000 gels,Placebo gel,No significant difference,No deaths or serious adverse events were regarded as related to study gels.,2956883
503,2376383,Mucositis throughout the study period,PTA lozenge,Placebo lozenge,No significant difference,"The mucositis according to the WHO score did not differ throughout the study period between both groups (P>0.5). In the PTA group, 80% of the patients developed grades 3 and 4 mucositis according to the WHO score, and in the placebo group 90%.",2376383
504,2376383,Need of feeding tube,PTA lozenge,Placebo lozenge,No significant difference,Six patients (19%) in the placebo group (n=32) and two patients (6%) in the PTA group (n=33) needed nasogastric tube feeding during the evaluation period (P=0.08).Body weight,2376383
505,2376383,Weight loss,PTA lozenge,Placebo lozenge,No significant difference,The mean weight loss after 5 weeks of radiation was less in the PTA group by 1.3 kg (s.d. 3.0) than in the placebo group 2.8 kg (s.d. 2.9) (P=0.05).,2376383
506,2376383,Candida sp. colonisation during the study,PTA lozenge,Placebo lozenge,Significantly decreased,"During the first two radiation weeks the colonisation for Candida species showed an increase in the placebo group and a decrease in the PTA group. After 2 weeks, an increase in both groups was found but the difference between the two groups remained significant during the total study period (P<0.05)",2376383
507,2376383,Aerobic Gram-negative bacilli colonisation at 3-5 weeks,PTA lozenge,Placebo lozenge,No significant difference,uring the first 2 weeks the carriage of aerobic Gram-negative bacilli was reduced in the PTA group (P<0.04). In weeks 3–5 the difference was no longer significant.,2376383
508,1964758,8-year survivorship,Initial Nottingham TSR design prosthesis,BioModular® shoulder prosthesis,Significantly increased,The eight year survivorship of the initial Nottingham TSR design (Group 2) was higher (p < 0.001) than observed in Group 1 patients with implanted BioModular® prostheses,1964758
509,1964758,4-year survivorship,Redesigned Nottingham TSR prosthesis,BioModular® shoulder prosthesis,Significantly increased,"The observed four-year survivorship of the patients in Group 3 was also significantly higher than the survivorship rates of the BioModular® prosthesis observed after the first four years after implantation (p = 0.02), with a 93.1% cumulative four year survivorship of the re-designed Nottingham TSR (Fig 10) comparing to the 80.9% of cumulative four year survivorship of the BioModular® prosthesis",1964758
510,1964758,8-year survivorship in patients with osteoarthritis,Initial Nottingham TSR design prosthesis,BioModular® shoulder prosthesis,Significantly increased,The initial Nottingham TSR prostheses showed higher eight year survivorship than BioModular® prostheses in patients with OA (p < 0.01). Survivorship of the BioModular® prosthesis in patients with primary osteoarthritis was 70.9% and 64.3% at five and eight years respectively and for the initial Nottingham TSR these values were 84.5% and 80.4%,1964758
511,2829413,Total cholesterol after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
512,2829413,Levels of LDL cholesterol after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
513,2829413,Levels of non-high-density lipoprotein cholesterol after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
514,2829413,Apolipoprotein-B levels after 6 weeks of treatment,Rosuvastatin,Atorvastatin,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 ± 11.38 vs. - 30.07 ± 10.46%, p < 0.001), LDL-C (48.04 ± 14.45 vs. 39.52 ± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 ± 13.15 vs. - 35.52 ± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 ± 18.85 vs. - 32.57 ± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.",2829413
515,2829413,Patients attaining the NCEP ATP III goal,Rosuvastatin,Atorvastatin,Significantly increased,"The percentage of patients who reached their ATP III LDL-C level goals was higher in the rosuvastatin group (87.6 vs. 69.9%, p < 0.001).",2829413
516,2829413,Changes in glucose and insulin levels,Rosuvastatin,Atorvastatin,No significant difference,Changes in glucose and insulin levels were not significantly different between the two groups,2829413
517,1261533,Adverse events,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,Both regimens were very well tolerated with no serious adverse events observed attributable to either combination.,1261533
518,1261533,Fever clearance times,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,There was no difference in fever clearance times between the two treatment groups,1261533
519,1261533,Decrease in haematocrit level at day 7,Artemether-lumefantrine,Mefloquine-artesunate,Significantly decreased,"The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (P = 0.023)",1261533
520,1261533,New P. falciparum infections during the 42-day follow-up,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,"During the 42-day follow-up period, 27 new P. falciparum infections occurred among artemether-lumefantrine and 24 among artesunate-mefloquine recipients (P > 0.05)",1261533
521,1261533,PCR-adjusted cure rates after 42 days,Artemether-lumefantrine,Mefloquine-artesunate,No significant difference,"The PCR-adjusted cure rates by day 42 were 98.8% (95% CI, 96.4% to 99.6%) in the ALN group and 96.3% (95% CI, 93.1% to 98.0%) in the MAS3 group (P = 0.08).",1261533
522,1261533,P. vivax parasitaemia diagnosed during follow up,Artemether-lumefantrine,Mefloquine-artesunate,Significantly increased,There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (P < 0.001).,1261533
523,3349250,Adverse events,Sunitinib,Interferon (IFN)-α,Significantly increased,There were more reported occurrences of most general adverse events of all grades in the sunitinib arm than in the IFN-α arm,3349250
524,3349250,Overall survival,Sunitinib,Interferon (IFN)-α,No significant difference,"overall survival was also longer with sunitinib than with IFN-α, although the difference did not reach statistical significance",3349250
525,3349250,Quality-of-life scores,Sunitinib,Interferon (IFN)-α,Significantly increased,"Quality-of-life scores as measured by the FACT-G and FKSI questionnaires were higher among patients randomised to sunitinib than among those randomised to IFN-α, with minimal regional variation",3349250
526,3349250,Quality-adjusted survival times,Sunitinib,Interferon (IFN)-α,Significantly increased,sunitinib had higher quality-adjusted survival times than IFN-α across the entire range of utility,3349250
527,3349250,Duration of median PFS,Sunitinib,Interferon (IFN)-α,Significantly increased,"Results from this phase III trial of sunitinib vs IFN-α showed that sunitinib was superior to IFN-α, based on a longer duration of median PFS",3349250
528,2361948,Overall survival time,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"Overall survival time differed significantly between the study groups in favour of 16 Gy/2 fr (median 8.0 months), compared to 20 Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).",2361948
529,2361948,6- and 12-month survival probabilities,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16 Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20 Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).",2361948
530,2361948,degree of relief of all analysed symptoms,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20 Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16 Gy/2 fr/day 1 and 8 (arm B),No significant difference,"The percentages of all evaluable patients reporting any symptomatic improvement were as follows: cough 51% (24 out of 47; for a median of six assessments, range: 1–10), dyspnoea 60% (26 out of 43; for a median of six assessments, range: 1–9), haemoptysis 86% (19 out of 22; for a median of eight assessments, range: 1–11), chest pain 83% (34 out of 41; for a median of four assessments, range: 1–9), dysphagia 71% (five out of seven; for a median of eight assessments, range: 1–9), SVCS 83% (five out of six; for a median of five assessments, range: 4–9). The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).",2361948
531,2364680,wound problem,opening subcutaneous tissues with electrocautery,opening subcutaneous tissues with scalpel,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4).,2364680
532,3221331,Continuous abstinence at 6 months,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8).,3221331
533,3221331,did not attempt to quit smoking at all,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,"At 6 months all participants were asked how many quit attempts they had made during the study period. In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.",3221331
534,3198285,low–glycemic index,low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean ± SEM 47 ± 1 vs. 53 ± 1; P < 0.001).,3198285
535,3198285,"birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,"At birth, there was no significant difference in birth weight (LGI 3.3 ± 0.1 kg vs. HF 3.3 ± 0.1 kg; P = 0.619), birth weight centile (LGI 52.5 ± 4.3 vs. HF 52.2 ± 4.0; P = 0.969), prevalence of macrosomia (LGI 2.1% vs. HF 6.7%; P = 0.157), insulin treatment (LGI 53% vs. HF 65%; P = 0.251), or adverse pregnancy outcomes.",3198285
536,3198285,"Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,Gestational age (weeks)	47	39.1 ± 0.1	45	39.2 ± 0.1	0.552Birth weight (kg)	47	3.3 ± 0.1	45	3.3 ± 0.1	0.619Birth weight centile	47	52.5 ± 4.3	45	52.2 ± 4.0	0.969LGA (%)	47	12.8	45	4.4	0.157Small for gestational age (%)	47	10.6	45	8.9	0.778Macrosomia (%)	47	2.1	45	6.7	0.286Infant head circumference (cm)	43	34.4 ± 0.2	39	34.6 ± 0.3	0.478Infant length (cm)	47	49.7 ± 0.3	45	49.7 ± 0.3	0.995Ponderal index (kg/m3)	47	27.2 ± 0.3	45	27.0 ± 0.4	0.614Maternal weight gain (kg)	44	11.9 ± 0.7	43	13.1 ± 0.9	0.305 Below target (%)†		31.8		25.6	0.520 Within target (%)†		43.2		32.6	0.307 Above target (%)†		25.0		41.9	0.095Insulin treatment (%)	47	53.2	45	65.1	0.251Final daily insulin dose (units)	47	17.7 ± 4.1	43	20.0 ± 3.8	0.676Emergency caesarean (%)	44	20.5	44	11.6	0.263,3198285
537,2722000,The incidence of bacterial infection,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).",2722000
538,2722000,Enteric bacteria,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"Enteric bacteria were more frequently identified in patients without antibiotic prophylaxis (0/62, 0% vs. 5/58, 8.6%, p=0.018).",2722000
539,2722000,rebleeding,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The rebleeding rate in the prophylactic group was significantly lower than that in the on-demand group (21/62, 33.9% vs. 36/58, 62.1%, p=0.004).",2722000
540,2722000,Total mortality and 30-day mortality,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,No significant difference,otal mortality and 30-day mortality were not different between the two groups (Table 7). The overall rate of survival was similar between the two groups (Fig. 4).,2722000
541,2650992,drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006),2650992
542,2650992,overall drain output,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.,2650992
543,2650992,The mean drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,No significant difference,The mean drainage duration was 3.3 days for the fibrin glue group and 3.8 days for the control group (p=0.067).,2650992
544,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,"Caring for ""Super Spreading Patient"" (No = 0: yes = 1)	3.57(1.94~6.57)	<0.001",2666722
545,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Number of pairs of gloves worn (Double = 0: single = 1)	4.13(1.99~8.55)	<0.001,2666722
546,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Performing tracheal intubations (No = 0: yes = 1)	2.76(1.16~6.53)	<0.05,2666722
547,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Avoiding face to face contact while caring for SARS patients		 Never	1.00	 Sometimes	0.67(0.36~1.24)	>0.05 Often	0.30(0.10~0.90)	<0.05 Every time	0.30(0.15~0.60)	<0.001,2666722
548,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Method of air ventilation in office and SARS ward		 Artificial central ventilation	1.00	 Natural ventilation	0.40(0.18~0.88)	<0.05 Natural ventilation and additional electronic exhaust fan	0.27(0.16~0.63)	<0.01,2666722
549,125315,Sequential Organ Failure Assessment (SOFA) score ,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,No statistically significant difference was found between the changes in the percentage of SOFA scores of the steroid therapy group (43.1 ± 26.5%) and the standard therapy group (45.4 ± 12.7%) in survivors (P = 0.624).,125315
550,125315,The 28-day mortality,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343).,125315
551,125315,The median stay in hospital,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,The median stay in hospital was 14 days (95% CI 11.09–20.08) in the steroid therapy group and 13 days (95% CI 10.13–16.37) in the standard therapy group (P = 0.406).,125315
552,2830179,pain during movement,attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1))",2830179
553,2830179,Pain on rest (0-10),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1)) and at rest (-2.0 (-3.8 to -0.2)) and",2830179
554,2830179,Qualeffo Total (0-100),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Qualeffo Total (0-100) 29 (10) 26 (7) 21 (11) 27 (8) -7.2 (11.2) 1.2 (4.1) -7.1 (-14.9 to 0.8),2830179
555,2830179,Timed loaded standing test (s),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Timed loaded standing test (s)	50 (39)	62 (49)	82 (44)	46 (50)	32.6 (34.1)	-16.7 (29.8)	46.7 (16.1 to 77.3),2830179
556,4785315,Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS),"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,no significant differences were seen in the mean EPDS (mean difference (MD) −0.59 (95% CI −1.24 to 0.06)) for all the women recruited,4785315
557,4785315,Antenatal attendances,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,"Antenatal attendances were high in the standard care control and did not increase further with addition of the POW intervention (10.1 vs 10.1 (mean difference; MD) −0.00, 95% CI (95% CI −0.37 to 0.37)).",4785315
558,4785315,Mother-to-infant bonding,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,Significantly increased,"Mother-to-infant bonding was significantly better in the intervention group for all women (MD −0.30 (95% CI −0.61 to −0.00) p=0.05),",4785315
559,2888205,perceived functional deficits,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"Compared to FME, the LPA group reported significantly less perceived functional deficits (P = .032)",2888205
560,2888205,pain,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"At post-testing, compared to the FME group, the LPA group reported significant reductions in the FIQ score (P = .032; Cohen's d = .53) and in pain (P = .006; Cohen's d = .67).",2888205
561,2888205,six-minute walk test,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,"There were no differences between the groups on the six-minute walk test (P = .067),",2888205
562,2888205,Fatigue severity scale,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Fatigue severity scale  Baseline 84 51.9 ± 9.3 52.3 ± 9.1 .4 (-3.6 to 4.4) 0.843 .04 Post intervention 73 50.6 ± 9.9 51.4 ± 10.1 .8 (-3.9 to 5.5) 0.727 .07,2888205
563,2888205,Number of tender points,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Baseline 84 16.2 ± 2.3 16.1 ± 3.2 .1 (-1.2 to 1.0) 0.979 .03 Post intervention 72 16.0 ± 2.3 16.8 ± 2.0 .8 (-.35 to 1.9) 0.172 .37,2888205
564,2888205,Body mass index (BMI),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Body mass index (BMI)  Baseline 82 31.4 ± 8.4 29.8 ± 6.2 1.6 (-4.7 to 1.7) 0.360 .22 Post intervention 60 31.0 ± 9.0 29.9 ± 6.2 1.1 (-5.3 to 2.9) 0.575 .14,2888205
565,2888205,Center for Epidemiologic Studies Depression Scale (CES-D),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,CES-D*  Baseline 84 23.4 ± 8.6 24.0 ± 10 .6 (-3.8 to 4.5) 0.798 .06 Post intervention 73 21.6 ± 9.8 21.2 ± 11.3 .4 (-5.3 to 4.6) 0.888 .04,2888205
566,3490871,weight change,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7 weeks of group support sessions,No significant difference,"Analysis of weight change in those successful at stopping smoking was underpowered (66%) but indicated greater mean weight gain in intervention subjects (3.9 (SD 3.1) vs. 2.7 (SD 3.7) kg). Between group differences were not significant (p = 0.23, 95% CI −0.9 to 3.5) however the confidence interval is wide and includes a loss of −0.9 kg, thus the possibility of an effect in favour of the intervention cannot be excluded.",3490871
567,3490871,Smoking cessation,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7 weeks of group support sessions,No significant difference,"Although the study was not powered to detect changes in smoking status these data were examined for completers and also using a sensitivity analysis. Both analyses showed a higher percentage of control participants still smoking at week 24 in comparison to intervention participants, however between group differences were not significant (Table 8).Table 8Comparison of Smoking Status between Intervention and Control Groups 	Intervention	Control	Odds Ratio	95% Confidence Interval	pCompleters	 	 	 	 	 Smoking at Week 6	9 (18.8%)	6 (11.3%)	1.74	0.40 to 7.66	0.46Smoking at Week 24	17 (42.5%)	25 (58.1%)	0.43	0.14 to 1.34	0.14Sensitivity analysis	 	 	 	 	 Smoking at Week 6	29 (42.6%)	23 (32.9%)	1.38	0.63 to 3.04	0.42Smoking at Week 24	45 (66.2%)	52 (74.3%)	0.58	0.25 to 1.36	0.20",3490871
568,5256321,The 10mWT (10-m walking test ),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,the results for the 10mWT showed only significant improvements in the experimental group (11.38±3.0 to 10.12±2.47 seconds; p=0.01); whereas the control group did not show significant improvements.,5256321
569,5256321,trunk strength (BPR score),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,he improvement levels of the trunk strength (BPR score) for the experimental group using Spine Balance 3D system's evaluation program showed significant improvements at the 15° open mode; whereas the control group did not show any significant improvement.,5256321
570,5256321,"he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I) ",Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",No significant difference,"The results of the BBS, FRT, TUG, KFES-I, and Biodex Balance System evaluation program improved in both groups after 7 weeks of balance training.",5256321
571,5602855,Quality of life,good motivation/capability,inadequate motivation/capability,No significant difference,"The EQ-5D-3L summary index is shown in Fig. 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (p = 0.26) or inadequate (p = 0.71) motivation/capability during the three years of follow-up. Additionally, no change was observed in the EQ-5D-3L summary index (p = 0.14), EQ VAS (p = 0.68) or the anxiety/depression dimension of the EQ-5D-3L system (p = 0.95) during the follow-up in those subjects who continued pulse palpation at least weekly at 36 months.Fig. 2",5602855
572,5602855,Health care burden,good motivation/capability,inadequate motivation/capability,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (p = 0.39) or to special healthcare outpatient clinics (p = 0.072) during the follow-up.,5602855
573,5602855,Self-detected pulse irregularity and outcome events,good motivation/capability,inadequate motivation/capability,No significant difference,"Irregular pulse findings were not significantly associated with the composite outcome variable (p = 0.06), stroke/TIA (p = 0.48), pacemaker implantation (p = 0.10) or death (p = 1.00).",5602855
574,4419460,HbA1c at 12 or 24 months.,"The Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE) is a structured educational group program, using psychological techniques, delivered primarily by diabetes nurses.",control,No significant difference,"Given that the trial found no evidence of benefits on venous HbA1c at 12 and 24 months and little evidence of benefits on secondary outcomes, the focus of this paper is to use the findings of the process evaluation to suggest how future structured education may be more effectively implemented.12",4419460
575,4577567,stride length,stride frequency manipulation,free stride frequency,Significantly increased,Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001),4577567
576,4577567,contact time,stride frequency manipulation,free stride frequency,Significantly increased,"With regard to the two training strategies, within the RWM group the CT significantly increased by 4.58% (p<0.001),",4577567
577,4577567,stride frequency,stride frequency manipulation,free stride frequency,Significantly decreased,a decreased stride frequency (4.44%; p<0.0001),4577567
578,4577567,internal work,stride frequency manipulation,free stride frequency,Significantly decreased,"nversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.",4577567
579,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"he precision of RSA corresponding to the 99% confidence interval was 1.36°, 1.36°, and 0.60° for X-, Y-, and Z-rotation and 0.40, 0.17, and 0.37 mm for X-, Y-, and Z-translation. The limit of agreement between CT and RSA was 1.51°, 2.17°, and 1.05° for rotation and 0.59, 0.56, and 0.74 mm for translation. The differences between CT and RSA are close to the described normal 99% confidence interval for precision in RSA: 0.3° to 2° for rotation and 0.15 to 0.6 mm for translation.",5294349
580,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"CT scans can be used for migration measurements in longitudinal evaluations of patients with RSA markers without losing clinically significant precision. The use of CT scans enables following RSA studies started earlier using a normal CT scan, thus avoiding the need for special RSA radiology facilities.",5294349
581,3329632,ICER (incremental cost-effectiveness ratio),ranibizumab ,ranibizumab combined with laser therapy,Significantly decreased,"Ranibizumab monotherapy was associated with an incremental gain of 0.17 QALY and cost of £4 191, corresponding to an ICER of £24 028 per QALY gained relative to laser monotherapy (table 3). Combination therapy provided an incremental gain of 0.13 QALY over laser monotherapy for an incremental cost of £4 695, leading to an ICER of £36 106 per QALY gained.",3329632
582,3800940,"Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss.",Gomutra sodhit Langali moola with honey for external application,Godugdha sodhit Langali moola with honey for external application,Significantly decreased,It was observed that after 60 days of treatment with Gomutrashodhit Langlimool in Group A there was reduction in Hair fall which is statistically highly significant (P<0.001) and highly significant improvement was observed in reducing dandruff.(p<0.001). Where as in Group B Godugdashodhit Langlimool application reduced the hair fall to statistically significant level (p<0.01) and statistically significant in reducing the dandruff in patient with Indralupta (P<0.01).,3800940
583,4819709,Bending the legs without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Bending the legs without discomfort	50	3·0	4·6	1·38 (1·14, 1·67)",4819709
584,4819709,Lifting heavy objects without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Lifting heavy objects without discomfort	50	4·8	9·8	1·97 (1·59, 2·44)90	16·9	34·5",4819709
585,4819709,Moving from standing to sitting without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Moving from standing to sitting without discomfort	50	1·9	3·7	1·63 (1·35, 1·97)",4819709
586,4819709,Standing still for a long time (> 15 min ) without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Standing still for a long time (> 15 min ) without discomfort	50	3·9	7·1	1·67 (1·36, 2·05)90	15·8	28·7",4819709
587,4819709,Walking short distances (< 20 min ) without discomfort,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Walking short distances (< 20 min ) without discomfort	50	1·9	4·4	2·00 (1·65, 2·42)90	8·2	19·1",4819709
588,4819709,Walking long distances (> 20 min),Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Walking long distances (> 20 min)	50	4·5	8·0	1·76 (1·45, 2·14)90	15·2	27·1",4819709
589,4819709,Having a bath or shower,Ultrasound‐guided foam sclerotherapy,surgery,No significant difference,"Having a bath or shower	50	5·4	4·9	0·85 (0·70, 1·03)90	11·4	10·3",4819709
590,4819709,Driving a car,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Driving a car	50	4·1	7·0	1·78 (1·45, 2·19)",4819709
591,4819709,Doing housework,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Doing housework	50	2·1	4·5	2·10 (1·72, 2·56)",4819709
592,4819709,Looking after children,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Looking after children	50	1·2	3·5	2·20 (1·61, 3·00)90	6·2	17·9",4819709
593,4819709,Wearing clothes that show the legs,Ultrasound‐guided foam sclerotherapy,surgery,No significant difference,"Wearing clothes that show the legs	50	12·4	12·8	1·03 (0·78, 1·35)90	56·6	58·7",4819709
594,4819709,Partial return to normal work/employment,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Partial return to normal work/employment	50	4·4	9·9	2·16 (1·72, 2·72)90	15·4	34·2",4819709
595,4819709,Full return to normal work/employment,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Full return to normal work/employment	50	4·8	11·7	2·56 (2·05, 3·21)90	14·9	36·2",4819709
596,4819709,Going out socially,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Going out socially	50	7·1	9·3	1·29 (1·06, 1·57)90	25·8	34·0",4819709
597,4819709,Sporting activity or exercise,Ultrasound‐guided foam sclerotherapy,surgery,Significantly increased,"Sporting activity or exercise	50	15·7	21·8	1·33 (1·05, 1·68)",4819709
598,4819709,"Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (> 15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise",Endovenous laser ablation,Ultrasound‐guided foam sclerotherapy,No significant difference,"Activity items Bending the legs without discomfort 50 2·7 3·0 0·94 (0·75, 1·17)90 12·6 14·1Lifting heavy objects without discomfort 50 5·9 4·8 1·11 (0·87, 1·42)90 20·5 16·9Moving from standing to sitting without discomfort 50 2·2 1·9 1·12 (0·90, 1·40)90 10·4 9·3Standing still for a long time (> 15 min) without discomfort 50 4·8 3·9 1·14 (0·90, 1·44)90 20·0 15·8Walking short distances (< 20 min) without discomfort 50 3·0 1·9 1·48 (1·19, 1·84)90 13·2 8·2Walking long distances (> 20 min) 50 5·6 4·5 1·32 (1·05, 1·66)90 19·8 15·2Having a bath or shower 50 5·5 5·4 1·19 (0·96, 1·48)90 12·8 11·4Driving a car 50 4·4 4·1 0·95 (0·74, 1·21)90 12·7 12·4Participation items Doing housework 50 2·5 2·1 1·03 (0·82, 1·29)90 8·4 7·3Looking after children 50 1·9 1·2 1·45 (1·04, 2·02)90 8·8 6·2Wearing clothes that show the legs 50 14·6 12·4 1·17 (0·83, 1·64)90 75·1 56·6Partial return to normal work/employment 50 6·3 4·4 1·17 (0·89, 1·52)90 21·1 15·4Full return to normal work/employment 50 7·7 4·8 1·43 (1·11, 1·85)90 23·5 14·9Going out socially 50 6·9 7·1 0·88 (0·70, 1·10)90 23·9 25·8Sporting activity or exercise 50 14·2 15·7 0·80 (0·61, 1·04)90 55·5 62·6",4819709
599,4819709,"walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment",Endovenous laser ablation,Ultrasound‐guided foam sclerotherapy,Significantly decreased,"Return to ‘walking short distances without discomfort’, ‘walking long distances’, ‘looking after children’ and ‘full return to normal work/employment’ took longer for the EVLA group than the UGFS group.",4819709
600,4819709,"Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (> 15 min) without discomfort, Walking short distances (< 20 min) without discomfort, Walking long distances (> 20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise, ",Endovenous laser ablation,surgery,Significantly increased,"Activity items				Bending the legs without discomfort	50	2·7	4·6	1·49 (1·19, 1·75)90	12·6	21·3Lifting heavy objects without discomfort	50	5·9	9·8	1·79 (1·39, 2·27)90	20·5	34·5Moving from standing to sitting without discomfort	50	2·2	3·7	1·56 (1·27, 1·96)90	10·4	17·5Standing still for a long time (> 15 min) without discomfort	50	4·8	7·1	1·41 (1·11, 1·79)90	20·0	28·7Walking short distances (< 20 min) without discomfort	50	3·0	4·4	1·30 (1·04, 1·61)90	13·2	19·1Walking long distances (> 20 min)	50	5·6	8·0	1·53 (1·06, 1·67)90	19·8	27·1Having a bath or shower	50	5·5	4·9	0·74 (0·59, 0·93)90	12·8	10·3Driving a car	50	4·4	7·0	1·82 (1·43, 2·33)90	12·7	21·1Participation items				Doing housework	50	2·5	4·5	1·89 (1·49, 2·38)90	8·4	15·7Looking after children	50	1·9	3·5	1·61 (1·15, 2·27)90	8·8	17·9Wearing clothes that show the legs	50	14·6	12·8	0·97 (0·69, 1·35)90	75·1	58·7Partial return to normal work/employment	50	6·3	9·9	1·75 (1·33, 2·27)90	21·1	34·2Full return to normal work/employment	50	7·7	11·7	1·79 (1·37, 2·27)90	23·5	36·2Going out socially	50	6·9	9·3	1·41 (1·12, 1·75)90	23·9	34·0Sporting activity or exercise	50	14·2	21·8	1·47 (1·12, 1·92)",4819709
601,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,glucose 5% solution,Significantly increased,TUR syndrome	17*	0	0,2891743
602,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,normal saline 0.9% solution,Significantly increased,TUR syndrome 17* 0 0,2891743
603,3418149,Morbidity after surgery,ipsilateral arm morbidity,contralateral arm morbidity,Significantly increased,"Comparison of ipsilateral vs. contralateral arm shows that changes affecting one limb strongly correlated with changes affecting the other limb (upper right quarter of Table 3). The highest correlations were abduction (R = 0.78), retroflexion (R = 0.73), scapular distance (R = 0.65), and arm volume (R = 0.57), all P-values <0.001.",3418149
604,5062194,neonatal outcome,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",No significant difference,There were no between-group differences regarding the neonatal outcome.,5062194
605,5062194,postoperative satisfaction,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
606,5062194,preoperative anxiety,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly decreased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
607,5062194,No statistical analysis because they are in tables,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,"Table 2Amsterdam Preoperative Anxiety and Information Scale, Maternal Satisfaction Scale for cesarean section, Apgar score and neonatal neurologic and adaptive capacity score in both groupsTable 3Blood gas analysis of umbilical artery blood samples in both groupsRegarding maternal hemodynamics, baseline HR, SBP, and DBP were comparable between the two groups before the administration of the tested drug. However, 5 min after injecting the tested drug, there was a significant decrease in all parameters in group (M) compared to group (S). During insertion of the spinal needle, there was a rise in HR and SBP in group (S) compared to group (M) while DBP was at a lower level in group (M). After the induction of spinal anesthesia and placing the patient into the tilted supine position, there was an increase in HR with some decrease in blood pressure parameters in both groups as shown in Tables 4–6.Table 4Maternal heart rate in both groupsTable 5Systolic blood pressure in both groupsTable 6Diastolic blood pressure in both groups",5062194
608,5577662,percentage changes in area,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,"percentage changes in area were significantly greater with CCH 0.40 mg (−80.1%, P = 0.0002) and CCH 0.60 mg (−78.2%, P = 0.0003), but not CCH 0.25 mg (−58.3%, P = 0.079), versus placebo (−42.2%) at post-treatment Week 8.",5577662
609,5577662,Mean change in nodular consistency and hardness,"receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (P ≤ 0.0139 for all).,5577662
610,5577662,global assessment of improvement,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,nvestigator global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ≤ 0.0014),5577662
611,5577662,percentage changes in area,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,"percentage changes in area were significantly greater with CCH 0.40 mg (−80.1%, P = 0.0002) and CCH 0.60 mg (−78.2%, P = 0.0003), but not CCH 0.25 mg (−58.3%, P = 0.079), versus placebo (−42.2%) at post-treatment Week 8.",5577662
612,5577662,global assessment of improvement,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ≤ 0.0014) but not statistically significant with CCH 0.25 mg versus placebo (P = 0.13).,5577662
613,4794897,pyridinoline,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p = 0.035 and p = 0.043),4794897
614,4794897,beta-isomer of carboxy-terminal telopeptide of type I collagen,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p = 0.035 and p = 0.043),4794897
615,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,No significant difference,The 24 h morphine requirement (mean ± standard deviation) was 34.57 ± 14.64 mg in TAP group and 32.76 ± 14.34 mg in local infiltration group (P = 0.688).,5062234
616,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,The number of patients requiring intraoperative supplemental fentanyl in TAP group was 8 and in local infiltration group was 16 (P = 0.028).,5062234
617,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,"At 4 h, none of the patients in the TAP group but seven patients (33.3%) in the control group had moderate to severe pain (VAS >3) at rest (P = 0.009*). At 4 h, eight patients (38.1%) in the TAP group and 15 patients (71.4%) in the control group had moderate to severe pain on coughing (P = 0.03*). At 12 h, six patients (28.5%) in the TAP group and 18 patients (85.7%) in the control group had moderate to severe pain on coughing (P < 0.001*).",5062234
618,4139977,decrease in abdominal pain and distension severity,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"here was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).",4139977
619,4139977,Improvement in bowel habit,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,mprovement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910).,4139977
620,4139977,quality-of-life ,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372),",4139977
621,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
622,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
623,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
624,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
625,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
626,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
627,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
628,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
629,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
630,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
631,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
632,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
633,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
634,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
635,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
636,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
637,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
638,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
639,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
640,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l)?Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	<0.001†?Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	<0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
641,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							?Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			<0.001†?Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			<0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
642,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							?Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949†?Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
643,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
644,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
645,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
646,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
647,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
648,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
649,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
650,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
651,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
652,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
653,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
654,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
655,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
656,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
657,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
658,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
659,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
660,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
661,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
662,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
663,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
664,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
665,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
666,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
667,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
668,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
669,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
670,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
671,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
672,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
673,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
674,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
675,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
676,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
677,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p?=?0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p?=?0.005).",2430614
678,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p?=?0.4)",2430614
679,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
680,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
681,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
682,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
683,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
684,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
685,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
686,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
687,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
688,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
689,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
690,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
691,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
692,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
693,43880,hospital costs per patient for the course of IV therapy,clinically indicated,routine replacement,Significantly decreased,"Mean hospital costs per patient for the course of IV therapy were significantly higher (P < 0.001) for those managed with routine resite (mean $55.42, SD $35.26) compared with resite on clinical indication (mean $43.35, SD $26.78).",2944158
694,24976,complete healing of the index ulcer at 1-year of follow-up,hyperbaric oxygen therapy,placebo,Significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).,2858204
695,24976,"In the intention-to-treat analysis, complete healing of the index ulcer",hyperbaric oxygen therapy,placebo,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).",2858204
696,24976,"In the per-protocol analysis, complete healing of the index ulcer",hyperbaric oxygen therapy,placebo,Significantly increased,"In the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009)",2858204
697,1852268,obstetric/postpartum infection or gynecologic/postoperative infection,"Inravenous ertapenem, 1 g once a day","Intravenous piperacillin–tazobactam, 3.375 g every 6 hours",No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.",1852268
698,3187863,Perineal outcome: the number of episiotomies or the incidence of sphincter injuries,Special unit,Normal unit & Special unit,No significant difference,"There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2). An episiotomy was performed on 22.7, 26.7 and 29.0% of the women in the MU, NU and SU, respectively (Table 3). A sphincter injury occurred in 1.3, 2.3 and 1.9% of the vaginal deliveries at the MU, NU and SU, respectively (Table 3).",3187863
699,3187863,Labour dystocia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89) (Table 2).",3187863
700,3187863,Oxytocin infusion for augmentation of labour,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86) (Table 2).",3187863
701,3187863,Pain relief: Epidural anesthesia,Midwife-led unit,Normal unit & Special unit,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",3187863
702,3187863,Pain relief: Acupuncture,Midwife-led unit,Normal unit & Special unit,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25–1.69) and SU (37.9%; RR 1.45, 95% CI 1.22–1.73) (Table 2).",3187863
703,3187863,Postpartum haemorrhage,Midwife-led unit,Normal unit & Special unit,No significant difference,"There was no statistically significant difference in the rate of postpartum haemorrhage between the three units (Table 2). The vast majority of all participants had normal postpartum haemorrhage of 500 ml or less (MU 90.3%, NU 88.7% and SU 84.0%; Table 3).",3187863
704,3187863,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth",Midwife-led unit,Normal unit & Special unit,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2).",3187863
705,2688140,The survival rate / overall mortality of patients with ARDS,Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).",2688140
706,2688140,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS",Decremental PEEP titration group,table-based PEEP (control) group,No significant difference,"The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents did not differ between the groups (Table 2).",2688140
707,4106715,Prolonged abstinence from smoking rates to 6 months,high Ab group,placebo,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71)",4106715
708,4106715,Prolonged abstinence from smoking rates to 6 months,low Ab group,placebo,No significant difference,"ith no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).",4106715
709,4106715,Prolonged abstinence from smoking rates to 12 months,high Ab group,placebo,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",4106715
710,4106715,Prolonged abstinence from smoking rates to 12 months,low Ab group,placebo,No significant difference,Prolonged abstinence from smoking rates to 6 months	low Ab group	placebo	No significant difference	ith no significant differences between the placebo,4106715
711,4106715,Reduction of daily cigarette consumption and cotinine,non-abstainers (weeks 19–52) with high Ab levels,non-abstainers in the placebo group,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19–52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C",4106715
712,4106715,attain 8 weeks continuous abstinence from weeks 19 through 26,recipients with the highest serum anti-nicotine antibody response (top 30% by AUC),placebo group,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).",4106715
713,2206488,"Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I",dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,"procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.",2206488
714,2206488,Cardiac index ,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly increased,Higher figures of the cardiac index (p = 0.010),2206488
715,2206488,systemic vascular resistance,dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,Significantly decreased,with reduced systemic vascular resistance (p = 0.005) were noted in group A.,2206488
716,2206488,C-reactive protein (mg/l),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,C-reactive protein (mg/l)?Group A	3.7 (1.0–22.6)				79.9 (50.0–131.7)	112.0 (61.1–177.6)	<0.001†?Group B	2.6 (0.6–10.5)				87.6 (52.4–143.0)	131.0 (71.0–228.0)	<0.001†	p = 0.068*				p = 0.092*	p = 0.168*,2206488
717,2206488,IL-6 (pg/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6 (pg/ml)							?Group A	1.6 (0.4–21.8)		95.0 (13.6–405.1)	46.3 (16.1–149.5)			<0.001†?Group B	2.0 (0.4–60.6)		130.5 (21.7–353.8)	49.2 (14.8–214.5)			<0.001†	p = 0.107*		p = 0.829*	p = 0.482*,2206488
718,2206488,IL-6r (ng/ml),dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass,identical amounts of gelatin infusion,No significant difference,IL-6r (ng/ml)							?Group A	43.6 (1.7–125.0)		47.4 (0.7–109.5)	56.2 (25.2–226.3)			0.949†?Group B	40.7 (15.6–94.6)		42.4 (22.2–100.5)	50.2 (13.2–104.9)			0.861†	p = 0.607*		p = 0.914*	p = 0.304*,2206488
719,1201146,"Pain, physical function, PGA, stiffness ",topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,"There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain (-5.2 vs. -3.3; p = 0.003,), physical function (-13.4 vs. -6.9; p = 0.001), PGA (-1.3 vs. -0.7; p = 0.0001) and stiffness (-1.8 vs. -0. 9; p = 0.002)",1201146
720,1201146,Pain on walking,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly decreased,There was a significantly greater improvement in score with topical diclofenac compared to vehicle control (Table 2) for pain on walking (-1.2 vs. -0.8; p = 0.014).,1201146
721,1201146,50% reduction in pain,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The response rate for at least a 50% reduction in pain (Table 3) was significantly greater following topical diclofenac treatment compared to vehicle control (46/105 [43.8%] vs. 27/107 [25.2%]; p = 0.004).,1201146
722,1201146,good or very good PGA response and OMERACT-OARSI responder,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,The topical diclofenac group had a significantly greater number of participants with good or very good PGA response (43.8% vs. 16.8%; p <0.0001) compared to the vehicle control group and of OMERACT-OARSI responders (65.7% vs. 49.5%; p = 0.017).,1201146
723,1201146,Dry skin at the application site,topical diclofenac solution (Pennsaid®),vehicle control solution (carrier with no diclofenac),Significantly increased,"The major adverse effect reported was dry skin at the application site, occurring in 42/107 (39.3%) and 23/109 (21.1%; p = 0.004) of topical diclofenac and vehicle control participants, respectively",1201146
724,2600646,mean Hb,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,Final mean Hb levels were 7.15 mmol/l ± 1.07 for the DP treatment group and 6.79 mmol/l ± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05).,2600646
725,2600646,Adverse events,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,"Most adverse events were mild, self limiting and consistent with symptoms of malaria. There was no significant difference between the two study groups",2600646
726,2600646,Gametocyte dynamics,arthemeter-lumefantrine (AL) ,dihydroartemisinin-piperaquine (AP),No significant difference,There was no difference between children older than 60 months and younger as regards carriage of gametocytes and density.,2600646
727,1468428,Puerperal and neonatal infection rates ,1 litre saline enema,no enema,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66)",1468428
728,1468428,Median labour time,1 litre saline enema,no enema,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).,1468428
729,1468428,Episiorraphy dehiscence rates,1 litre saline enema,no enema,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30).,1468428
730,1468428,You must have prompts generated from different sections.,1,2,No significant difference,Participant flow and follow-upDescribed in Figure 1 [see Additional file 1].,1468428
731,2607225,cognitive functioning,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months. There were no other main effects of treatments.",2607225
732,2607225,Appetite loss,"individual support, group rehabilitation and a combination of the two (Group rehabilitation)",standard care,Significantly decreased,. Pairwise comparisons revealed a statistically significant mean difference between GR and non-GR patients at 12 months (mean=5.8 vs 2.4).,2607225
733,2720945,change of FVC and VC,cineole,placebo,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant.,2720945
734,2720945,Side effects,cineole,placebo,No significant difference,The difference between the two treatment groups was neither clinically relevant nor statistically significant. Safety examinations of the global assessment showed no difference between the two treatment groups.,2720945
735,2720945,Quality of life,cineole,placebo,Significantly increased,At 6 months the mean improvement of SGRQ total symptom score was -9.1 after treatment with cineole and -4.1 after treatment with placebo (table 5).,2720945
736,2720945,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment",cineole,placebo,Significantly decreased,"Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*	PLACEBO	CINEOLE		SCORE	SCORE	P VALUE†Sum of exacerbations (number)#	0.9 ± 1.46	0.4 ± 0.82	0.0069Sum of duration (days)#	5.7 ± 8.9	4.0 ± 10.9	0.0210Sum of severity (score)#	1.4 ± 2.2	0.8 ± 1.5	0.0242Summarized parameter(directional test)			0.0120",2720945
737,2720945,"Trouble in breathing, dyspnea in the morning and dyspnea at rest",cineole,placebo,Significantly decreased,Trouble in breathing #	1.8 ± 0.9	2.1 ± 0.9	2.2 ± 1.0	1.9 ± 0.9	2.4 ± 1.0	2.5 ± 1.1	0.0103&Dyspnea in the morning $	1.1 ± 0.7	0.9 ± 0.7	0.7 ± 0.7	1.1 ± 0.8	0.7 ± 0.7	0.5 ± 0.6	0.0466&Dyspnea at rest $	0.7 ± 0.7	0.4 ± 0.6	0.4 ± 0.6	0.6 ± 0.6	0.3 ± 0.5	0.3 ± 0.5	0.0156&,2720945
738,2720945,Dyspnea during exercise,cineole,placebo,No significant difference,Dyspnea during exercise $	2.0 ± 0.6	1.8 ± 0.7	1.7 ± 0.8	2.0 ± 0.6	1.7 ± 0.7	1.5 ± 0.9	0.1252&,2720945
739,3446002,The duration of phototherapy,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001).,3446002
740,3446002,side effects,single dose of 50 mg/kg clofibrate,control group,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed. Also for a period of two months no complication was detected.,3446002
741,3446002,Total serum bilirubin level,single dose of 50 mg/kg clofibrate,control group,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001).,3446002
742,1913177,Postoperative Mortality,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,There was no 30-day mortality.,1913177
743,1913177,Wound complications,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR.,1913177
744,1913177,Reherniation,components separation technique (CST),prosthetic repair with e-PTFE patch (PR),Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR.,1913177
745,1876597,unadjusted risk of recurrent falciparum parasitemia,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"The unadjusted risk of recurrent falciparum parasitemia was significantly lower for participants treated with DP than for those treated with AL after 28 d (11% versus 29%; risk difference [RD] 18%, 95% confidence interval [CI] 11%–26%) and 42 d (43% versus 53%; RD 9.6%, 95% CI 0%–19%) of follow-up.",1876597
746,1876597,the risk of recurrent parasitemia due to possible recrudescence,dihydroartemisinin-piperaquine ,artemether-lumefantrine,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%–12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%–16%).",1876597
747,1876597,Adverse Events,dihydroartemisinin-piperaquine ,artemether-lumefantrine,No significant difference,"Overall, there was no difference in the proportion of study participants who experienced any adverse event of moderate or greater severity between the DP (46%) and AL (42%) treatment groups (p = 0.47).",1876597
748,3387601,Period of mechanical ventilation ,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,"Children in the PE group had a shorter period of MV (median 11 days, IQR 11.0 to 13.0) compared to IVIG group (median 13 days, IQR 11.3 to 14.5) with p = 0.037.",3387601
749,3387601,Pediatric Intensive Care Unit (PICU) stay,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly decreased,Those in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,3387601
750,3387601,could walk unaided within four weeks after PICU discharge,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606).,3387601
751,3387601,negative correlation between CSF protein and duration of mechanical ventilation,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),Significantly increased,"Examining the treatment groups separately, the significant negative correlation remained for the PE group (p-value = 0.037) and not for the IVIG group (p-value 0.132)",3387601
752,3387601,side effects,plasma exchange (PE) ,intravenous immunoglobulin (IVIG),No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients.,3387601
753,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, p?=?0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, p?=?0.005).",2430614
754,2430614,the parasitological and clinical failure rate at day 28 post treatment,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD),No significant difference,"However, the PCF28 corrected for re-infection was lower, though not significantly, in the AS+AQ group compared to the AL or the AS+CD groups (AS+AQ 18.3%; AL 24.2%; AS+CD 20.8%, p?=?0.4)",2430614
755,2430614,parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children,Artesunate+amodiaquine (AS+AQ),artemether-lumefantrine (AL),No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups,2430614
756,2847809,Complications and mortality,Clopidogrel,Placebo,No significant difference,Complication	All patients (%)	Clopidogrel (%)	Placebo (%)	P valueGI bleeding	5 (5.3)	2 (2.1)	3 (3.2)	0.31Non GI tract bleeding	9 (9.6)	5 (5.3)	4 (4.3)	0.63Death events	4 (4.3)	2 (2.1)	2 (2.1)	0.47,2847809
757,2847809,First hemodialysis success,Clopidogrel,Placebo,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008).,2847809
758,2847809,The primary arteriovenous fistula failures at two months,Clopidogrel,Placebo,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03).,2847809
759,2447617,The modified Functional Independence Measure scores,progesterone,placebo,Significantly increased,he modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01).,2447617
760,2447617,The mortality rate,progesterone,placebo,Significantly decreased,he mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05).,2447617
761,2447617,The mean intracranial pressure values 72 hours and 7 days after injury,progesterone,placebo,No significant difference,"he mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).",2447617
762,2447617,Instances of complications and adverse events,progesterone,placebo,No significant difference,Instances of complications and adverse events associated with the administration of progesterone were not found.,2447617
763,2447617,The analysis using the dichotomization of GOS scores at 3 months post injury,progesterone,placebo,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034). There was an unfavorable outcome in 53% of the patients receiving progesterone and in 70% of the placebo group (P = 0.022).,2447617
764,2447617,The analysis using the dichotomization of GOS scores at 6 months post injury,progesterone,placebo,Significantly increased,The percentage of favorable outcome was 58% for the patients who were given progesterone and was 42% in the placebo group (P = 0.048). Forty-one percent of patients who were given progesterone and 57% of the placebo group exhibited an unfavorable outcome (P = 0.048).,2447617
765,2899760,Fusion rate,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,"usion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).",2899760
766,2899760,clinical outcomes,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused.,2899760
767,2899760,Radiological fusion,raditional Smith–Robinson (SR) procedure with autograft ,anterior cervical decompression and fusion (ACDF) with Trabecular Metal™ (TM),Significantly increased,Fusion rate (I + IIA)		69		92,2899760
768,3108665,Postoperative complications,somatostatin,No medication was given to the control group,Significantly decreased,"Initially, 6 of 35 (17%) in the treated group who received somatostatin developed complications, whereas 18 of 32 (56%) in the control group developed complications.",3108665
769,2361948,Overall survival time,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"Overall survival time differed significantly between the study groups in favour of 16?Gy/2 fr (median 8.0 months), compared to 20?Gy/5 fr (median 5.3 months), P=0.016 (Figure 7).",2361948
770,2361948,6- and 12-month survival probabilities,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B),Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42–72%) and 27% (95% CI: 14–40%) for patients receiving 16?Gy/2 fr, and 30% (95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients receiving 20?Gy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).",2361948
771,2361948,degree of relief of all analysed symptoms,palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A),palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B),No significant difference,"The percentages of all evaluable patients reporting any symptomatic improvement were as follows: cough 51% (24 out of 47; for a median of six assessments, range: 1–10), dyspnoea 60% (26 out of 43; for a median of six assessments, range: 1–9), haemoptysis 86% (19 out of 22; for a median of eight assessments, range: 1–11), chest pain 83% (34 out of 41; for a median of four assessments, range: 1–9), dysphagia 71% (five out of seven; for a median of eight assessments, range: 1–9), SVCS 83% (five out of six; for a median of five assessments, range: 4–9). The numbers of patients achieving symptomatic improvement did not differ between study groups for all analysed symptoms (Table 3).",2361948
772,2364680,wound problem,opening subcutaneous tissues with electrocautery,opening subcutaneous tissues with scalpel,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4).,2364680
773,3221331,Continuous abstinence at 6 months,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8).,3221331
774,3221331,did not attempt to quit smoking at all,"an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses.",set a quit date and received a general health video message sent to their phone every 2 weeks.,No significant difference,"At 6 months all participants were asked how many quit attempts they had made during the study period. In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.",3221331
775,3198285,low–glycemic index,low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean ± SEM 47 ± 1 vs. 53 ± 1; P < 0.001).,3198285
776,3198285,"birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,"At birth, there was no significant difference in birth weight (LGI 3.3 ± 0.1 kg vs. HF 3.3 ± 0.1 kg; P = 0.619), birth weight centile (LGI 52.5 ± 4.3 vs. HF 52.2 ± 4.0; P = 0.969), prevalence of macrosomia (LGI 2.1% vs. HF 6.7%; P = 0.157), insulin treatment (LGI 53% vs. HF 65%; P = 0.251), or adverse pregnancy outcomes.",3198285
777,3198285,"Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean",low–glycemic index diet (target glycemic index [GI] ~50),high-fiber moderate-GI diet (HF) (target glycemic index GI ~60),No significant difference,Gestational age (weeks)	47	39.1 ± 0.1	45	39.2 ± 0.1	0.552Birth weight (kg)	47	3.3 ± 0.1	45	3.3 ± 0.1	0.619Birth weight centile	47	52.5 ± 4.3	45	52.2 ± 4.0	0.969LGA (%)	47	12.8	45	4.4	0.157Small for gestational age (%)	47	10.6	45	8.9	0.778Macrosomia (%)	47	2.1	45	6.7	0.286Infant head circumference (cm)	43	34.4 ± 0.2	39	34.6 ± 0.3	0.478Infant length (cm)	47	49.7 ± 0.3	45	49.7 ± 0.3	0.995Ponderal index (kg/m3)	47	27.2 ± 0.3	45	27.0 ± 0.4	0.614Maternal weight gain (kg)	44	11.9 ± 0.7	43	13.1 ± 0.9	0.305?Below target (%)†		31.8		25.6	0.520?Within target (%)†		43.2		32.6	0.307?Above target (%)†		25.0		41.9	0.095Insulin treatment (%)	47	53.2	45	65.1	0.251Final daily insulin dose (units)	47	17.7 ± 4.1	43	20.0 ± 3.8	0.676Emergency caesarean (%)	44	20.5	44	11.6	0.263,3198285
778,2722000,The incidence of bacterial infection,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).",2722000
779,2722000,Enteric bacteria,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"Enteric bacteria were more frequently identified in patients without antibiotic prophylaxis (0/62, 0% vs. 5/58, 8.6%, p=0.018).",2722000
780,2722000,rebleeding,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,Significantly decreased,"The rebleeding rate in the prophylactic group was significantly lower than that in the on-demand group (21/62, 33.9% vs. 36/58, 62.1%, p=0.004).",2722000
781,2722000,Total mortality and 30-day mortality,received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days,received antibiotics only when infection was suspected or established,No significant difference,otal mortality and 30-day mortality were not different between the two groups (Table 7). The overall rate of survival was similar between the two groups (Fig. 4).,2722000
782,2650992,drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006),2650992
783,2650992,overall drain output,fibrin glue group (glue sprayed onto the axillary dissection site),control group,Significantly decreased,overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.,2650992
784,2650992,The mean drainage duration,fibrin glue group (glue sprayed onto the axillary dissection site),control group,No significant difference,The mean drainage duration was 3.3 days for the fibrin glue group and 3.8 days for the control group (p=0.067).,2650992
785,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,"Caring for ""Super Spreading Patient"" (No = 0: yes = 1)	3.57(1.94~6.57)	<0.001",2666722
786,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Number of pairs of gloves worn (Double = 0: single = 1)	4.13(1.99~8.55)	<0.001,2666722
787,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly increased,Performing tracheal intubations (No = 0: yes = 1)	2.76(1.16~6.53)	<0.05,2666722
788,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Avoiding face to face contact while caring for SARS patients		?Never	1.00	?Sometimes	0.67(0.36~1.24)	>0.05?Often	0.30(0.10~0.90)	<0.05?Every time	0.30(0.15~0.60)	<0.001,2666722
789,2666722,the risk of SARS infection,health care workers with IgG against Severe acute respiratory syndrome,health care workers without IgG against Severe acute respiratory syndrome,Significantly decreased,Method of air ventilation in office and SARS ward		?Artificial central ventilation	1.00	?Natural ventilation	0.40(0.18~0.88)	<0.05?Natural ventilation and additional electronic exhaust fan	0.27(0.16~0.63)	<0.01,2666722
790,125315,Sequential Organ Failure Assessment (SOFA) score ,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,No statistically significant difference was found between the changes in the percentage of SOFA scores of the steroid therapy group (43.1 ± 26.5%) and the standard therapy group (45.4 ± 12.7%) in survivors (P = 0.624).,125315
791,125315,The 28-day mortality,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343).,125315
792,125315,The median stay in hospital,received standard therapy for sepsis and physiological-dose steroid therapy for 10 days;,received only standard therapy for sepsis,No significant difference,The median stay in hospital was 14 days (95% CI 11.09–20.08) in the steroid therapy group and 13 days (95% CI 10.13–16.37) in the standard therapy group (P = 0.406).,125315
793,2830179,pain during movement,attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1))",2830179
794,2830179,Pain on rest (0-10),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly decreased,"Compared with the control group, the intervention group showed significant reductions in pain during movement (mean difference (95% CI) -1.8 (-3.5 to -0.1)) and at rest (-2.0 (-3.8 to -0.2)) and",2830179
795,2830179,Qualeffo Total (0-100),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Qualeffo Total (0-100) 29 (10) 26 (7) 21 (11) 27 (8) -7.2 (11.2) 1.2 (4.1) -7.1 (-14.9 to 0.8),2830179
796,2830179,Timed loaded standing test (s),attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary,received no treatment,Significantly increased,Timed loaded standing test (s)	50 (39)	62 (49)	82 (44)	46 (50)	32.6 (34.1)	-16.7 (29.8)	46.7 (16.1 to 77.3),2830179
797,4785315,Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS),"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,no significant differences were seen in the mean EPDS (mean difference (MD) ?0.59 (95% CI ?1.24 to 0.06)) for all the women recruited,4785315
798,4785315,Antenatal attendances,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,No significant difference,"Antenatal attendances were high in the standard care control and did not increase further with addition of the POW intervention (10.1 vs 10.1 (mean difference; MD) ?0.00, 95% CI (95% CI ?0.37 to 0.37)).",4785315
799,4785315,Mother-to-infant bonding,"additional lay support (in this instance Pregnancy Outreach Workers, POWs)",standard maternity care,Significantly increased,"Mother-to-infant bonding was significantly better in the intervention group for all women (MD ?0.30 (95% CI ?0.61 to ?0.00) p=0.05),",4785315
800,2888205,perceived functional deficits,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"Compared to FME, the LPA group reported significantly less perceived functional deficits (P = .032)",2888205
801,2888205,pain,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,Significantly decreased,"At post-testing, compared to the FME group, the LPA group reported significant reductions in the FIQ score (P = .032; Cohen's d = .53) and in pain (P = .006; Cohen's d = .67).",2888205
802,2888205,six-minute walk test,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,"There were no differences between the groups on the six-minute walk test (P = .067),",2888205
803,2888205,Fatigue severity scale,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Fatigue severity scale ?Baseline 84 51.9 ± 9.3 52.3 ± 9.1 .4 (-3.6 to 4.4) 0.843 .04?Post intervention 73 50.6 ± 9.9 51.4 ± 10.1 .8 (-3.9 to 5.5) 0.727 .07,2888205
804,2888205,Number of tender points,"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Baseline 84 16.2 ± 2.3 16.1 ± 3.2 .1 (-1.2 to 1.0) 0.979 .03?Post intervention 72 16.0 ± 2.3 16.8 ± 2.0 .8 (-.35 to 1.9) 0.172 .37,2888205
805,2888205,Body mass index (BMI),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,Body mass index (BMI) ?Baseline 82 31.4 ± 8.4 29.8 ± 6.2 1.6 (-4.7 to 1.7) 0.360 .22?Post intervention 60 31.0 ± 9.0 29.9 ± 6.2 1.1 (-5.3 to 2.9) 0.575 .14,2888205
806,2888205,Center for Epidemiologic Studies Depression Scale (CES-D),"lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week",fibromyalgia (FM) education control (FME) group - received information and support,No significant difference,CES-D* ?Baseline 84 23.4 ± 8.6 24.0 ± 10 .6 (-3.8 to 4.5) 0.798 .06?Post intervention 73 21.6 ± 9.8 21.2 ± 11.3 .4 (-5.3 to 4.6) 0.888 .04,2888205
807,3490871,weight change,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7?weeks of group support sessions,No significant difference,"Analysis of weight change in those successful at stopping smoking was underpowered (66%) but indicated greater mean weight gain in intervention subjects (3.9 (SD 3.1) vs. 2.7 (SD 3.7) kg). Between group differences were not significant (p?=?0.23, 95% CI ?0.9 to 3.5) however the confidence interval is wide and includes a loss of ?0.9?kg, thus the possibility of an effect in favour of the intervention cannot be excluded.",3490871
808,3490871,Smoking cessation,24-week intervention focussed on improving food choice and minimising weight gain,Usual care comprised of 7?weeks of group support sessions,No significant difference,"Although the study was not powered to detect changes in smoking status these data were examined for completers and also using a sensitivity analysis. Both analyses showed a higher percentage of control participants still smoking at week 24 in comparison to intervention participants, however between group differences were not significant (Table 8).Table 8Comparison of Smoking Status between Intervention and Control Groups 	Intervention	Control	Odds Ratio	95% Confidence Interval	pCompleters	 	 	 	 	 Smoking at Week 6	9 (18.8%)	6 (11.3%)	1.74	0.40 to 7.66	0.46Smoking at Week 24	17 (42.5%)	25 (58.1%)	0.43	0.14 to 1.34	0.14Sensitivity analysis	 	 	 	 	 Smoking at Week 6	29 (42.6%)	23 (32.9%)	1.38	0.63 to 3.04	0.42Smoking at Week 24	45 (66.2%)	52 (74.3%)	0.58	0.25 to 1.36	0.20",3490871
809,5256321,The 10mWT (10-m walking test ),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,the results for the 10mWT showed only significant improvements in the experimental group (11.38±3.0 to 10.12±2.47 seconds; p=0.01); whereas the control group did not show significant improvements.,5256321
810,5256321,trunk strength (BPR score),Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",Significantly increased,he improvement levels of the trunk strength (BPR score) for the experimental group using Spine Balance 3D system's evaluation program showed significant improvements at the 15° open mode; whereas the control group did not show any significant improvement.,5256321
811,5256321,"he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I) ",Spine Balance 3D (CyberMedic),"Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA)",No significant difference,"The results of the BBS, FRT, TUG, KFES-I, and Biodex Balance System evaluation program improved in both groups after 7 weeks of balance training.",5256321
812,5602855,Quality of life,good motivation/capability,inadequate motivation/capability,No significant difference,"The EQ-5D-3L summary index is shown in Fig. 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (p = 0.26) or inadequate (p = 0.71) motivation/capability during the three years of follow-up. Additionally, no change was observed in the EQ-5D-3L summary index (p = 0.14), EQ VAS (p = 0.68) or the anxiety/depression dimension of the EQ-5D-3L system (p = 0.95) during the follow-up in those subjects who continued pulse palpation at least weekly at 36 months.Fig. 2",5602855
813,5602855,Health care burden,good motivation/capability,inadequate motivation/capability,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (p = 0.39) or to special healthcare outpatient clinics (p = 0.072) during the follow-up.,5602855
814,5602855,Self-detected pulse irregularity and outcome events,good motivation/capability,inadequate motivation/capability,No significant difference,"Irregular pulse findings were not significantly associated with the composite outcome variable (p = 0.06), stroke/TIA (p = 0.48), pacemaker implantation (p = 0.10) or death (p = 1.00).",5602855
815,4419460,HbA1c at 12 or 24?months.,"The Child and Adolescent Structured Competencies Approach to Diabetes Education (CASCADE) is a structured educational group program, using psychological techniques, delivered primarily by diabetes nurses.",control,No significant difference,"Given that the trial found no evidence of benefits on venous HbA1c at 12 and 24?months and little evidence of benefits on secondary outcomes, the focus of this paper is to use the findings of the process evaluation to suggest how future structured education may be more effectively implemented.12",4419460
816,4577567,stride length,stride frequency manipulation,free stride frequency,Significantly increased,Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001),4577567
817,4577567,contact time,stride frequency manipulation,free stride frequency,Significantly increased,"With regard to the two training strategies, within the RWM group the CT significantly increased by 4.58% (p<0.001),",4577567
818,4577567,stride frequency,stride frequency manipulation,free stride frequency,Significantly decreased,a decreased stride frequency (4.44%; p<0.0001),4577567
819,4577567,internal work,stride frequency manipulation,free stride frequency,Significantly decreased,"nversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.",4577567
820,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"he precision of RSA corresponding to the 99% confidence interval was 1.36°, 1.36°, and 0.60° for X-, Y-, and Z-rotation and 0.40, 0.17, and 0.37?mm for X-, Y-, and Z-translation. The limit of agreement between CT and RSA was 1.51°, 2.17°, and 1.05° for rotation and 0.59, 0.56, and 0.74?mm for translation. The differences between CT and RSA are close to the described normal 99% confidence interval for precision in RSA: 0.3° to 2° for rotation and 0.15 to 0.6?mm for translation.",5294349
821,5294349,datasets of 3D coordinates,CT scan,2–4 stereo radiograph pair examinations,No significant difference,"CT scans can be used for migration measurements in longitudinal evaluations of patients with RSA markers without losing clinically significant precision. The use of CT scans enables following RSA studies started earlier using a normal CT scan, thus avoiding the need for special RSA radiology facilities.",5294349
822,3329632,ICER (incremental cost-effectiveness ratio),ranibizumab ,ranibizumab combined with laser therapy,Significantly decreased,"Ranibizumab monotherapy was associated with an incremental gain of 0.17 QALY and cost of £4 191, corresponding to an ICER of £24?028 per QALY gained relative to laser monotherapy (table 3). Combination therapy provided an incremental gain of 0.13 QALY over laser monotherapy for an incremental cost of £4 695, leading to an ICER of £36?106 per QALY gained.",3329632
823,3800940,"Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss.",Gomutra sodhit Langali moola with honey for external application,Godugdha sodhit Langali moola with honey for external application,Significantly decreased,It was observed that after 60 days of treatment with Gomutrashodhit Langlimool in Group A there was reduction in Hair fall which is statistically highly significant (P<0.001) and highly significant improvement was observed in reducing dandruff.(p<0.001). Where as in Group B Godugdashodhit Langlimool application reduced the hair fall to statistically significant level (p<0.01) and statistically significant in reducing the dandruff in patient with Indralupta (P<0.01).,3800940
824,4819709,Bending the legs without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Bending the legs without discomfort	50	3·0	4·6	1·38 (1·14, 1·67)",4819709
825,4819709,Lifting heavy objects without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Lifting heavy objects without discomfort	50	4·8	9·8	1·97 (1·59, 2·44)90	16·9	34·5",4819709
826,4819709,Moving from standing to sitting without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Moving from standing to sitting without discomfort	50	1·9	3·7	1·63 (1·35, 1·97)",4819709
827,4819709,Standing still for a long time (>?15 min ) without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Standing still for a long time (>?15 min ) without discomfort	50	3·9	7·1	1·67 (1·36, 2·05)90	15·8	28·7",4819709
828,4819709,Walking short distances (<?20 min ) without discomfort,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Walking short distances (<?20 min ) without discomfort	50	1·9	4·4	2·00 (1·65, 2·42)90	8·2	19·1",4819709
829,4819709,Walking long distances (>?20 min),Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Walking long distances (>?20 min)	50	4·5	8·0	1·76 (1·45, 2·14)90	15·2	27·1",4819709
830,4819709,Having a bath or shower,Ultrasound?guided foam sclerotherapy,surgery,No significant difference,"Having a bath or shower	50	5·4	4·9	0·85 (0·70, 1·03)90	11·4	10·3",4819709
831,4819709,Driving a car,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Driving a car	50	4·1	7·0	1·78 (1·45, 2·19)",4819709
832,4819709,Doing housework,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Doing housework	50	2·1	4·5	2·10 (1·72, 2·56)",4819709
833,4819709,Looking after children,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Looking after children	50	1·2	3·5	2·20 (1·61, 3·00)90	6·2	17·9",4819709
834,4819709,Wearing clothes that show the legs,Ultrasound?guided foam sclerotherapy,surgery,No significant difference,"Wearing clothes that show the legs	50	12·4	12·8	1·03 (0·78, 1·35)90	56·6	58·7",4819709
835,4819709,Partial return to normal work/employment,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Partial return to normal work/employment	50	4·4	9·9	2·16 (1·72, 2·72)90	15·4	34·2",4819709
836,4819709,Full return to normal work/employment,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Full return to normal work/employment	50	4·8	11·7	2·56 (2·05, 3·21)90	14·9	36·2",4819709
837,4819709,Going out socially,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Going out socially	50	7·1	9·3	1·29 (1·06, 1·57)90	25·8	34·0",4819709
838,4819709,Sporting activity or exercise,Ultrasound?guided foam sclerotherapy,surgery,Significantly increased,"Sporting activity or exercise	50	15·7	21·8	1·33 (1·05, 1·68)",4819709
839,4819709,"Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>?15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise",Endovenous laser ablation,Ultrasound?guided foam sclerotherapy,No significant difference,"Activity items Bending the legs without discomfort 50 2·7 3·0 0·94 (0·75, 1·17)90 12·6 14·1Lifting heavy objects without discomfort 50 5·9 4·8 1·11 (0·87, 1·42)90 20·5 16·9Moving from standing to sitting without discomfort 50 2·2 1·9 1·12 (0·90, 1·40)90 10·4 9·3Standing still for a long time (>?15 min) without discomfort 50 4·8 3·9 1·14 (0·90, 1·44)90 20·0 15·8Walking short distances (<?20 min) without discomfort 50 3·0 1·9 1·48 (1·19, 1·84)90 13·2 8·2Walking long distances (>?20 min) 50 5·6 4·5 1·32 (1·05, 1·66)90 19·8 15·2Having a bath or shower 50 5·5 5·4 1·19 (0·96, 1·48)90 12·8 11·4Driving a car 50 4·4 4·1 0·95 (0·74, 1·21)90 12·7 12·4Participation items Doing housework 50 2·5 2·1 1·03 (0·82, 1·29)90 8·4 7·3Looking after children 50 1·9 1·2 1·45 (1·04, 2·02)90 8·8 6·2Wearing clothes that show the legs 50 14·6 12·4 1·17 (0·83, 1·64)90 75·1 56·6Partial return to normal work/employment 50 6·3 4·4 1·17 (0·89, 1·52)90 21·1 15·4Full return to normal work/employment 50 7·7 4·8 1·43 (1·11, 1·85)90 23·5 14·9Going out socially 50 6·9 7·1 0·88 (0·70, 1·10)90 23·9 25·8Sporting activity or exercise 50 14·2 15·7 0·80 (0·61, 1·04)90 55·5 62·6",4819709
840,4819709,"walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment",Endovenous laser ablation,Ultrasound?guided foam sclerotherapy,Significantly decreased,"Return to ‘walking short distances without discomfort’, ‘walking long distances’, ‘looking after children’ and ‘full return to normal work/employment’ took longer for the EVLA group than the UGFS group.",4819709
841,4819709,"Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>?15 min) without discomfort, Walking short distances (<?20 min) without discomfort, Walking long distances (>?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise, ",Endovenous laser ablation,surgery,Significantly increased,"Activity items				Bending the legs without discomfort	50	2·7	4·6	1·49 (1·19, 1·75)90	12·6	21·3Lifting heavy objects without discomfort	50	5·9	9·8	1·79 (1·39, 2·27)90	20·5	34·5Moving from standing to sitting without discomfort	50	2·2	3·7	1·56 (1·27, 1·96)90	10·4	17·5Standing still for a long time (>?15 min) without discomfort	50	4·8	7·1	1·41 (1·11, 1·79)90	20·0	28·7Walking short distances (<?20 min) without discomfort	50	3·0	4·4	1·30 (1·04, 1·61)90	13·2	19·1Walking long distances (>?20 min)	50	5·6	8·0	1·53 (1·06, 1·67)90	19·8	27·1Having a bath or shower	50	5·5	4·9	0·74 (0·59, 0·93)90	12·8	10·3Driving a car	50	4·4	7·0	1·82 (1·43, 2·33)90	12·7	21·1Participation items				Doing housework	50	2·5	4·5	1·89 (1·49, 2·38)90	8·4	15·7Looking after children	50	1·9	3·5	1·61 (1·15, 2·27)90	8·8	17·9Wearing clothes that show the legs	50	14·6	12·8	0·97 (0·69, 1·35)90	75·1	58·7Partial return to normal work/employment	50	6·3	9·9	1·75 (1·33, 2·27)90	21·1	34·2Full return to normal work/employment	50	7·7	11·7	1·79 (1·37, 2·27)90	23·5	36·2Going out socially	50	6·9	9·3	1·41 (1·12, 1·75)90	23·9	34·0Sporting activity or exercise	50	14·2	21·8	1·47 (1·12, 1·92)",4819709
842,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,glucose 5% solution,Significantly increased,TUR syndrome	17*	0	0,2891743
843,2891743,transurethral resection (TUR) syndrome,glycine 1.5% solution as irrigating fluid,normal saline 0.9% solution,Significantly increased,TUR syndrome 17* 0 0,2891743
844,3418149,Morbidity after surgery,ipsilateral arm morbidity,contralateral arm morbidity,Significantly increased,"Comparison of ipsilateral vs. contralateral arm shows that changes affecting one limb strongly correlated with changes affecting the other limb (upper right quarter of Table 3). The highest correlations were abduction (R = 0.78), retroflexion (R = 0.73), scapular distance (R = 0.65), and arm volume (R = 0.57), all P-values <0.001.",3418149
845,5062194,neonatal outcome,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",No significant difference,There were no between-group differences regarding the neonatal outcome.,5062194
846,5062194,postoperative satisfaction,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
847,5062194,preoperative anxiety,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly decreased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,5062194
848,5062194,No statistical analysis because they are in tables,intravenous dose of 0.035 mg/kg of midazolam,"equal volume of normal saline, 30 min before spinal anesthesia",Significantly increased,"Table 2Amsterdam Preoperative Anxiety and Information Scale, Maternal Satisfaction Scale for cesarean section, Apgar score and neonatal neurologic and adaptive capacity score in both groupsTable 3Blood gas analysis of umbilical artery blood samples in both groupsRegarding maternal hemodynamics, baseline HR, SBP, and DBP were comparable between the two groups before the administration of the tested drug. However, 5 min after injecting the tested drug, there was a significant decrease in all parameters in group (M) compared to group (S). During insertion of the spinal needle, there was a rise in HR and SBP in group (S) compared to group (M) while DBP was at a lower level in group (M). After the induction of spinal anesthesia and placing the patient into the tilted supine position, there was an increase in HR with some decrease in blood pressure parameters in both groups as shown in Tables 4–6.Table 4Maternal heart rate in both groupsTable 5Systolic blood pressure in both groupsTable 6Diastolic blood pressure in both groups",5062194
849,5577662,percentage changes in area,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,"percentage changes in area were significantly greater with CCH 0.40 mg (?80.1%, P = 0.0002) and CCH 0.60 mg (?78.2%, P = 0.0003), but not CCH 0.25 mg (?58.3%, P = 0.079), versus placebo (?42.2%) at post-treatment Week 8.",5577662
850,5577662,Mean change in nodular consistency and hardness,"receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (P ? 0.0139 for all).,5577662
851,5577662,global assessment of improvement,"receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH)","dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",Significantly increased,nvestigator global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ? 0.0014),5577662
852,5577662,percentage changes in area,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,"percentage changes in area were significantly greater with CCH 0.40 mg (?80.1%, P = 0.0002) and CCH 0.60 mg (?78.2%, P = 0.0003), but not CCH 0.25 mg (?58.3%, P = 0.079), versus placebo (?42.2%) at post-treatment Week 8.",5577662
853,5577662,global assessment of improvement,receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH),"dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio)",No significant difference,global assessment of improvement was significantly greater with CCH 0.40 mg and 0.60 mg (P ? 0.0014) but not statistically significant with CCH 0.25 mg versus placebo (P = 0.13).,5577662
854,4794897,pyridinoline,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p?=?0.035 and p?=?0.043),4794897
855,4794897,beta-isomer of carboxy-terminal telopeptide of type I collagen,resistance training dyrung radiation therapy,passive physical therapy,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p?=?0.035 and p?=?0.043),4794897
856,5062234,The 24 h morphine requirement,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,No significant difference,The 24 h morphine requirement (mean ± standard deviation) was 34.57 ± 14.64 mg in TAP group and 32.76 ± 14.34 mg in local infiltration group (P = 0.688).,5062234
857,5062234,intraoperative supplemental fentanyl,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,The number of patients requiring intraoperative supplemental fentanyl in TAP group was 8 and in local infiltration group was 16 (P = 0.028).,5062234
858,5062234,The visual analog scale scores at rest and on coughing,Transversus abdominis plane block with 0.375% ropivacaine ,local anesthetic infiltration of the port site.,Significantly decreased,"At 4 h, none of the patients in the TAP group but seven patients (33.3%) in the control group had moderate to severe pain (VAS >3) at rest (P = 0.009*). At 4 h, eight patients (38.1%) in the TAP group and 15 patients (71.4%) in the control group had moderate to severe pain on coughing (P = 0.03*). At 12 h, six patients (28.5%) in the TAP group and 18 patients (85.7%) in the control group had moderate to severe pain on coughing (P < 0.001*).",5062234
859,4139977,decrease in abdominal pain and distension severity,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"here was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).",4139977
860,4139977,Improvement in bowel habit,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,mprovement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910).,4139977
861,4139977,quality-of-life ,"receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles","similar placebo, twice daily after a meal for 14 consecutive days",No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372),",4139977
862,4078386,mean of HCV-RNA numbers in 12 weeks of therapy,20 mg atorvastatin nightly for 3 months,placebo,No significant difference,"we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12th week of Statins therapy (P > 0.05),",4078386
863,4078386,mean of HCV-RNA numbers at the end of treatment ,20 mg atorvastatin nightly for 3 months,placebo,No significant difference,"we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12th week of Statins therapy (P > 0.05), at the end of treatment (P > 0.05)",4078386
864,4078386,mean of HCV-RNA numbers 6 months after treatment ,20 mg atorvastatin nightly for 3 months,placebo,No significant difference,"we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12th week of Statins therapy (P > 0.05), at the end of treatment (P > 0.05) and 6 months after treatment (P > 0.05)",4078386
865,5680306,Serum 25(OH)D concentrations,"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks",Significantly increased,"Serum 25(OH)D concentrations increased significantly in the vitamin D group, from 31.4?±?12.6 at baseline to 88.4?±?21.0 nmol/L at 16 weeks (p?<?0.001), with no change in the placebo group for the same time-period (34.2?±?10.0 and 36.1?±?15.3 nmol/L, respectively; p?=?0.5)",5680306
866,5680306,"hsCRP, TNF, MCP-1, IFN-?, any of the interleukins","vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks",No significant difference,"There were no differences between vitamin D and placebo groups in change in hsCRP (?0.1?±?1.4 versus ?0.4?±?2.3?mg/L, p?=?0.9), TNF (?8.0?±?109.4 versus ?2.9?±?103.9?pg/ml, p?=?0.9), MCP-1 (?234.8?±?1071.9 versus ?58.8?±?819.4?pg/ml, p?=?0.6) or IFN-? (11.1?±?85.8 versus ?1.3?±?22.7?pg/ml, p?=?0.9). Similarly, no differences between vitamin D and placebo groups were found for any of the interleukins (all p?>?0.1; Table 2).",5680306
867,5680306,NF?B activity,"vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily","the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks",No significant difference,NF?B activity also did not differ between vitamin D and placebo groups in this subgroup (p?=?0.3;,5680306
868,5332972,FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set;,after 4 weeks of repetitive facilitative exercises  and orthotic treatment.,before repetitive facilitative exercises  and orthotic treatment.,Significantly increased,"In terms of lower-limb motor performance, FMA-LE increased significantly from 22.96 ± 4.07 to 25.85 ± 4.03 (p<0.01), and SIAS increased significantly from 46.59 ± 8.34 to 53.63 ± 7.63 (p<0.01).",5332972
869,5332972,TUG: Timed “Up & Go” test;,after 4 weeks of repetitive facilitative exercises  and orthotic treatment.,before repetitive facilitative exercises  and orthotic treatment.,Significantly decreased,"TUG decreased significantly from 17.35 ± 5.57 seconds to 14.02 ± 4.46 seconds (p<0.01),",5332972
870,5332972,comfortable gait speed and fast gait speed ,after 4 weeks of repetitive facilitative exercises and orthotic treatment.,before repetitive facilitative exercises and orthotic treatment.,Significantly increased,"comfortable gait speed increased significantly from 0.68 ± 0.22 (m/sec) to 0.81 ± 0.24 (m/sec) (p<0.01), and fast gait speed increased significantly from 0.80 ± 0.28 (m/sec) to 0.96 ± 0.31 (m/sec) (p<0.01).",5332972
871,5209819,Pre-treatment testing performed within the ADDO,"After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.",Significantly increased,Pre-treatment testing performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 60.8–69.6%) with no difference between intervention districts.,5209819
872,5209819,The proportion of patients present at the ADDO who received a diagnostic test ,"After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.","Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results.",Significantly increased,The proportion of patients present at the ADDO who received a diagnostic test increased from 19% pre-intervention to 74% post-intervention in the intervention districts and from 3 to 18% in the control district (p < 0.01 for both groups).,5209819
873,5729252,hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF),bosentan,no treatment,Significantly increased,"At the time of survival time analysis, hospital-free survival was 358.87?±?68.65 days (mean?±?SE) (median, 331 days) in the untreated group, which was significantly different from that in the drug-treated group (603.44?±?50.074 days) as assessed by proportional hazard analysis (hazard ratio of the drug-treated group to the untreated group, 0.19, P?=?0.017; log-rank test, P?=?0.019; and Wilcoxon test, P?=?0.014).",5729252
874,5729252,overall survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF),bosentan,no treatment,Significantly increased,"(671 days vs. 433.78?±?66.98 days; HR, 0.10; P?=?0.0082).",5729252
875,2974815,percentage of patients with controlled blood pressure,phone calls” group,“no phone calls” group,No significant difference,There was no difference in the percentage of patients with controlled blood pressure in the “phone calls” group and “no phone calls” group or in the “traditional” and “current” groups.,2974815
876,2974815,discontinued treatment,phone calls” group,“no phone calls” group,Significantly decreased,Significantly fewer patients in the “phone calls” group discontinued treatment compared to those in the “no phone calls” group (4 vs. 30; p<0.0094).,2974815
877,2974815,The percentage of patients with controlled blood pressure (<140/90 mmHg),phone calls” group,“no phone calls” group,Significantly increased,"The percentage of patients with controlled blood pressure (<140/90 mmHg) was increased at the end of the treatment (74%), reaching 80% in the “uncomplicated” group and 67% in the “complicated” group (p<0.000001).",2974815
878,4088715,rate of intubations,CPAP + standard of care (nCPAP group),standard group,Significantly decreased,"Finally, the rate of intubations was higher in the standard group (n = 8, n = 3) than the nCPAP group (P < 0.01).",4088715
879,4088715,hospital and ICU length of stay,CPAP + standard of care (nCPAP group),standard group,Significantly decreased,"The nCPAP group also had a shorter hospital and ICU length of stay compared with the standard group (4 vs 5 days, and 2 vs 3 days, respectively).",4088715
880,4088715,"tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI)",CPAP + standard of care (nCPAP group),standard group,Significantly increased,"Subjects in the nCPAP group had a greater improvement for various parameters compared with the standard group including TV (0.8 l, 0.3 l), EtCO2 (30 mmHg, 38 mmHg) and RSBI (39, 150), respectively.",4088715
881,5539984,Primary outcome effect,The Network for Mental Health (NWpG-IC),standard mental health care,No significant difference,"ixed-models for EPAS total score (see Table 3) indicated a significant effect of time (b = 0.07, p < 0.001), but no significant group by time interaction effect (b = 0.02; p = 0.258). This means with regard to the parameterisation of the mixed effects model that there was a significant change of overall empowerment in the control group, but NWpG-IC treatment had no additional effect on improvement of overall empowerment during the 18 month study period.",5539984
882,5539984,prevalence of psychiatric inpatient admission,The Network for Mental Health (NWpG-IC),standard mental health care,No significant difference,"The results of the mixed effects logistic regression model (not presented) did neither show differences of the prevalence of psychiatric inpatient admission between groups during the six months before baseline assessment (OR 0.99; p = 0.985), nor a change over time (OR 0.62; p = 0.086) in either groups or a difference between the groups (OR 0.97; p = 0.878) during the study period.",5539984
883,5539984,reduction of total needs and the increase of met needs,The Network for Mental Health (NWpG-IC),standard mental health care,No significant difference,"However, as indicated by the non-significant group by time interaction, there was no difference between groups regarding the reduction of total needs (b = 0.09; p = 0.217) or the increase of met needs (b = 0.01; p = 0.621).",5539984
884,5514258,survival,major salivary gland cancer in high risk group plus adjuvant radiation therapy,major salivary gland cancer in high risk group without adjuvant radiation therapy,Significantly increased,"Patients in the high-risk group had greater survival (hazard ratio [HR], 0.76; P = .002; 95% confidence interval [CI], 0.64-0.91) if they received adjuvant radiation therapy.",5514258
885,5514258,survival,major salivary gland cancer in low/intermediate risk group plus adjuvant radiation therapy,major salivary gland cancer in low/intermediate risk group without adjuvant radiation therapy,No significant difference,"patients in the intermediate- (HR, 1.01; P = .904; 95% CI, 0.85-1.20) and low-risk groups (HR, 0.85; P = .427; 95% CI, 0.57-1.26) did not experience a survival benefit with adjuvant radiation therapy.",5514258
886,4804575,The average TB incidence rate attributable to reinfection in the first year,during isoniazid preventive therapy,after isoniazid preventive therapy,Significantly decreased,"The average TB incidence rate attributable to reinfection in the first year was estimated at 1.3/100 pyrs, compared to an observed rate of 2.2/100 pyrs (95 % CI, 1.8–2.7).",4804575
887,5801479,"gene expression of interleukin (IL), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?) ","vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks",placebo (n = 30) every 2 weeks for 12 weeks,Significantly decreased,"Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1? (P = 0.02), tumor necrosis factor alpha (TNF-?) (P = 0.02) and interferon gamma (IFN-?) (P = 0.03) in PBMCs of diabetic HD patients.",5801479
888,5801479,"gene expression of transforming growth factor beta (TGF-?), protein kinase C (PKC), mitogen-activated protein kinases 1 (MAPK1) ","vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks",placebo (n = 30) every 2 weeks for 12 weeks,Significantly decreased,"Additionally, vitamin D supplementation, compared to the placebo, downregulated gene expression of TGF-? (P = 0.04), PKC (P = 0.001), and MAPK1 (P = 0.02) in PBMCs of diabetic HD patients",5801479
889,5801479,"nuclear factor kappa B (NF-kB), interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF) ","vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks",placebo (n = 30) every 2 weeks for 12 weeks,No significant difference,"Although not significant, vitamin D supplementation let to a reduction of nuclear factor kappa B (NF-kB) (p = 0.75) expression in PBMCs isolated from diabetic patients compared to the placebo group. There was no statistically significant change following supplementation with vitamin D on gene expression of interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF) in PBMCs of diabetic HD patients.",5801479
890,5519461,H. pylori eradication,"amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week.","amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week.",No significant difference,"The eradication rates of the EAC and RAC regimen groups were 79.8% [95% confidential interval (CI): 71.7-89.0%] and 74.7% (66.0-83.4%) for the per protocol (PP) analysis and 75.8% (67.4-84.2%) and 71.0% (62.1-79.9%) for the intention-to-treat (ITT) analysis, respectively (Fig. 2A). No significant differences were observed between the two regimens.",5519461
891,5519461,Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype.,"amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week.","amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week.",No significant difference,"The eradication rate of the EAC and RAC regimens in the homo EM patients was 73.3% (CI: 57.5-89.1%) and 76.7% (CI: 61.6-91.8%), respectively. In the hetero IM and PM patients, the eradication rate of the EAC regimen was 82.8% (73.6-92.0%), and that of the RAC regimen was 73.8% (63.1-84.5%). The eradication rates of the EAC and RAC regimen groups were not significantly different between the patients with homo EM genotype and those with hetero IM or PM genotype.",5519461
892,5618071,"ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month",after Non-Invasive Brain Stimulation (NIBS),before Non-Invasive Brain Stimulation (NIBS),Significantly decreased,"As a global result (G1 + G2), a significant decrease in the total score was observed in ADI-R, ABC, and ATEC scales one month after the intervention (Wilcoxon matched pair test; ABC, Z = 3.823, p = 0.000131; ADI-R, 3.337, p = 0.000846; ATEC, Z = 3.723, p = 0.000196).",5618071
893,4005450,pain experience,injected with lidocaine solutions 2%,"injected with lidocaine solutions 0,4%",No significant difference,Group A	Group B	Total	P valuePain severity 				0.003Mild	36	41	77	Moderate	6	6	12	Sever	8	3	11,4005450
894,4140547,"The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6)",belatacept groups,tacrolimus groups,Significantly increased,". Demographic characteristics were similar among groups. The proportion of patients who met the primary end point (composite of acute rejection, graft loss, death by month 6) was higher in the belatacept groups (42–48%) versus tacrolimus groups (15–38%), with the highest number of deaths and grafts losses in the belatacept LD group.",4140547
895,4140547,"By month 12, the proportion surviving with a functioning graft",belatacept groups,tacrolimus groups,Significantly decreased,"By month 12, the proportion surviving with a functioning graft was higher with tacrolimus + MMF (93%) and lower with belatacept LD (67%) versus other groups (90%: basiliximab + belatacept HD; 83%: belatacept HD; 88%: tacrolimus).",4140547
896,4140547,Mean calculated GFR at 1 year.,belatacept groups,tacrolimus groups,Significantly increased,The proportion of patients with >10 mL/min improvement in cGFR from baseline to month 12 was 47–65% in the belatacept groups versus 12–27% in the tacrolimus groups.,4140547
897,1198254,total fecal counts of lactobacilli,L. fermentum ME-3 fermented goat milk,goat milk,Significantly increased,"Increase of total fecal counts of lactobacilli in healthy volunteers consuming of ME-3 in fermented goat milk and probiotic capsule. 1 – Day 0, 2 – Day 21 Significantly different from pre-treatment values (Student's t-test): * p < 0.05; Significantly different from control (Student's t-test): ‡ p = 0.01",1198254
898,1198254,glutathione red-ox ratio,"Capsule trial, ME-3",Placebo,No significant difference,"When the probiotic was consumed in capsulated form, no significant decrease was noticed in the glutathione red-ox ratio.",1198254
899,1198254,glutathione red-ox ratio,L. fermentum ME-3 fermented goat milk,goat milk,No significant difference,"The effect of goat-milk consumption on the TAA and TAS values was significantlyhigher (p < 0.001) than by the consumption of the capsulated probiotic (Fig. 3). The decrease of the glutathione red-ox ratio was significant in both groups: the study Group (from 0.15 ± 0.01 to 0.11 ± 0.04 ?g/ml, p < 0.01) and control (from 0.14 ± 0.03 to 0.11 ± 0.02 ?g/ml, p < 0.01) in the goat milk trial.",1198254
900,1198254,Total Antioxidative Activity,L. fermentum ME-3 fermented goat milk,goat milk,Significantly increased,"The positive effect on the blood ox stress markers as TAA and TAS was seen in the case of both formulations (Fig. 3). Particularly, the additive increase in goat milk group was 6% and 9% respectively as compared to control group, however only 4% for TAA and 2.5% for TAS in probiotic capsule study group as compared to placebo.",1198254
901,4677000,On average (median) pain  in the paediatric population,lidocaine gel (2%),placebo,Significantly decreased,On average (median) pain has been reduced by 2.0/5 (verum) versus 1.2/5 (placebo) (Table 3). Nonparametric analysis (Mann-Whitney??U test) of treatment related difference in pain assessment yielded a statistical significance (p < 0.001) of the observed effect in favour of the 2% lidocaine gel (verum). A similar result (p < 0.002) was achieved also for the measurement of pain reduction from T1 to T3.,4677000
902,4677000,pain  in the paediatric population,lidocaine gel (2%),placebo,Significantly decreased,The observed ratings consequently showed statistically significant reduction of pain (Wilcoxon signed rank test results; T2: p value < 0.0001 and T3: p value < 0.0001).,4677000
903,4320624,peak FEV1,Abediterol,placebo,Significantly increased,"Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo, from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 ?g, respectively (p?<?0.0001 all doses)",4320624
904,4320624,peak FEV1,Abediterol,salbutamol,No significant difference,"Abediterol 0.625, 1.25, and 2.5 ?g had similar magnitude of peak FEV1 effect to salbutamol.",4320624
905,4320624,Dose-dependent changes from baseline in trough FEV1,Abediterol,placebo,Significantly increased,"Dose-dependent changes from baseline in trough FEV1 versus placebo were 0.219 (95% CI 0.136, 0.302) to 0.400 L (95% CI 0.317, 0.483) for abediterol 0.313 to 2.5 ?g, respectively (p?<?0.0001).",4320624
906,4320624,"Change from baseline in normalized FEV1 AUC0–6, FEV1 AUC0–12, and FEV1 AUC0–2",Abediterol,placebo,Significantly increased,"Change from baseline in normalized FEV1 AUC0–6, FEV1 AUC0–12, and FEV1 AUC0–24 was significantly higher for all doses of abediterol versus placebo (p?<?0.0001 for all, Table 2), with dose-related effects observed.",4320624
907,5816054,The duration of nebulization,furosemide,0.9% saline,No significant difference,"The duration of nebulization was not significantly different across treatments: 0.9% saline, 35.7 ± 1.0 min; 40 mg furosemide, 36.4 ± 1.2 min; and 120 mg furosemide, 39.2 ± 1.1 min (p = 0.075).",5816054
908,5816054,"breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments.",furosemide,0.9% saline,No significant difference,"The relative contributions of breathlessness [0.9% saline, 41.9 ± 3.4%; 40 mg furosemide, 40.2 ± 3.6%; 120 mg furosemide, 39.4 ± 4.0% (p = 0.876)], leg discomfort [0.9% saline, 55.4 ± 4.1%; 40 mg furosemide, 54.4 ± 4.2%; 120 mg furosemide, 51.7 ± 4.6% (p = 0.746)] and chest tightness [0.9% saline, 2.4 ± 1.5%; 40 mg furosemide, 0.8 ± 0.8%; 120 mg furosemide, 6.0 ± 3.3% (p = 0.170)] to exercise cessation were not significantly different across treatments.",5816054
909,2774638,Estimation of total daily calcium intake,calcium-focused food frequency questionnaire (CFFFQ),24-hour recall,Significantly increased,"The CFFFQ estimated greater total daily calcium intake than did the 24-hour recall (mean [SD], 1,021 [624] mg/d vs 800 [433] mg/d, P < .001).",2774638
910,2774638,Estimation of underreported calcium as daily calcium intake increased,calcium-focused food frequency questionnaire (CFFFQ),24-hour recall,Significantly decreased,"As daily calcium intake increased, the 24-hour recall increasingly underreported calcium (r = 0.41, P < .001) compared with the CFFFQ.",2774638
911,2774638,obtained calcium from dairy ,white women,black women,Significantly increased,"White women obtained more calcium (630 [423] mg) from dairy than did black women (424 [373] mg, P < .004).",2774638
912,2774638,difference in mean (SD) dairy calcium,white women,black women,Significantly increased,"Calcium from grains primarily came from fortified foods. Dairy was also the primary calcium source when the 24-hour recall data were analyzed, and a significant difference in mean (SD) dairy calcium intake between racial groups was found (243 [273] mg for black women, 444 [360] mg for white women, P < .001).",2774638
913,4713214,catheter related bladder discomfort During the first three days of post-operative period,"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.",no treatment before operation.,Significantly decreased,"During the first three days of post-operative period, the incidence of patients' CRBD was lower in Group I than that in Group II (25% vs. 75%, P=0.001, Fisher's exact test).",4713214
914,4713214,required tolterodine,"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.",no treatment before operation.,Significantly decreased,"Finally, less patients in RTX group required tolterodine, compared with control, P=0.009.",4713214
915,4713214,catheter related bladder discomfort On the fifth day after surgery,"received, intravesically, 40 mL of 20 nM Resiniferatoxin 20 hours before operation.",no treatment before operation.,No significant difference,"On the fifth day after surgery, although the incidence of CRBD was still lower in Group I than that in Group II (50% vs. 75%), there was no significant difference between them (P=0.135, Fisher's exact test).",4713214
916,5332489,"International Prostate Symptom Score (IPSS),  BPH Impact Index (BII), question 8 of the IPSS (IPSS-Q8)]",fixed-dose combination (FDC) of dutasteride and tamsulosin,watchful waiting (WW),No significant difference,"The adjusted mean decrease in IPSS, BII and IPSS-Q8 at each post-baseline visit over 24 months appeared greater in the FDC (n = 369) and WW-no treatment groups (n = 144) than in the WW-TAM group (n = 229)",5332489
917,3616124,risk of the primary outcome or preeclampsia,daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery.,placebo from 9-16 weeks gestation until delivery.,No significant difference,Vitamin supplementation did not reduce the risk of the primary outcome or preeclampsia in women of any phenotype.,3616124
918,3616124,preeclampsia risk  in Hispanic Hp 2-2 women.,daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery.,placebo from 9-16 weeks gestation until delivery.,Significantly increased,"Hispanic 2-2 women who were not taking prenatal vitamins at randomization had a smaller increase in preeclampsia risk with supplementation than Hispanic 2-2 women who were taking prenatal vitamins at randomization (2.01; 0.80–5.01, p?=?0.14 vs. 7.83; 2.01–30.53, p<0.01, Table 4).",3616124
919,3616124,preeclampsia risk,"Haptoglobin’s (Hp)  1-1, 2-1, ",Haptoglobin’s (Hp) 2-2 phenotypes,No significant difference,"Hp phenotype does not influence preeclampsia risk, or identify a subset of women who may benefit from vitamin C and E supplementation to prevent preeclampsia.",3616124
920,3015551,The mean time to remove both tubal segments,undergo a tubal resection after Pomeroy ligation,undergo a tubal resection after bipolar coagulation with Kleppinger forceps,No significant difference,"The mean time to remove both tubal segments was not different between techniques (7 minutes, 21 seconds; range, 4 minutes, 25 seconds to 15 minutes, 43 seconds).",3015551
921,3015551,Postoperative pain at 6 hours,undergo a tubal resection after Pomeroy ligation,undergo a tubal resection after bipolar coagulation with Kleppinger forceps,No significant difference,"Pain at incision sites or in the pelvis was described by the patient as being usually mild or moderate 6 hours postoperatively (mean score: 4.6 out of 10 for ligation, 4.0 of 10 for coagulation) except in 6 patients (ligation 4, coagulation 2) that required overnight admission for parenteral morphine or meperidine.",3015551
922,3015551,Outpatient recovery,undergo a tubal resection after Pomeroy ligation,undergo a tubal resection after bipolar coagulation with Kleppinger forceps,No significant difference,"Outpatient recovery was the same, unless pelvic pain required overnight observation (ligation, 4 patients; coagulation, 2 patients).",3015551
923,5295802,cytokine levels at baseline,levocarnitine,placebo,No significant difference,"There was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown).",5295802
924,5295802,IFN-? and VEGF in depression patients,after intervention,before intervention,Significantly decreased,IFN-? (p=0.005) and VEGF (p=0.045),5295802
925,5295802,"all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF)",after intervention,before intervention,Significantly decreased,"Among 101 analyzable patients, all ten cytokines/growth factors examined were highly elevated at baseline and all significantly decreased at week 4 (p<0.001) regardless of treatment intervention.",5295802
926,3220090,thickness of the keratinized tissue (TKT),coronally positioned flap (CPF) with acellular dermal matrix allograft (ADMA).,coronally positioned flap (CPF) without acellular dermal matrix allograft (ADMA).,Significantly increased,"However, on comparison between the test and control group, only TKT parameter showed statistically significant result, indicating that acellular dermal matrix has significantly contributed to the thickness in the test group.",3220090
927,4192987,17-hydroxy progesterone and testosterone levels,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 09.00-10.00 pm ,No significant difference,The three different regimens were found to be similar in their ability to control 17-hydroxyprogesterone and testosterone levels.,4192987
928,4192987,Median 17-hydroxy progesterone and testosterone levels,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm,10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm.,No significant difference,Serum 17-hydroxyprogesterone and testosterone values at the end of 3 different treatment regimens of the thirteen patents studied are shown in Table 4.,4192987
929,4183415,patient adherence,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,No significant difference,There was no difference in patient adherence between arms (Table 6).,4183415
930,4183415,Completed treatment,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,No significant difference,"Completed treatment was 70% in the control arm and 68% in the intervention arm (adjusted risk ratio [aRR] = 0.96 [95% CI: 0.82, 1.1]; p [adjusted] = 0.6), with a similar percentage of patients adherent to each of the four age-appropriate blister packs and no important differences between arms.",4183415
931,4183415,completion of each dose at the correct time,receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL).,no text message,No significant difference,"or as completion of each dose at the correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9). Further studies on the potential of text messages to improve adherence are needed.",4183415
932,5462761,cold perception thresholds,"2?mA anodal tDCS, when applied for 15?min over the motor cortex",baseline,Significantly increased,"In details, 15?minutes 2?mA anodal tDCS induced a significant increase in cold perception thresholds immediately after the end of the stimulation (p?=?0.039) (see Fig. 3).Figure 3",5462761
933,5462761,"cold perception threshold, warm perception threshold, cold pain threshold and heat pain threshold",2?mA anodal tDCS when applied over the Pcor for 15?minutes,baseline,No significant difference,"Moreover, 2?mA anodal tDCS when applied over the Pcor for 15?minutes induced no significant changes in all the studied parameters (one-way follow-up ANOVA for cold perception: F(2,18)?=?3,33; p?=?0.058), we only observed a tendency to increase the cold perception (Baseline vs Post 25; p?=?0.058).",5462761
934,4264479,blood-stage infection,"aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge)",nothing,Significantly increased,All participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR).,4264479
935,4264479,blood-stage infection,definitely exposed volunteers for both antigens ,minimally exposed volunteers for both antigens,Significantly increased,A significant difference was seen between minimally and definitely exposed volunteers for both antigens (Anti-schizont = p ? 0.0001; Anti-MSP2 = p = 0.006; Mann–Whitney test).,4264479
936,4918678,Writing,soundfield amplification devices in the classroom,nothing,No significant difference,"Between groups	t(28)=.59,	P=.561	F(1,17)=1.33,	P=.265",4918678
937,4918678,Reading,soundfield amplification devices in the classroom,nothing,No significant difference,"Between groups	t(28)=.39,	P=.702	F(1,17)=.04,	P=.841",4918678
938,4918678,Arithmetic,soundfield amplification devices in the classroom,nothing,No significant difference,"Between groups	t(28)=.89,	P=.383	F(1,17)=1.19,	P=.291",4918678
939,4918678,Silent reading,soundfield amplification devices in the classroom,nothing,No significant difference,"Between goups	t(28)=1.44,	P=.167	F(1,17)=1.02,	P=.327",4918678
940,4918678,Oral reading,soundfield amplification devices in the classroom,nothing,No significant difference,"between goups	t(28)=.62,	P=.541	F(1,17)=.06,	P=.812",4918678
941,3039191,the result of frequency doubling technique (FDT) perimetry.,"IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL)",clear IOL was used as a control.,No significant difference,"There were no statistically significant differences for MD and PSD between the clear IOL and Hoya YA60BBR IOL groups (MD: clear IOL, -5.09 ± 4.72 Db; Hoya YA60BBR IOL, -3.68 ± 3.83 dB; p = 0.21 / PSD: clear IOL, 4.26 ± 2.45 dB; Hoya YA60BBR IOL, 3.81 ± 1.99; p = 0.27, Mann-Whitney U-test). There were no statistically significant differences for MD and PSD the clear IOL and Alcon SN60WF IOL groups (MD: clear IOL, -5.09 ± 4.72 dB; Alcon SN60WF IOL, -2.47 ± 2.61 dB; p = 0.11 / PSD: clear IOL, 4.26 ± 2.45 dB; Alcon SN60WF IOL, 3.28 ± 1.23 dB; p = 0.22, Mann-Whitney U-test). No statistically significant differences were observed between the two types of yellow IOL groups (MD: Hoya YA60BBR, -3.68 ± 3.83 dB; Alcon SN60WF, -2.47 ± 2.61 dB; p = 0.33 / PSD: Hoya YA60BBR, 3.81 ± 1.99 dB; Alcon SN60WF, 3.28 ± 1.23; p = 0.56, Mann-Whitney U-test).",3039191
942,5551012,"birthweight, incidence of congenital birth defect and mean Apgar scores",antibiotics,no antibiotics,No significant difference,"Intrapartum antibiotic exposure did not significantly affect the birthweight, incidence of congenital birth defect and mean Apgar scores.",5551012
943,5551012,mean Apgar,antibiotics in less than 24 h to parturition,no antibiotics,Significantly decreased,"when mothers were treated with antibiotics in less than 24 h to parturition, there was a statistically significant decrease in mean Apgar than those not treated with antibiotics i.e. (7.86 ± 1.72 vs 8.4 ± 1.30 p = 0.002, F = 13.65) after adjusting for the effects of the mode of delivery.",5551012
944,5504551,physical activity ,awareness of wearing an accelerometer (nonblinded group),no awareness of wearing an accelerometer (blinded group),No significant difference,the awareness of wearing an accelerometer has no influence on physical activity patterns in young people.,5504551
945,5504551,The duration of wearing the accelerometer,awareness of wearing an accelerometer (nonblinded group),no awareness of wearing an accelerometer (blinded group),No significant difference,"The duration of wearing the accelerometer did not differ between the 2 groups for the overall 4-day-period, nor did it differ after separating school days from school-free days.",5504551
946,4693888,"Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group)",Custodiol-N,Custodiol,No significant difference,"Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group) was similar in both groups.",4693888
947,4693888,peak CKMB,Custodiol-N,Custodiol,Significantly decreased,"Although the trial was designed for non-inferiority, peak CKMB (52 ± 40 vs. 41 ± 30 U/l, superiority p < 0.002) was significantly lower in the Custodiol-N group.",4693888
948,4693888,CKMB AUC and Troponin-T AUC,Custodiol-N,Custodiol,No significant difference,"CKMB AUC (878 ± 549 vs. 778 ± 439 h*U/l, non-inferiority p < 0.001) and Troponin-T AUC (12990 ± 8347 vs. 13498 ± 6513 h*pg/ml, non-inferiority p < 0.001) was similar in both groups.",4693888
949,3278655,maximum total point motion (MTPM),The trabecular metal tibial monoblock component (TM),cemented component.,No significant difference,"At the 5-year follow-up, there was no difference in MTPM between the cemented group and the trabecular metal group (p = 0.9)",3278655
950,3278655,subsidence,The trabecular metal tibial monoblock component (TM),cemented component.,Significantly increased,The TM components had significantly greater subsidence than the cemented components (p = 0.001).,3278655
951,3278655,The proportion of “at risk” components at 5 years,The trabecular metal tibial monoblock component (TM),cemented component.,No significant difference,The proportion of “at risk” components at 5 years was 2 of 18 in the cemented group and 0 of 27 in the TM group (p = 0.2).,3278655
952,3597472,"the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice","The routine interventions included praziquantel chemotherapy and controlling snails plus new interventions, mainly consisting of building fences to limit the grazing area for bovines, building safe pastures for grazing, improving the residents' health conditions and facilities,","The routine interventions included praziquantel chemotherapy and controlling snails,",Significantly decreased,"Results showed that the rate of S. japonicum infection in humans, bovines, snails, cow dung and mice in the intervention group decreased from 3.41% in 2008 to 0.81% in 2011, 3.3% to none, 11 of 6,219 to none, 3.9% to none and 31.7% to 1.7%, respectively (P<0.001 for all comparisons).",3597472
953,3597472,infection risk in humans,"The routine interventions included praziquantel chemotherapy and controlling snails plus new interventions, mainly consisting of building fences to limit the grazing area for bovines, building safe pastures for grazing, improving the residents' health conditions and facilities,","The routine interventions included praziquantel chemotherapy and controlling snails,",Significantly decreased,"The generalized linear model (Table 3), yielding odds ratios (OR) adjusted for participants' age and gender, showed a higher infection risk in humans in the control villages than the intervention villages (OR?=?1.250, P?=?0.001); and an overall significant downward trend in infection risk during the study period.",3597472
954,3330821,Beck Depression Inventory-II (BDI-II) after 4 months,trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP),Employee Assistance Program,Significantly decreased,"The BDI-II scores fell from the mean of 17.3 at baseline to 11.0 in the intervention group and to 15.7 in the control group after 4 months (p<0.001, Effect size?=?0.69, 95%CI: 0.32 to 1.05).",3330821
955,3330821,absolute and relative presenteeism,trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP),Employee Assistance Program,No significant difference,"However, there was no statistically significant decrease in absolute and relative presenteeism (p?=?0.44, ES?=?0.15, ?0.21 to 0.52, and p?=?0.50, ES?=?0.02, ?0.34 to 0.39, respectively).",3330821
956,3330821,The overall satisfaction score,trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP),Employee Assistance Program,Significantly increased,The overall satisfaction score for the services was 3.57 (3.31 to 3.81) for the EAP alone group and 4.42 (4.17 to 4.67) for the tCBT +EAP group (p<0.001).,3330821
957,4803984,the frequency of Apgar score?8 in the first and 5th minutes ,supportive care or acupuncture group,control groups,Significantly increased,"The lowest mean lengths of the first and second stages of labor (157.0±29.5 and 58.9±25.8, respectively) were related to the supportive care group, while the highest mean lengths (281.0±79.8 and 128.4±44.9, respectively) were observed in the control group (Table 1).Table 1",4803984
958,4803984,The mean length of the first and second stages of labor,supportive care or acupuncture group,control groups,Significantly decreased,"The mean length of the first and second stages of labor was respectively 157.0±29.5 and 58.9±25.8 minutes in the supportive care group, 161.7±37.3 and 56.1±31.4 minutes in the acupressure group, ad 281.0±79.8 and 128.4±44.9 minutes in the control group.",4803984
959,2656477,self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors.,lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification,usual care,Significantly increased,There was a significant improvement for self-efficacy related to social pressure (p = .03) and restraint (p = .02) in the LI group.,2656477
960,2656477,"emotional well-being quality of life, self-efficacy related to negative emotions, food availability in overweight and obese endometrial cancer survivors.",lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification,usual care,Significantly increased,"There was a significant difference for emotional well-being quality of life (p = .02), self-efficacy related to negative emotions (p < .01), food availability (p = .03), and physical discomfort (p = .01) in women who lost weight as compared to women who gained weight.",2656477
961,2656477,depression,lost weight,no weight lost,Significantly decreased,Women who lost weight had improvement in depression (2.3 versus 1.2) and TFEQ restraint score (2.8 versus 0.1).,2656477
962,4889691,return of spontaneous circulation (ROSC),AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),Significantly increased,the ROSC rate was significantly higher in the AutoPulse CPR group than in the Manual CPR group (44.9% vs. 23.4%; p = 0.009).,4889691
963,4889691,The 24-h survival rate of OHCA,AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),Significantly increased,The 24-h survival rate of OHCA patients was significantly higher in the AutoPulse CPR group than in the Manual CPR group (39.1% vs. 21.9%; p = 0.03).,4889691
964,4889691,The hospital discharge rate of the patients with OHCA,AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),Significantly increased,The hospital discharge rate of the patients with OHCA was significantly higher in the AutoPulse CPR group than in the Manual CPR group (18.8% vs. 6.3%; p = 0.03).,4889691
965,4889691,The proportion of patients with OHCA and a cerebral performance category score of 1 or 2 points at hospital discharge ,AutoPulse automated chest compression device,manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA),No significant difference,"The proportion of patients with OHCA and a cerebral performance category score of 1 or 2 points at hospital discharge was higher in the AutoPulse CPR group than in the Manual CPR group, but the difference was not statistically significant (16.2% vs. 13.4%, p = 1.00).",4889691
966,5372931,14 (poly)phenol metabolites,cranberry juices,nothing,Significantly increased,14 (poly)phenol metabolites displayed a linear dose-response curve (r2 ? 0.89) in plasma (Figure 1) with slopes significantly different from zero (p < 0.05):,5372931
967,5372931,"flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes ",cranberry juices,nothing,Significantly increased,"Linear regression analysis was performed between the TP level in the intervention and the AUC of each class of compounds. The AUC for flavonols produced the highest r2 (0.97, p < 0.001), followed by the valerolactones (r2 = 0.89, p < 0.005), benzoic acids (r2 = 0.85, p < 0.01), cinnamic acids (r2 = 0.72, p < 0.05), phenylacetic acids (r2 = 0.71, p < 0.05), benzaldehydes (r2 = 0.65, p < 0.05)",5372931
968,5372931,12 (poly)phenol metabolites,cranberry juices,nothing,Significantly increased,"A positive, linear dose response for total excretion over 24 h of each urinary metabolite was assessed and of the 60 identified metabolites, 12 (poly)phenol metabolites displayed a positive linear dose-response curve (r2 ? 0.66) in urine with slopes significantly different from zero (p < 0.05)",5372931
969,3491047,Short-term adherence to the program at 3 months,Walking and Behavioural intervention (WB),Self-directed control (C),Significantly increased,Statistically significant results for short-term adherence rates favoured participants in the WB group (80.2%) compared to the self-directed (C) group (65.2%) (p&lt;0.012) after 3 months.,3491047
970,3491047,Long-term adherence to the program,Walking and Behavioural intervention (WB),Self-directed control (C),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
971,3491047,Total adherence to the program,Walking and Behavioural intervention (WB),Self-directed control (C),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
972,3491047,Long-term adherence to the program,Walking and Behavioural intervention (WB),Walking intervention (W),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
973,3491047,Total adherence to the program,Walking and Behavioural intervention (WB),Walking intervention (W),No significant difference,"No statistical significance (p&gt; 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.",3491047
974,3798949,Treatment cost,"Academic, non-commercial sponsored trials",Commercial sponsored trials,Significantly increased,The average TC for 27 non-commercial trials was an excess of £431 (range £6393 excess to £6005 saving) and for 26 commercial trials was an average saving of £9294 (range £0 to £71?480).,3798949
975,3798949,Savings in drugs and dispensing costs,"Academic, non-commercial sponsored trials",Commercial sponsored trials,Significantly decreased,"In general, it can be seen that both commercial and non-commercial trials saved drug costs, whereas the extent of drug and dispensing cost savings was markedly higher for commercial compared with non-commercial trials.",3798949
976,3798949,Extra clinic visits and CT scans assessments,"Academic, non-commercial sponsored trials",Commercial sponsored trials,Significantly decreased,"The contribution of extra clinic visits and investigations, in particular CT scans used for response assessment, was significantly higher for commercial compared with non-commercial trials.",3798949
977,5619630,Improvement in the Hamilton Rating Scale for Depression at 12 weeks,Medication plus exercise,Medication only,Significantly increased,"The medication-plus-exercise group showed a greater improvement in HRSD scores (change in score from baseline) than the medication-only group from the first follow-up, at 6 weeks, and this difference became statistically significant at weeks 12 (P = 0.04, t = 2.10) and 24 (P = 0.02, t = 2.42)",5619630
978,5619630,Improvement in the Hamilton Rating Scale for Depression at 24 weeks,Medication plus exercise,Medication only,Significantly increased,"The medication-plus-exercise group showed a greater improvement in HRSD scores (change in score from baseline) than the medication-only group from the first follow-up, at 6 weeks, and this difference became statistically significant at weeks 12 (P = 0.04, t = 2.10) and 24 (P = 0.02, t = 2.42)",5619630
979,5619630,Improvement in Presumptive Stressful Life Events Scale,Medication plus exercise,Medication only,No significant difference,there was no significant difference between the groups’ PSLES scores at any follow-up point.,5619630
980,5619630,Relapse rates,Medication plus exercise,Medication only,No significant difference,"In total, nine patients relapsed, two from the medication-plus-exercise group (both in week 18) and seven from the medication-only group (one relapse in week 6, two in week 12 and four in week 24). This difference in relapse rates did not reach significance (Fisher’s exact test: one-tailed, P = 0.07; two-tailed, P = 0.14).",5619630
981,5490116,Glucometric random blood sugar at 24 hours,"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)",Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C),Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P &lt; 0.005) higher in Group B compared to Groups A and C at 24 h,5490116
982,5490116,Mean visual analog scale,"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)",Ropivacaine 0.2% alone (Group A) ,Significantly decreased,"VAS scores were significantly lower in Groups B and C at 8 h, 12 h, and 24 h compared to Group A.",5490116
983,5490116,Mean visual analog scale,Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C),Ropivacaine 0.2% alone (Group A) ,Significantly decreased,"VAS scores were significantly lower in Groups B and C at 8 h, 12 h, and 24 h compared to Group A.",5490116
984,5490116,Glucometric random blood sugar at 24 hours,"Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B)",Ropivacaine 0.2% alone (Group A),Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P &lt; 0.005) higher in Group B compared to Groups A and C at 24 h,5490116
985,5062220,Time to tracheal extubation,Bispectral index (BIS) guided anesthesia,Standard end-tidal anesthetic gas (ETAG) guided anesthesia,Significantly increased,"Mean time to tracheal extubation was significantly longer in BIS group (9.63 ± 3.02 min) as compared to ETAG group (5.29 ± 1.51 min), mean difference 4.34 min with 95% confidence interval (3.106, 5.982) (P &lt; 0.05).",5062220
986,5062220,Perioperative complications,Bispectral index (BIS) guided anesthesia,Standard end-tidal anesthetic gas (ETAG) guided anesthesia,No significant difference,"All the patients were extubated in the operating room, and no significant complication was noted during perioperative period in any patient.",5062220
987,2920262,Improvement in HAD anxiety score,Singing classes,Usual care,Significantly increased,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03.,2920262
988,2920262,Improvement in SF-36 physical component score,Singing classes,Usual care,Significantly increased,"In singers, there was a significant improvement in HAD anxiety score -1.1(2.7) vs. +0.8(1.7) p = 0.03 and SF-36 physical component score +7.5(14.6) vs. -3.8(8.4) p = 0.02.",2920262
989,2920262,Breath hold time,Singing classes,Usual care,Significantly decreased,Breath hold time actually increased in the control group relative to the singing group -0.3(6.9) sec vs. +5.3(5.7) sec (p = 0.03).,2920262
990,2920262,Single breath counting and functional exercise capacity,Singing classes,Usual care,No significant difference,"There was no significant difference in single breath counting, functional exercise capacity or recovery times following ISWT",2920262
991,2920262,Recovery time after incremental shuttle walk test,Singing classes,Usual care,No significant difference,"There was no significant difference in single breath counting, functional exercise capacity or recovery times following ISWT",2920262
992,3074545,Changes in total Composite Abuse Scale score,Non-professional mentor support,Non-mentored group,Significantly increased,"The adjusted difference in the total CAS score from baseline was greater in the mentored compared with the non-mentored arm (Adj Diff = -8.67, range -16.2 to -1.15), but the evidence for this difference was weaker after PS adjustment.",3074545
993,3074545,Depression mean scores,Non-professional mentor support,Non-mentored group,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.",3074545
994,3074545,Use of health care services,Non-professional mentor support,Non-mentored group,No significant difference,There were no significant differences in use of health care services between groups over the 12 month follow-up period.,3074545
995,3074545,Improvements in physical and mental wellbeing,Non-professional mentor support,Non-mentored group,Significantly increased,"There was weak evidence for a difference between the intervention and comparison arms in general wellbeing improvements at follow-up, while mean adjusted differences on both the Mental and Physical Components Scores (MCS and PCS) favoured the intervention arm.",3074545
996,3074545,Changes in total Composite Abuse Scale score,Non-professional mentor support,Non-mentored group,Significantly increased,"The adjusted difference in the total CAS score from baseline was greater in the mentored compared with the non-mentored arm (Adj Diff = -8.67, range -16.2 to -1.15), but the evidence for this difference was weaker after PS adjustment.",3074545
997,3074545,Depression mean scores,Non-professional mentor support,Non-mentored group,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.",3074545
998,3074545,Use of health care services,Non-professional mentor support,Non-mentored group,No significant difference,There were no significant differences in use of health care services between groups over the 12 month follow-up period.,3074545
999,3074545,Improvements in physical and mental wellbeing,Non-professional mentor support,Non-mentored group,Significantly increased,"There was weak evidence for a difference between the intervention and comparison arms in general wellbeing improvements at follow-up, while mean adjusted differences on both the Mental and Physical Components Scores (MCS and PCS) favoured the intervention arm.",3074545
1000,3878029,Smoking status,Hypnotherapy,Relaxation,No significant difference,The intervention had no effect on smoking status (p =?.73),3878029
1001,3878029,Cigarettes smoked per day,Hypnotherapy,Relaxation,No significant difference,The intervention had no effect on smoking status (p =?.73) or on the number of cigarettes smoked per day (p =?.56).,3878029
1002,3878029,Smoking abstinence after 2 weeks,Hypnotherapy,Relaxation,No significant difference,"At the two-week follow-up, 38 (33.3%) of the participants in the hypnosis group and 26 (24.5%) of those in the relaxation group reported smoking abstinence in the previous seven days. The effect of the intervention was not significant (OR =?1.73, SE =?0.60, 95% CI [0.84, 3.57], t =?1.58, p =?.13).",3878029
1003,3878029,Adverse reactions,Hypnotherapy,Relaxation,No significant difference,Both interventions produced few adverse reactions (p =?.81).,3878029
1004,3442969,Disease control rates,FUFOX,CAPOX,No significant difference,"Disease control rates (DCR) were 77%, 81% and 88%, respectively, which was not statistically significant (Table3, p?=?0.29).",3442969
1005,3442969,Median progression-free survival,FUFOX,CAPOX,No significant difference,"The median PFS in all patients of the KRAS subcohort was not statistically different in relation to the KRAS mutational status (wild type: 7.5?months, mutation codon 12: 8.2?months, mutation codon 13: 10.0?months; p?=?0.71)",3442969
1006,3442969,Overall survival,FUFOX,CAPOX,No significant difference,"Evaluating the different treatment arms separately, we found comparable survival times without significant differences",3442969
1007,3442969,Progression-free survival in patients with codon 13 mutations,FUFOX,CAPOX,Significantly decreased,"Interestingly, we found a substantial difference in PFS between patients with codon 12 and 13 mutant tumors when looking at infusional 5-FU versus capecitabine based regimens. Patients with codon 13 mutations seem to benefit more in terms of PFS from the oral capecitabine based protocols.",3442969
1008,5003313,Symptom severity after 8 weeks ,Stretching exercises,No exercises,Significantly decreased,The symptom severity of this syndrome meaningfully changed eight weeks after intervention in the intervention group compared to the control group (P &lt; 0.001).,5003313
1009,5003313,Symptom severity after 4 weeks ,Stretching exercises,No exercises,Significantly decreased,the results of t-test show that the changes in the severity of RLS symptoms before intervention and after 4 weeks were not statistically meaningful between intervention and control groups.,5003313
1010,5018157,Risk of hypotension,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,Significantly decreased,"The incidence rate of hypotension in the preeclamptic patients (55.8%) was less than that of the healthy parturients (89.2%) (Table 2), despite the former receiving smaller volumes of intravenous fluids (2.4 versus 2.5 lit) (Table 1) (P = 0.001).",5018157
1011,5018157,IV ephedrine total dosage,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,Significantly decreased,The total doses of IV ephedrine for treating hypotension were significantly lower among the preeclamptic patients (3.2 mg in preeclamptic patients versus 7.6 mg in normotensive patients) (P = 0.02).,5018157
1012,5018157,One-minute Apgar score,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,Significantly decreased,The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 ± 0.7 versus 7.2 ± 1.5) (P = 0.001),5018157
1013,5018157,Five-minute Apgar score,Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients,Low-dose bupivacaine spinal anesthesia in healthy parturients,No significant difference,there was no significant difference in the five-minute Apgar scores between the two groups.,5018157
1014,5101425,Thrombocytopenia rate,Desmopressin,Placebo,Significantly decreased,The analysis revealed that the rate of thrombocytopenia after surgery was higher in the control group (P = 0.012).,5101425
1015,5101425,Bleeding rate after surgery,Desmopressin,Placebo,No significant difference,No significant difference was noted between the groups regarding the rate of bleeding after surgery (359.3 ± 266.2 in group D vs. 406.3 ± 341.6 in group P (control group); P = 0.208).,5101425
1016,5101425,Complications,Desmopressin,Placebo,No significant difference,"there was no significant difference between the groups regarding the outbreak of complications such as nausea, vomiting, blood pressure alteration, and the amount of bleeding (P &gt; 0.05).",5101425
1017,5101425,Hb levels,Desmopressin,Placebo,No significant difference,"the Hb levels decreased significantly in each group after surgery (P = 0.0001), but the difference was not statistically significant between the groups (0.134).",5101425
1018,3159986,Improvement in myasthenia score,Respiratory muscle endurance training,Baseline characteristics,Significantly increased,Myasthenia score improved from 0.71 ± 0.1 to 0.56 ± 0.1 (P = 0.007).,3159986
1019,3159986,Improvement in respiratory endurance,Respiratory muscle endurance training,Baseline characteristics,Significantly increased,Respiratory endurance time increased from 6.1 ± 0.8 to 20.3 ± 3.0 min (P &lt; 0.001).,3159986
1020,3159986,Lung function parameters,Respiratory muscle endurance training,Baseline characteristics,No significant difference,"RMET induced mild but not significant increases in VC (P1: 95.9 ± 3.5%, P4: 99.2 ± 4.1%, P = 0.39), FEV1 (P1: 93.1 ± 2.7%, P4: 96.3 ± 3.8%, P = 0.28), PEF (P1: 90.0 ± 4.8%, P4: 95.7 ± 5.4%, P = 0.07), MVV (P1: 95.6 ± 6.0%, P4: 101.0 ± 6.5%, P = 0.24), and PImax (P1: 79.2 ± 5.4%, P4: 78.0 ± 6.4%, P = 0.42)",3159986
1021,4895766,Adverse reactions,Katupila Kalka with Tila Taila,Betadine ointment,No significant difference,"In both the groups, no patients reported any adverse drug reaction during the entire course of treatment as well as in follow-up period.",4895766
1022,4895766,Healing of diabetic wounds,Katupila Kalka with Tila Taila,Betadine ointment,Significantly increased,"In Group A, diabetic wounds treated with Katupila paste got healed within 28 days with minimal scar formation without any complications, whereas in Group B, wound was healed completely only in two patients within 28 days.",4895766
1023,4895766,Control of foul smell,Katupila Kalka with Tila Taila,Betadine ointment,Significantly increased,"foul smell was controlled after 3 days in Group A patients, which was found statistically significant (P &lt; 0.001). In Group B, foul smell from ulcer continues until the wound was healed",4895766
1024,4895766,Control of infection,Katupila Kalka with Tila Taila,Betadine ointment,No significant difference,Both drugs have shown statistically highly significant (P &lt; 0.001) result in controlling infection.,4895766
1025,4486943,Programme engagement,Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20,Standard quitline treatment,Significantly increased,"Programme engagement was measured as the number of counselling calls completed by participants:1 planned programme counselling calls,2 participant-initiated inbound calls, or3 IVR-transferred counselling calls (table 2). Overall, the average number of total calls completed was 3.9 (SD=1.7; range 2–19). There was a statistical difference between groups; the TEQ-10 and TEQ-20 groups completed slightly more calls than the standard study group due to the additional IVR-transferred counselling calls they received after a positive screen (p&lt;0.001).",4486943
1026,4486943,Number of positive screens,Technology Enhanced Quitline-10 ,Technology Enhanced Quitline-20,Significantly decreased,"There was a statistical difference in the number of positive screens between the two intervention groups, with TEQ-20 having slightly more positive screens than TEQ-10 (on average, 1.52 (SD=1.66) for TEQ-10 and 1.82 (SD=1.99) for TEQ-20, p=0.003).",4486943
1027,4486943,Time to relapse,Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20,Standard quitline treatment,No significant difference,There was no significant association between time to relapse and randomisation group,4486943
1028,4486943,Tobacco abstinence,Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20,Standard quitline treatment,No significant difference,there were no differences in tobacco abstinence rates between the control (standard QFL) and technology-enhanced (IVR-delivered risk assessments and transfer for counselling) groups at 6-month and 12-month follow-up.,4486943
1029,4221638,Intracranial haemorrhage,Tranexamic acid,Placebo,No significant difference,Progressive intracranial haemorrhage was present in 21 (18%) of patients allocated to TXA and in 32 (27%) of patients allocated to placebo. The difference was not statistically significant [RR?=?0.65 (95% CI 0.40 to 1.05)].,4221638
1030,4221638,Risk of death,Tranexamic acid,Placebo,No significant difference,There were no significant difference in the risk of death from all causes in patients allocated to TXA compared with placebo [RR?=?0.69 (95% CI 0.35 to 1.39,4221638
1031,4221638,Risk of thromboembolic events,Tranexamic acid,Placebo,No significant difference,There was no evidence of increased risk of thromboembolic events in those patients allocated to TXA.,4221638
1032,4221638,Risk of unfavorable outcome on the Glasgow Outcome Score,Tranexamic acid,Placebo,No significant difference,There were no significant difference in the risk of death from all causes in patients allocated to TXA compared with placebo [RR?=?0.69 (95% CI 0.35 to 1.39)] and the risk of unfavourable outcome on the Glasgow Outcome Scale [RR?=?0.76 (95% CI 0.46 to 1.27)].,4221638
1033,4138383,Negative feelings,Self-referral treatment,Inpatient treatment,Significantly decreased,"Patients with a contract also expressed less resignation, hopelessness and powerlessness than patients without a contract.",4138383
1034,4138383,Self-confidence in applying methods to deal with mental illness,Self-referral treatment,Inpatient treatment,Significantly increased,One of the findings in the present study was that patients with a contract for self-referral described more confidence in applying coping strategies than patients without a contract.,4138383
1035,4138383,Patients striving for recovery,Self-referral treatment,Inpatient treatment,Significantly increased,"The findings in the present study indicate that patients who have had the opportunity to decide whether and when they needed referral to inpatient treatment are more actively pursuing recovery, both from and in mental illness.",4138383
1036,4588874,Baseline nicotine concentrations,E-cigarettes ,Conventional tobacco cigarette,No significant difference,"Baseline nicotine concentrations were below the limit of quantification in the majority of subjects and mean baseline nicotine concentrations were comparable across study products, all representing less than half the limit of quantification of 0.200&nbsp;ng/mL",4588874
1037,4588874,Urge to smoke,E-cigarettes ,Conventional tobacco cigarette,No significant difference,No statistically significant differences were found in the maximal smoking urge reduction parameters Emax0–30 and Emaxreduction0–30 (all differences within 11&nbsp;%) or the overall smoking urge reduction parameter AUEC0-30 (all differences within 21&nbsp;%) between the use of a single tobacco cigarette and each of the e-cigarettes during the controlled use period.,4588874
1038,4588874,Serious adverse events,E-cigarettes ,Conventional tobacco cigarette,No significant difference,There were no serious adverse events reported and no subjects were discontinued due to AEs.,4588874
1039,4588874,Level of exhaled CO,E-cigarettes ,Conventional tobacco cigarette,Significantly decreased,"Furthermore, it was also observed that the use of the e-cigarettes produced no increase the exhaled CO levels, whereas the cigarette significantly increased the exhaled CO more than eight (8) times above the baseline.",4588874
1040,4588874,Nicotine concentration after ad lib use,E-cigarettes ,Conventional tobacco cigarette,Significantly decreased,"Following ad lib use of all products for 60&nbsp;min, the tobacco cigarette yielded a significantly higher nicotine concentration (C90) compared to each of the e-cigarettes. T",4588874
1041,5746685,Weight rebound after 12 months,Enhanced weight loss maintenance program,Basic weight loss maintenance program,No significant difference,"There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group (mean: basic 1.3%, enhanced 1.5%)",5746685
1042,5746685,Change in body mass index,Enhanced weight loss maintenance program,Basic weight loss maintenance program,No significant difference,"There were no significant between-group differences in the primary outcome of change in BMI (basic ?0.5 (1.9) kg/m2, enhanced ?0.5 (1.6) kg/m2, p = 0.93).",5746685
1043,5746685,Attrition after 12 months,Enhanced weight loss maintenance program,Basic weight loss maintenance program,No significant difference,"There was no significant between-group difference in attrition after 12 months, basic 18.4% and enhanced 23.9%, p = 0.31.",5746685
1044,4748685,Systolic blood pressure,CAPSYS system,Standard care,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.",4748685
1045,4748685,LDL values,CAPSYS system,Standard care,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.",4748685
1046,4748685,Triglyceride levels,CAPSYS system,Standard care,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = –9 mmHg; p = 0.03; 95 % CI = [–17.29, –0.71]), LDL (pseudo-median of the differences = –7.9 mg/dl; p = 0.04; 95 % CI = [–18.5, –0.5]) and triglyceride values (pseudo-median of the differences = –12.5 mg/dl; p = 0.04; 95 % CI = [–26, –0.5]) in the intervention group, while no such changes could be observed in the control group.",4748685
1047,4748685,Self-reported consumption of fruits and vegetables,CAPSYS system,Standard care,Significantly increased,"Concerning the secondary dependent measures, we could observe the following statistically significant results:Increase of self-reported fruit and vegetable consumption in IC group (Wilcoxon signed-rank test: pseudo-median of the differences = 5.4 servings/week; p = 0.04; 95 % CI = [0.5, 10.5]; r = 0.26: medium effect size)",4748685
1048,4748685,Self-reported consumption of sweets,CAPSYS system,Standard care,Significantly decreased,"Furthermore, we detected a statistically significant increase in self-reported fruit and vegetable consumption (pseudo-median of the differences = 5.4 servings/week; p = 0.04; 95 % CI = [0.5, 10.5]) and a decrease in sweets consumption (pseudo-median of the differences = –2 servings/week; p = 0.04; 95 % CI = [–4, –0.00001]) in the intervention group.",4748685
1049,5089605,Improvement in patient?reported outcomes at the end of treatment,Golimumab plus?MTX,Placebo?plus MTX or Golimumab,No significant difference,Improvements from baseline to week 256 in patient?reported outcomes were generally similar among the treatment groups,5089605
1050,5089605,ACR20/50/70 response,Golimumab plus?MTX,Placebo?plus MTX or Golimumab,No significant difference,"Among all randomized patients in the GO?BEFORE trial, 72.8% of patients had an ACR20 response, 54.6% had an ACR50 response, and 38.0% had an ACR70 response at week 256 (when all patients were receiving golimumab), with no appreciable differences among the treatment groups.",5089605
1051,4075638,Decrease in symptoms among patients with low immature defense style after 1 year,Short-term psychotherapy,Long-term psychotherapy,Significantly increased,"During the first year of the follow-up, a statistically larger symptom reduction in the short-term therapy group than in the long-term therapy group (18–45% vs. 9–31%, respectively) was found among patients with low immature defense style according to all six outcome measures.",4075638
1052,4075638,Decrease in symptoms among patients with high immature defense style after 3 years,Short-term psychotherapy,Long-term psychotherapy,Significantly decreased,"At the end of the 3-year follow-up, on the other hand, a statistically larger symptom reduction in the long-term therapy group than in the short-term therapy group (26–64% vs. 21–45%, respectively) was found among patients with high immature defense style according to five outcome measures.",4075638
1053,4075638,Overall symptom reduction after 3 years,Short-term psychotherapy,Long-term psychotherapy,No significant difference,"During the 3-year follow-up, a statistically significant symptom reduction was found in all six outcome measures (BDI, HDRS, SCL-90-Anx, HARS, SCL-90-GSI, GAF) in both short-term and long-term therapy groups",4075638
1054,2223531,Median AUC(inf),Oral etoposide phosphate,Oral etoposide,No significant difference,The median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9). The difference in favour of etoposide phosphate was borderline significant: median 9.9 mg l(-1) h (95% CI 0.1-32.8 mg l(-1) h; P = 0.05).,2223531
1055,2223531,Toxicity,Oral etoposide phosphate,Oral etoposide,No significant difference,Toxicities of oral etoposide phosphate were not different from those known for etoposide,2223531
1056,2223531,Different section ,-,-,No significant difference,Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.,2223531
1057,3787573,Numerical Rating Scale,NMES plus exercise,Exercise alone,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63)",3787573
1058,3787573,Timed Up and Go test,NMES plus exercise,Exercise alone,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63)",3787573
1059,3787573,Western Ontario and McMaster Universities Osteoarthritis Index for pain,NMES plus exercise,Exercise alone,No significant difference,"No significant differences between groups were found on the pain, physical function, and stiffness subscales of the WOMAC index on ITT analysis.",3787573
1060,3787573,Western Ontario and McMaster Universities Osteoarthritis Index for physical function,NMES plus exercise,Exercise alone,No significant difference,"No significant differences between groups were found on the pain, physical function, and stiffness subscales of the WOMAC index on ITT analysis.",3787573
1061,3787573,Western Ontario and McMaster Universities Osteoarthritis Index for stiffness,NMES plus exercise,Exercise alone,No significant difference,"No significant differences between groups were found on the pain, physical function, and stiffness subscales of the WOMAC index on ITT analysis.",3787573
1062,5100099,Blood pH levels,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,No significant difference,"There were no statistically significant differences on blood pH levels between the two modes of ventilation (7.32?±?0.02 vs. 7.32?±?0.04, P?=?0.34).",5100099
1063,5100099,Peak inspiratory pressures,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,Significantly decreased,"Ventilation with NAVA delivered lower peak inspiratory pressures than with CV: -32.7&nbsp;% (95&nbsp;% CI: -48.2 to –17.1&nbsp;%, P?=?0.04)",5100099
1064,5100099,Systolic arterial pressure,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,Significantly increased,"With regard to hemodynamics, systolic arterial pressures were higher using NAVA: +8.4&nbsp;% (95&nbsp;% CI: +3.3 to +13.6&nbsp;%, P?=?0.03).",5100099
1065,5100099,Cardiac index improvement,Neurally Adjusted Ventilatory Assist,Conventional Ventilation,No significant difference,Cardiac index during NAVA compared to CV did not statistically differ.,5100099
1066,520750,"HAMD17 total score,",A mixed-effects model repeated measures approach (MMRM),analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA),Significantly increased,"In the case of the HAMD17 total score, advantages for duloxetine over placebo at endpoint (Week 9) from MMRM in Studies 1 and 2 were 4.86 (p &lt; .001) and 2.17 (p = .024), respectively.",520750
1067,520750, VAS overall pain,A mixed-effects model repeated measures approach (MMRM),analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA),Significantly increased,"For VAS overall pain, the advantage of duloxetine over placebo at endpoint from MMRM in Studies 1 and 2 were 5.88 (p = .055) and 4.40 (p = .135), respectively.",520750
1068,520750,Standard errors,A mixed-effects model repeated measures approach (MMRM),analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA),Significantly increased,Standard errors from LOCF_ANCOVA were approximately 5% smaller than the Week 9 standard errors from MMRM for both the HAMD17 total score and VAS overall pain.,520750
1069,4821226,clinical outcome,core decompression with the application of bone marrow aspirate concentrate,core decompression only,No significant difference,"However, there was no difference in the clinical outcome between the two study groups (Figures 1 and 2).",4821226
1070,4821226,femoral head necrosis (FHN),core decompression with the application of bone marrow aspirate concentrate,core decompression only,No significant difference,"n contrast to the clinical outcome, we could not perceive any significant change in the volume of FHN in both treatment groups related to the longitudinal course after treating (Figure 3). Again no statistically significant difference was detected between the groups.",4821226
1071,4821226,the head survival rate,core decompression with the application of bone marrow aspirate concentrate,core decompression only,No significant difference,"Over the period of two years there was no significant difference between the head survival rate of 8/14 (57%) in the control group, and 7/11 (64%) in the verum group. There was no difference between the two groups with regard to the interval between core decompression with or without BMAC application and THA.",4821226
1072,4821226,fibroblast colony forming units (CFU-Fs).,core decompression with the application of bone marrow aspirate concentrate,core decompression only,Significantly increased,"Table 2 shows the significant increase in the number of nucleated cells due to the centrifugation step. Additionally, the number of CFU that best represents the number of MSC shows a significant increase (Table 2).",4821226
1073,1562433,Maximum voluntary isometric contractions,knee extension at 90° of flexion,hip abduction at 0° and 30°,Significantly increased,"Maximum voluntary isometric contractions for knee extension at 90° of flexion resulted in a significantly higher EMG activity for the VMO muscle compared with hip abduction at 0° and 30° of abduction for both male (p &lt; 0.008) and female (p &lt; 0.0005) subjects (Table 1, Figure 5).",1562433
1074,1562433,vastus medialis obliquus (VMO) EMG activity ,knee extension at 90° of flexion,hip abduction at 0° and 30°,Significantly increased,Significantly higher VMO activity for both male and female subjects performing MVIC knee extension at 90° of flexion when compared to MVIC hip abduction at 0° and 30° of abduction.,1562433
1075,1562433,vastus lateralis longus (VLL) EMG activity,knee extension at 90° of flexion,hip abduction at 0° and 30°,No significant difference,VLL EMG activity without significant differences among the three exercises tested.,1562433
1076,1562433,vastus lateralis obliquus (VLO) EMG activity,knee extension at 90° of flexion,hip abduction at 0° and 30°,Significantly increased,Significantly higher VLO activity for male subjects was observed in MVIC knee extension at 90° of flexion compared with MVIC hip abduction at 0° and 30° of abduction and for female subjects performing MVIC knee extension at 90° of flexion when compared with MVIC hip abduction at 0° and 30° of abduction.,1562433
1077,4667210,"The intensity of the MSG symptom complex (characterized by unpleasant reactions such as numbness, tingling, headaches, muscle tightness, general weakness, and flushing )",Capsules (300 mg) containing Lactobacillus brevis G101 (1×1010 CFU/individual),maltodextrin (placebo),Significantly decreased,The intensity of the MSG symptom complex was significantly reduced in respondents of the G101 intake group (2.87 ± 0.73) compared to that in those treated with the placebo (3.63 ± 1.03) (P = 0.0016).,4667210
1078,4667210,the appearance time of the MSG symptom complex,Capsules (300 mg) containing Lactobacillus brevis G101 (1×1010 CFU/individual),maltodextrin (placebo),No significant difference,"Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo,",4667210
1079,4667210,disappearance in &lt; 3 h  of the MSG symptom complex,Capsules (300 mg) containing Lactobacillus brevis G101 (1×1010 CFU/individual),maltodextrin (placebo),Significantly increased,Disappearance of the MSG symptom complex in less than 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841).,4667210
1080,4565804,morphine doses,gabapentin (10 mg/kg),Placebo,Significantly decreased,"Dogs in the Placebo group received significantly more morphine doses than the Gabapentin group (P=0.021), despite no significant differences in pain scores. Perioperative gabapentin reduced the postoperative morphine requirements in dogs after mastectomy.",4565804
1081,4565804,You must have prompts generated from different sections.,1,2,No significant difference,Article TitleGabapentin as an adjuvant for postoperative pain management in dogs undergoing mastectomyPubMed Id25816802PMC4565804,4565804
1082,5610854,intraocular pressure (IOP),laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly increased,"At each visit, the IOP was significantly lower in group 2 (p &lt; 0.001).",5610854
1083,5610854,intraocular pressure (IOP)-lowering medications,laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly increased,"Five eyes in group 1 required trabeculectomy: 1 eye at 6 months, 2 eyes at 12 months, and 2 eyes at 18 months. 17 of the 38 eyes (44.7%, CI: 28.9%–60.5%) in group 1 required a mean of 1.8 IOP-lowering medications while seven of the 111 eyes (6.3%, CI: 1.8%–10.8%) in group 2 required a mean of 1.1 medications (Pearson's chi-square value?=?30.940, p &lt; 0.001).",5610854
1084,5610854,The absolute risk for ?2 lost lines of vision,laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly decreased,The absolute risk for ?2 lost lines of vision in the trabeculectomy group was 18% (20 of 111) compared to 16% (6 of 38) in the LPI group. The absolute risk increased with trabeculectomy is 2% and the number needed to harm (NNH) is 50.,5610854
1085,5610854,Cataract progression,laser peripheral iridotomy (LPI) group 1,primary trabeculectomy group 2,Significantly decreased,"Cataract progression as defined was documented in 2 eyes (5.3%, CI: ?1.8%–12.4%) in group 1 and 16 eyes (14.4%, CI: 7.9%–20.9%) in group 2 (Pearson's chi-square value?=?2.232, p = 0.135). The absolute risk increased in cataract formation with trabeculectomy is 9% and translates into a NNH of 11.",5610854
1086,4395717,repositioning error in flexion and right and left side-bending and reduction in pain,upper thoracic manipulation (UTM),cervical stability training (CST),Significantly decreased,The UTM showed significantly smaller repositioning error in flexion and right and left side-bending and greater reduction in pain than the CST group (p&lt;0.01).,4395717
1087,4395717,reduction in pain,upper thoracic manipulation (UTM),cervical stability training (CST),Significantly increased,The UTM showed significantly smaller repositioning error in flexion and right and left side-bending and greater reduction in pain than the CST group (p&lt;0.01).,4395717
1088,4082484, flow-mediated vasodilation (FMD),single serving of curry meal,spice-free control meal,Significantly increased,"On the other hand, the consumption of the curry increased FMD from 5.2?±?2.5% to 6.6?±?2.0% (P?=?0.001),",4082484
1089,4082484,postprandial FMD,single serving of curry meal,spice-free control meal,Significantly increased,"and the postprandial FMD after the curry meal was higher than that after the control meal (5.1?±?2.3% vs. 6.6?±?2.0%, P?=?0.002).",4082484
1090,4082484,"systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers",single serving of curry meal,spice-free control meal,No significant difference,"Presence of spices in the curry did not alter significantly the systemic and forearm hemodynamics, or any biochemical parameters including oxidative stress markers measured.",4082484
1091,2644667,Mean ± SD patient global assessment scores at the end of the SR phase,hydromorphone,morphine,No significant difference,Mean ± SD patient global assessment scores at the end of the SR phase were 3.2 ± 1.14 for the OROS® hydromorphone group and 3.3 ± 0.98 for the CR morphine group (p = 0.6696);,2644667
1092,2644667,mean ± SD investigator global assessment scores,hydromorphone,morphine,No significant difference,"mean ± SD investigator global assessment scores were 3.2 ± 1.07 and 3.3 ± 0.91, respectively (p = 0.4760).",2644667
1093,2644667,mean scores for the secondary efficacy variables  and MMSE and ECOG scores,hydromorphone,morphine,No significant difference,"At the end of the IR phase, mean scores for the secondary efficacy variables (other assessments of pain from the BPI [Table 3 and Figure 4], and MMSE and ECOG scores [data not shown]) were similar for IR hydromorphone and IR morphine,",2644667
1094,2644667,'pain now PM',hydromorphone,morphine,Significantly decreased,"'pain now PM' was significantly lower in the OROS® hydromorphone group compared with the CR morphine group (LS mean [SE] scores, 2.6 [0.3] versus 3.4 [0.3], respectively; p = 0.0372)",2644667
1095,2644667,"the time to withdrawal, irrespective of phase",hydromorphone,morphine,No significant difference,"There was no statistically significant difference between treatment groups in the time to withdrawal, irrespective of phase (IR phase, p = 0.6537; SR phase, p = 0.2827).",2644667
1096,4109867,average daily gain (ADG) of Hanwoo steers,2% seamustard,basal diet,Significantly increased,The average daily gain (ADG) of Hanwoo steers was increased in SW supplemented group compared to control (p&lt;0.05).,4109867
1097,4109867,average daily feed intake (ADFI),2% seamustard,basal diet,Significantly decreased,"However, in the present study, significantly decreased average daily feed intake (ADFI) and increased gain:feed was found in the SW dietary group compared to control (p&lt;0.05).",4109867
1098,4109867,gain:feed,2% seamustard,basal diet,Significantly increased,"However, in the present study, significantly decreased average daily feed intake (ADFI) and increased gain:feed was found in the SW dietary group compared to control (p&lt;0.05).",4109867
1099,4109867,IgG concentrations,2% seamustard,basal diet,Significantly increased,The SW supplementation significantly increased (p&lt;0.05) IgG concentrations,4109867
1100,4109867,IgM concentrations,2% seamustard,basal diet,No significant difference,The SW supplementation significantly increased (p&lt;0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4).,4109867
1101,4109867,Meat cholesterol concentration,2% seamustard,basal diet,Significantly decreased,Meat cholesterol concentration in the SW group was significantly lower (p&lt;0.05) than in the control group (Table 6).,4109867
1102,4109867,myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration,2% seamustard,basal diet,Significantly decreased,"Dietary SW supplementation significantly reduced the myristic acid (C14:0) and palmitoleic acid (C16:ln-7) concentration,",4109867
1103,4109867,concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3),2% seamustard,basal diet,Significantly increased,while SW increased the concentration of stearic acid (C18:0) and linolenic acid (C18:3n-3) compared to control (p&lt;0.05).,4109867
1104,4109867,"saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles",2% seamustard,basal diet,No significant difference,"Dietary SW supplementation had no effect on saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles.",4109867
1105,5064802,Hemodynamic data,Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.,no helium,No significant difference,Data are presented as mean ± SD; no significant differences were observed between groups,5064802
1106,5064802,Postoperative troponin T,Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.,no helium,No significant difference,"Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), p = 0.13].",5064802
1107,5064802,"activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart",Helium preconditioning (3 × 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp.,no helium,No significant difference,"No effect was observed of helium preconditioning, postconditioning or the combination thereof on activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart.",5064802
1108,4940009,Postoperative myalgia (POM),"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",Significantly decreased,"Grade 1 POM was lower in Group K when compared with Group N (nine in Group K versus 33 in Group N; P&lt;0.001),",4940009
1109,4940009,Changes in heart rate after induction and intubation,"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",No significant difference,Changes in heart rate after induction and intubation between the two groups were compared and repeated measures of variance analysis showed no significant difference in the two groups (P&gt;0.05; Table 3).,4940009
1110,4940009,the incidence of POM,"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",Significantly decreased,"Overall, the incidence of POM in Group K was significantly less, when compared with Group N (P&lt;0.05),",4940009
1111,4940009,grade 2 of POM,"Group K, 0.5 mg/kg of ketamine was injected intravenously,","Group N, the same volume (5 mL) of normal saline was injected",No significant difference,both groups were comparable based on the grade 2 of POM,4940009
1112,3423952,"erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood, and decreased plasma nitric oxide.",3000 IU d?1 oral superoxide dismutase (SOD) powder  for 6?wks - treatment group (TRT),placebo (cellulose powder) for 6?wks,No significant difference,There were no TRT effects detected for any parameter measured (P &gt; 0.05).,3423952
1113,3423952,"erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood",exercise,no exercise,Significantly increased,"Exercise resulted in increased (P &lt; 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood,",3423952
1114,3423952,plasma nitric oxide,exercise,no exercise,Significantly decreased,Plasma NO decreased (P = 0.002; Figure 1(d)) from 30?min POST to 24?h POST and returned to PRE values at 36?h POST.,3423952
1115,3423952,"chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2, ",exercise,no exercise,Significantly increased,"Exercise increased (P &lt; 0.05) SF CS and adjusted-PGE2, and higher (P &lt; 0.05) CS and PGE2 were found in hock versus carpus joints.",3423952
1116,5215617,received colostrum as the first food,receive exclusive breastfeeding counselling from the counsellors,receive the usual health messages from the Matlab regular health staff,Significantly increased,"In the breastfeeding counselling group, 95.5% of the babies had received colostrum as the first food, compared with 85.8% in the usual health message group (p &lt; 0.001).",5215617
1117,5215617,The median duration of exclusive breastfeeding,receive exclusive breastfeeding counselling from the counsellors,receive the usual health messages from the Matlab regular health staff,Significantly increased,"The median duration of exclusive breastfeeding was longer in the breastfeeding counselling group (135 days, 95% CI: 131–139) than in usual health message group (75 days, 95% CI: 68–82) – a difference of 60 days (p &lt; 0.001).",5215617
1118,3577738,website use and terms of the number of pages visited and terms of time on the website,website with social presence elements.,website without social presence elements.,No significant difference,"but did not differ in website use in comparison with the control condition; neither in terms of the number of pages visited (t(456)?=?1.44, p?=?.15), nor in terms of time on the website (t(456)?=?0.01, p?=?.99).",3577738
1119,3577738,focused on the social presence elements in terms of frequency and duration,website with social presence elements.,website without social presence elements.,Significantly increased,"Participants in the experimental condition focused on the social presence elements, both in terms of frequency (F(1, 98)?=?40.34, p&lt;.001) and duration (F(1, 88)?=?39.99, p&lt;.001),",3577738
1120,3577738,"efficiency, effectiveness, enjoyment, active trust, and interest",website with social presence elements.,website without social presence elements.,No significant difference,"There were no differences between conditions in terms of efficiency (F(1, 456)?=?0.84, p?=?.36), effectiveness (F(1, 456)?=?0.03, p?=?.87), enjoyment (F(1, 456)?=?0.08, p?=?.78), active trust (F(1, 456)?=?0.03, p?=?.87) and interest (F(1, 456)?=?0.07, p?=?.80).",3577738
1121,5489138,confirmed disability progression,"timed 25-foot walk [T25FW],",Expanded Disability Status Scale [EDSS],Significantly increased,CDP rates defined by a ?20% increase in T25FW were higher than those defined by EDSS score at 12 and 24 months.,5489138
1122,5489138,confirmed disability progression,"timed 25-foot walk [T25FW],",9-hole peg test [9HPT],Significantly increased,CDP rates defined by T25FW or EDSS score were higher than those defined by 9HPT score.,5489138
1123,5489138,confirmed disability progression,EDSS/T25FW/9HPT,EDSS/T25FW or EDSS/9HPT,Significantly increased,"UDP proportions were consistently higher than CDP proportions for all measures, with a considerably greater difference between UDP and CDP in the cumulative incidence of the composite of all 3 individual measures (1 year: 63.8% and 41.4%, respectively; 2 years: 82.1% and 63.9%, respectively) compared with the cross-sectional proportions (1 year: 47.8% and 37.5%, respectively; 2 years: 57.5% and 52.8%, respectively).",5489138
1124,3611646,"names forgotten, numbers forgotten, memory impairment in recalling special events in life, forgetfulness, losing of valuables, difficulty in remembering multiple items to be purchased, inability to concentrate, impaired recognition, memory impairment of recall of previous histories, difficulty in recalling information quickly, depression, and inability to relax ","administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly increased,"In comparison to Group B, Group A showed highly significant relief in symptoms such as names forgotten (63.56%), numbers forgotten (61.62%), and memory impairment in recalling special events in life (59.71%) at a level of P`0.001, and forgetfulness (68.60%), losing of valuables (73.64%), difficulty in remembering multiple items to be purchased (68.21%), inability to concentrate (68.14%), impaired recognition (79.7%), memory impairment of recall of previous histories (60.66%) at a level of P`0.01, and a significant relief (P`0.05) from difficulty in recalling information quickly (71.57%), depression (89.66%), and inability to relax (82.93%) [Table 3].",3611646
1125,3611646,"serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels","administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly decreased,"With regard to the biochemical parameters, Group A showed highly significant decrease (P`0.01) in serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels,",3611646
1126,3611646,high density lipoprotein (HDL),"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly increased,while high density lipoprotein (HDL) increased highly significantly (P`0.01),3611646
1127,3611646,overall effect,"administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cow’s ghee and sugar.",administered Sarkaradi Granules (SG).,Significantly increased,"Regarding the overall effect, Group A showed marked improvement in 18.6% patients, moderate improvement in 74.4% patients and mild improvement in 7.0% patients, while Group B showed moderate improvement in 32.2% patients and mild improvement in 67.8% patients.",3611646
1128,5936036,drop-out rates,simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD),the SCBT with medication group or regular medication group,No significant difference,"there was no significant difference among the drop-out rates of the three groups (X2=1.41, df=2, p=0.494) with the drop-out rate of the medication only group being the highest. The summation of drop-out rates of the SCBT group and SCBT with medication group was 24.8%.",5936036
1129,5936036,"quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met.",simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD),the SCBT with medication group ,No significant difference,"As stated in Table 1, participants in the SCBT group and SCBT with medication group were not significantly different in satisfaction factors, such as the quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met.",5936036
1130,5225252,Gag-specific IFN-? enzyme-linked immunospot–determined response rates and geometric mean responses,groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA),a single dose of Ad35-GRIN or SeV-Gag,Significantly increased,"Gag-specific IFN-? enzyme-linked immunospot–determined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for ?8 months after completion of the prime-boost regimen.",5225252
1131,5225252,"Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay",groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA),a single dose of Ad35-GRIN or SeV-Gag,Significantly increased,"Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay were also seen in the SLA and SHA groups after Ad35-GRIN boost, compared with those who received either vaccine alone.",5225252
1132,5225252,The GMTs,ASH group,"SLA, SHA, SHSH, and placebo groups,",Significantly increased,"The GMTs were significantly higher (P &lt; .0001, by the Kruskal-Wallis test) in the ASH group after the SeV boost than in the other groups (53, 53, 245, 50, and 59 in the SLA, SHA, ASH, SHSH, and placebo groups, respectively; Figure 4).",5225252
1133,5225252,the Gag response rate,SLA and SHA groups,ASH group,Significantly increased,"In the SLA and SHA groups combined, the Gag response rate was significantly higher 2 weeks after the second vaccination (95.7%), compared with the rate in the ASH group 2 weeks after either the Ad35-GRIN prime or the SeV-Gag boost (54.5% for both; P = .008).",5225252
1134,4627811,VO2peak tended,high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,No significant differences were observed between both interventions (Table 2).,4627811
1135,4627811,"brachial and superficial femoral artery diameter, peak blood flow, and FMD",high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,"We found no significant changes in brachial and superficial femoral artery diameter, peak blood flow, and FMD (Table 3).",4627811
1136,4627811,Quality of life,high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,"5). There was a significant increase in the SF-36 subscale 'physical function' after training (P = 0.004, Table 5), which did not differ between groups (time*group P = 0.11).",4627811
1137,4627811,maximal oxygen uptake,high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III,continuous training (CT) 12-weeks inpatients NYHA II-III,No significant difference,"We found no changes over the 12-week period in maximal oxygen uptake (17.4±5.9 versus 17.5±5.8 ml/min/kg, P = 0.79) or in any of the other parameters of physical fitness (all P&gt;0.05, S1 Table).",4627811
1138,4627811,"maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse",training for 12-weeks in patients NYHA II-III,no training for 12-weeks inpatients NYHA II-III,No significant difference,"Training improved maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak, oxygen uptake at the anaerobic threshold, and maximal oxygen pulse (all P&lt;0.05), whilst no differences were present between HIT and CT (N.S.).",4627811
1139,3895597,The VAS scores of abdominal pain at week 4,tiropramide 100,octylonium 20 mg,No significant difference,"The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference,-0.26 mm; 95% CI,-4.33-3.82; P = 0.901).",3895597
1140,3895597,"Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL",tiropramide 100,octylonium 20 mg,No significant difference,"Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ.",3895597
1141,3895597,The incidence of adverse events,tiropramide 100,octylonium 20 mg,No significant difference,"The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.",3895597
1142,3895597,the degree of symptom reduction in abdominal pain using symptom diaries from week 1 ,tiropramide 100,octylonium 20 mg,Significantly increased,"Furthermore, the degree of symptom reduction in abdominal pain using symptom diaries was higher in the tiropramide group than in the octylonium group from week 1 (P = 0.033).",3895597
1143,3742017,performed on KABC-II Composite Index Simultaneous Processing and on subtest Rover,E-group - The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) provides a system of NICU care and environmental structure that supports preterm infants’ early brain development.,"C-group - the Newborn Intensive Care Unit (NICU) experience (exposure to bright lights, heightened sound, frequent interventions), which alters brain development.",Significantly increased,E-performed significantly better than the C-children on KABC-II Composite Index Simultaneous Processing and on subtest Rover; subtest Triangles showed a trend [Table 4].,3742017
1144,4893237,mortality in old people with femoral neck fracture.,pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL,no comorbidities,Significantly increased,"In the final model (Model C.) all significant variables in the two multivariate models above were combined; pulmonary emboli (HR 69.396, CI: 7.107–677.632), cancer (HR 3.393, CI: 1.959–5.877), cardiac failure (HR 2.221, CI: 1.148–4.294), cardiovascular disease (HR 2.026, CI: 1.160–3.539), dementia (HR 1.883, CI: 1.091–3.250) and dependence in P-ADL (HR 2.362, CI: 1.271–4.387)",4893237
1145,5851630,absolute beta power (ABP) after exercise,Taurine combined with Ethanol (TA+ET),Placebo—PL,Significantly increased,"However, in the ET+TA treatment, ABP values were greater after exercise, except for Fp1.",5851630
1146,5851630,absolute beta power (ABP) after exercise,exercise,no exercise,Significantly decreased,"Difference was found at Fp1 between the baseline and post-exercise moments (p&lt;0.05) and between peak and post-exercise (p&lt;0.05) for the PL, ET and TA treatments.",5851630
1147,5626376,"At early follow-up (3 months), total WOMAC scores Western Ontario and McMaster Universities Arthritis Index (WOMAC)",five injections of HA1 (Suprahyal®/Adant®),standard care (control),Significantly increased,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1148,5626376,"At early follow-up (3 months), total WOMAC scores the Western Ontario and McMaster Universities Arthritis Index (WOMAC)",four injections of HA2 (Orthovisc®);,standard care (control),No significant difference,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1149,5626376,"At early follow-up (3 months), total WOMAC scores the Western Ontario and McMaster Universities Arthritis Index (WOMAC)",three injections of HA3 (Synvisc®),standard care (control),Significantly increased,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1150,5626376,"At early follow-up (3 months), total WOMAC scores the Western Ontario and McMaster Universities Arthritis Index (WOMAC)",a single injection of PRP (GPS™ II),standard care (control),Significantly increased,"At early follow-up (3 months), total WOMAC scores improved in all groups compared to baseline with reductions of 44.79% (HA1), 24.02% (HA2), 40.38% (HA3), 39.77% (PRP), and 27.64% (control) (p=0.002 HA1 compared to HA2).",5626376
1151,5626376,"At 18 months, the higher improvement in total WOMAC",five injections of HA1 (Suprahyal®/Adant®),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1152,5626376,"At 18 months, the higher improvement in total WOMAC",a single injection of PRP (GPS™ II),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1153,5626376,"At 18 months, the higher improvement in total WOMAC",three injections of HA3 (Synvisc®),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1154,5626376,"At 18 months, the higher improvement in total WOMAC",four injections of HA2 (Orthovisc®),standard care (control),Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3).",5626376
1155,5626376,The percentage of patients achieving the MCII for both pain and function at 18 months,1) five injections of HA1 (Suprahyal®/Adant®); 2) four injections of HA2 (Orthovisc®); 3) three injections of HA3 (Synvisc®); 4) a single injection of PRP (GPS™ II);,standard care (control),Significantly increased,"At the end of follow-up, a growing number of patients experienced a clinically significant improvement in HA1 with a 100% responders rate, followed by HA3 (80%). In the group treated with HA2 and in those treated with PRP, the results reached 60% responders, whereas in the control group, all patients returned to near pre-arthroscopy levels of pain and impairment and none of the patients reached the 20% MCII cutoff (",5626376
1156,3296686,HCV RNA at day-14,Pioglitazone (30 mg/day for 14 days),baseline,Significantly decreased,"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n?=?10; difference of means?=?205,618 IU/ml; 95% CI 26,600 to 384,600; P&lt;0.001).",3296686
1157,3296686,HCV RNA at day-14,Prednisone (40 mg/day for 4 days),baseline,Significantly increased,"Although Prednisone did increase serum HCV RNA at day-4 (n?=?10; change from baseline?=??42,786 IU/ml; 95% CI ?85,500 to ?15,700; P?=?0.049),",3296686
1158,3296686,day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT ,Pioglitazone (30 mg/day for 14 days),baseline,Significantly decreased,Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean change?=?8.2 mg/dL; P?=?0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean change?=?18.8 mg/dL; P?=?0.001) ( Table 4 ).,3296686
1159,3296686,serum ALT and AST values,Pioglitazone (30 mg/day for 14 days),baseline,Significantly decreased,Pioglitazone treatment decreased at day-14 serum ALT levels (mean change?=?7.5 IU/ml; 95% CI: 2.1 to 12.9; P?=?0.012) and to a smaller degree serum AST levels (mean change?=?2.6 IU/ml; 95% CI: ?0.6 to 5.8; P?=?0.096) ( Table 5 ).,3296686
1160,3296686,serum IL-8 levels at day-14,Pioglitazone (30 mg/day for 14 days),baseline,Significantly increased,ioglitazone increased serum IL-8 levels at day-14 when compared to baseline day-0 values (mean change?=??166.8 IU/ml; 95% CI: ?300.1 to ?33.5; P?=?0.019),3296686
1161,3296686,"day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF",Pioglitazone (30 mg/day for 14 days),baseline,No significant difference,"We found no statistically significant differences between day-0 and day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF ( Table 6 ).",3296686
1162,3296686,fasting serum glucose and 2-hr (Glucose-120 min) after an OGTT,Prednisone (40 mg/day for 4 days),baseline,Significantly increased,"Prednisone treatment increased by day-4, when compared to baseline day-0 values, fasting serum glucose (Glucose-0) (mean change?=?9.0 mg/dL; 95% CI: 20.4 to ?2.4; P?=?0.108) as well as the 2-hr (Glucose-120 min) after an OGTT (mean change?=?11.0 mg/dL; 95% CI: 17.9 to 4.1; P?=?0.006).",3296686
1163,3296686,"serum ALT, AST, IL-8 or other inflammatory mediators",Prednisone (40 mg/day for 4 days),baseline,No significant difference,"Prednisone treatment did not affect at day-4 either serum ALT, AST, IL-8 or other inflammatory mediators ( Tables 9 and 10 ).",3296686
1164,4223523,sleep efficiency ,olanzapine,placebo,Significantly increased,"Two two-way repeated-measures ANOVA showed an increase in TST (trend for main effect of treatment, F[1,23]?=?3.69, p?=?0.067) and sleep efficiency (main effect of treatment, F[1,23]?=?5.10, p?=?0.034)",4223523
1165,4223523,awake time,olanzapine,placebo,Significantly decreased,"ut by Day 28–31, olanzapine treatment was significantly decreasing amount of awake time participants experienced (t23?=?2.26, p?=?0.003).",4223523
1166,4223523,Montgomery-Asberg Depression Rating Scale and Hamilton Depression Rating Scale-17 item (HDRS-17),olanzapine,placebo,Significantly decreased,"One-way repeated measures ANOVA showed a significant decrease in total MADRS score from baseline to the end of the trial (day 28–31) for olanzapine-treated patients (main effect of time: F[1,14]?=?6.03, p?=?.022), where as placebo treatment did not show a decrease (F[1,9]?=?0.529, p?=?.486). HDRS scores also significantly decreased over time in the olanzapine-treated group (F[1,14] =19.6, p?=?.001), but the placebo-treated group did not (F[1,9] =4.67, p?=?.059).",4223523
1167,4223523,"Spatial Working Memory (SWM), Spatial Span (SSP), and Reaction Time (RTI) tasks",olanzapine,placebo,No significant difference,"There was no significant difference between olanzapine- and placebo-treated participants in SWM, SSP or RTI tasks.",4223523
1168,5354011,willingness?to?pay.,after treatment ,before treatment,Significantly increased,The significance tests show the WTP values between ‘&lt;25%’ and ‘51–75%’ to be significantly increased as percentage change in MMAS increases (P = 0.033; P &lt; 0.05).,5354011
1169,3697211,serum level of IgM,type 1 DM,type 2 DM,No significant difference,There are no significant differences between serum level of IgM between patients with T1D and T2D (181.1 ± 58.8 vs 183.8 ± 54.1 mg/dl respectively) and these values are less than reference value of healthy subjects in the laboratory (219 ± 44 mg/dl).,3697211
1170,3224529,Proportions of REM sleep duration,neurally adjusted ventilatory assist (NAVA),pressure support ventilation (PSV),Significantly increased,"Proportions of REM sleep duration were different in the two ventilatory modes (4.5% (range, 3-11%) in PSV and 16.5% (range, 13-29%) during NAVA (p = 0.001)),",3224529
1171,3224529,fragmentation index,neurally adjusted ventilatory assist (NAVA),pressure support ventilation (PSV),Significantly decreased,"as well as the fragmentation index, with 40 ± 20 arousals and awakenings per hour in PSV and 16 ± 9 during NAVA (p = 0.001).",3224529
1172,3224529,episodes of central apnea and ineffective efforts,neurally adjusted ventilatory assist (NAVA),pressure support ventilation (PSV),Significantly decreased,The mean index of sleep apneas (number of apneas per hour of sleep) was 10.5 ± 11 apneas during PSV and 0 during NAVA (p = 0.005) and ineffective efforts (number of ineffective efforts per hour of sleep) was 24 ± 23 ineffective efforts during PSV and 0 during NAVA (p = 0.001).,3224529
1173,4821313,the pH of urine,sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast),sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr).,No significant difference,"Regarding the pH of urine, we found that it was (5.95 ± 0.26) in group 1 and (5.97 ± 0.24) in group 2, showing no statistical difference and highlighting the fact that both regimen had almost the same alkalinizing efficacy with no proven extra benefit for patients with pH values greater than 6.",4821313
1174,4821313,serum creatinine,sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast),sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr).,Significantly increased,"We observed a significant increase in S. Cr. and significant decrease in eGFR calculated by MDRD formula in (group 1) when we compare their levels prior to contrast administration with their levels 48 hr after the intervention (S. Cr: 2.32 ± 0.41 vs. 2.42 ± 0.48) and (eGFR by MDRD: 30.22 ± 6.07 vs, 28.97 ± 6.57). Regarding group 2, the results of our study showed no statistical difference in S. Cr. and eGFR calculated by MDRD 48 hr post-procedure (S. Cr: 2.26 ± 0.47 vs. 2.26 ± 0.49) and (eGFR by MDRD: 30.97 ± 7.13 vs. 31.06 ± 7.41).",4821313
1175,4821313,eGFR ,sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast),sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr).,Significantly decreased,"We observed a significant increase in S. Cr. and significant decrease in eGFR calculated by MDRD formula in (group 1) when we compare their levels prior to contrast administration with their levels 48 hr after the intervention (S. Cr: 2.32 ± 0.41 vs. 2.42 ± 0.48) and (eGFR by MDRD: 30.22 ± 6.07 vs, 28.97 ± 6.57). Regarding group 2, the results of our study showed no statistical difference in S. Cr. and eGFR calculated by MDRD 48 hr post-procedure (S. Cr: 2.26 ± 0.47 vs. 2.26 ± 0.49) and (eGFR by MDRD: 30.97 ± 7.13 vs. 31.06 ± 7.41).",4821313
1176,3752932,the mean number of incontinence episodes/24 h and the mean number of micturitions/24 h,mirabegron (50 and 100 mg),placebo,Significantly decreased,"Mirabegron at doses of 50 and 100 mg once daily demonstrated statistically significant improvement from baseline to Final Visit compared with placebo in reducing the mean number of incontinence episodes/24 h and the mean number of micturitions/24 h (p &lt; 0.05 for all comparisons; Table 2 and Figures 3 and 4, respectively). The adjusted mean (95% CI) change from baseline to Final Visit in the mean number of incontinence episodes/24 h was ?1.10 (?1.23, ?0.97), ?1.49 (?1.63, ?1.36) and ?1.50 (?1.67, ?1.34) in the placebo, mirabegron 50 and 100 mg groups, respectively, and ?1.20 (?1.34, ?1.06), ?1.75 (?1.89, ?1.61), ?1.74 (?1.91, ?1.56) for the adjusted mean change from baseline to Final Visit in the mean number of micturitions/24.",3752932
1177,3752932,"mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h",mirabegron (50 and 100 mg),placebo,Significantly decreased,"Both 50 and 100 mg mirabegron doses were associated with statistically significant improvements from baseline to Final Visit compared with placebo for the key secondary efficacy end-points of mean volume voided/micturition (p &lt; 0.05 for all comparisons; Table 2), mean level of urgency, mean number of urgency episodes (grade 3 or 4)/24 h and mean number of urgency incontinence episodes/24 h (p &lt; 0.05 for all comparisons; Table 2 and Figure 5).",3752932
1178,3752932,mean number of nocturia episodes/24 h,mirabegron (50 and 100 mg),placebo,Significantly decreased,"Significant improvements were also evident in the pooled efficacy analysis with respect to the change from baseline to Final Visit (95% CI) in the mean number of nocturia episodes/24 h in the mirabegron 50 mg [?0.55 (?0.62, ?0.49)] and mirabegron 100 mg groups [?0.54 (?0.62, ?0.46)] vs. placebo [?0.42 (?0.48, ?0.35)] (p &lt; 0.05; Table 2).",3752932
1179,3752932,the Treatment Satisfaction-Visual Analogue Scale (TS-VAS),mirabegron (50 and 100 mg),placebo,Significantly increased,"In health-related quality of life outcomes, mirabegron 50 and 100 mg was associated with a statistically significant improvement in the TS-VAS score at Final Visit compared with placebo (p &lt; 0.05; Table 2). The adjusted mean (95% CI) changes from baseline to Final Visit were 1.25 (1.08, 1.42), 2.01 (1.84, 2.19) and 2.33 (2.11, 2.55) for the placebo, mirabegron 50 and 100 mg groups, respectively.",3752932
1180,5002324,the limits of stability (LOS) performance and one-leg stance (OLS) tests,a balance-based exergaming group for an 8-week balance training period.,a balance training group for an 8-week balance training period.,Significantly increased,"Within-group post hoc analysis revealed that balance-based exergaming training significantly improved LOS performance (improving reaction time from 0.96?±?0.33 to 0.74?±?0.24 s, end point excursion from 75.2?±?12.48 to 84?±?12.04 % and directional control from 75.7?±?8.78 to 78.9?±?7.65 %) and OLS on the less affected leg in the eyes-closed condition (from 3.35?±?2.85 to 6.1?±?8.65 s).",5002324
1181,5002324,directional control in the LOS test,a balance-based exergaming group for an 8-week balance training period.,a balance training group for an 8-week balance training period.,Significantly increased,"Furthermore, balance-based exergaming training resulted in significantly better performance in directional control in the LOS test (78.9?±?7.65 %) compared with conventional balance training (70.6?±?9.37 %).",5002324
1182,5064056,Mean pain intensity,"tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice",no therapy,Significantly decreased,Mean pain intensity reported for all participants was 38 over the pre-treatment baseline period and 18 over the post-treatment baseline period on the Visual Analogue Scale.,5064056
1183,5064056,Mean disability,"tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice",no therapy,Significantly decreased,"ean disability was 43 over the pre-treatment baseline period and 23 over the post-treatment baseline period, on a similar 0-100 scale.",5064056
1184,4653470,Absolute increase in performance of insulin therapy for DM.,serious game called InsuOnLine©,traditional on-site learning activity,Significantly increased,"Absolute increase in performance was higher in the game group (40%) than in control (34%, p=0.01).",4653470
1185,3971783,"O2sat, PaO2","breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping",no breathing exercises ,Significantly increased,"Likewise, O2sat, PaO2 in the case group were higher than the control group (P &lt; 0.0001).",3971783
1186,3971783,The nocturnal enuresis,"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping",no breathing exercises ,Significantly decreased,"After intervention, the median of nocturnal enuresis frequency in the case group was significantly lower than the control group (P &lt; 0.001).",3971783
1187,3971783,PaCO2 and Respiratory rates ,"breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping",no breathing exercises ,Significantly decreased,After intervention the means of PaCO2 and RR in the control group were significantly higher than the case group (P &lt; 0.0001).,3971783
1188,5122238,incidence and intensity of shivering,received 1 mg/kg and 2 mg/kg hydrocortisone,received normal saline,Significantly decreased,"while the incidence and intensity of shivering had a significant difference between the two groups of hydrocortisone of 1 mg/kg and placebo group (P = 0.039 and P = 0.018, respectively). Moreover, the incidence and intensity of shivering had a significant difference between the two groups of hydrocortisone of 2 mg/kg and placebo group (P = 0.0001 and P = 0.001, respectively).",5122238
1189,5122238,"Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate",received 1 mg/kg and 2 mg/kg hydrocortisone,received normal saline,No significant difference,Figure 1Mean central temperature from 0 to 60 min recovery in the three groups (P = 0.64)Figure 2Mean peripheral temperature from 0 to 60 min recovery in the three groups (P = 0.31)Figure 3Mean blood pressure from 0 to 60 min recovery in the three groups (P = 0.82)Figure 4Mean heart rate from 0 to 60 min recovery in the three groups (P = 0.77),5122238
1190,3743641,mean daily number of moderate to severe hot flushes at week 4,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"In SMART-2, at week 4, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a significant decrease (P &lt; 0.001) in the adjusted mean daily number of moderate to severe hot flushes as compared with placebo.",3743641
1191,3743641,mean daily number of moderate to severe hot flushes at week 12,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"At week 12, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a decrease (P &lt; 0.001) in the adjusted mean daily number of moderate to severe hot flushes, reaching a 74% and a 80% reduction, respectively, representing a clinically meaningful reduction of approximately 7–8 hot flushes per day, compared with a 51% reduction (representing a reduction of approximately five hot flushes per day) in the placebo group (Figure 1).18",3743641
1192,3743641,mean proportion of superficial cells,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,BZA 20 mg/CE 0.45 or 0.625 mg showed a significantly greater increase from baseline in the mean proportion of superficial cells compared with placebo (P &lt; 0.001).,3743641
1193,3743641,reduction from baseline in the mean proportion of parabasal cells,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,Both BZA/CE groups also showed a significantly greater reduction from baseline in the mean proportion of parabasal cells (P &lt; 0.001),3743641
1194,3743641,increase from baseline in the mean proportion of intermediate cells,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,and a significantly greater increase from baseline in the mean proportion of intermediate cells (P &lt; 0.05) compared with placebo at weeks 4 and 12.,3743641
1195,3743641,vaginal pH,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"Additionally, treatment with BZA 20 mg/CE 0.625 mg resulted in a significantly greater decrease from baseline in vaginal pH (P &lt; 0.001)",3743641
1196,3743641,improvement in the women’s most bothersome vulvovaginal atrophy symptoms,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,and a greater improvement in the women’s most bothersome vulvovaginal atrophy symptoms (P &lt; 0.05) compared with placebo (Figure 4).19,3743641
1197,3743641,reduction in the incidence of dyspareunia,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,"This maturation of the vaginal epithelium was associated with a statistically significant reduction in the incidence of dyspareunia relative to placebo during weeks 9–12 of therapy (P &lt; 0.001) and in ease of lubrication score from baseline compared with placebo (P &lt; 0.05) on the Arizona Sexual Experiences scale.17,19",3743641
1198,3743641,sexual function and total scores,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,"Additionally, in SMART-3 (subjects with vulvovaginal atrophy), the Menopause-Specific Quality of Life questionnaire results at week 12 showed significant improvements in sexual function and total scores with both BZA/CE doses versus placebo or BZA 20 mg (P &lt; 0.001).",3743641
1199,3743641,lumbar spine bone mineral density (BMD),"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly increased,"Two clinical trials (SMART-1 and SMART-5) evaluated the safety and efficacy of BZA/CE for the prevention of osteoporosis.17,20 Among subjects ?5 years since menopause (substudy II of SMART-1 and SMART-5), significant (P &lt; 0.001) increases from baseline to month 12 in lumbar spine bone mineral density (BMD) were demonstrated for both the BZA 20 mg/CE 0.45 mg (1.05% and 0.24% in SMART-1 and SMART-5, respectively) and BZA 20 mg/CE 0.625 mg (1.05% and 0.60%, in SMART-1 and SMART-5, respectively) treatment groups compared with placebo (?1.81% and ?1.28%, in SMART-1 and SMART-5, respectively).17,20",3743641
1200,3743641,breast tenderness,"BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,Significantly decreased,"In SMART-5, the incidence of breast tenderness in subjects treated with BZA/CE was significantly lower than that in subjects treated with CE 0.45 mg/MPA 1.5 mg (P &lt; 0.001, Figure 7)",3743641
1201,3743641,"risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer,","BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE),",placebo,No significant difference,"No apparent increased risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, was observed with either dose strength of BZA/CE.",3743641
1202,4280954,"DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)","high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA;",No significant difference,the DM + Flax + E group received a high-fat diet enriched with flaxseed and vitamin E.,4280954
1203,4280954,serum glucose,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,The addition of flaxseed or/and vitamin E to the high-fat diet led to significant reductions of serum glucose levels compared with those in the DM group (Table II).,4280954
1204,4280954,serum TC and non-HDL-C levels ,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; ","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,Flaxseed supplementation significantly decreased serum TC and non-HDL-C levels and increased HDL-C levels (Table II) compared with those in the unsupplemented DM group.,4280954
1205,4280954,HDL-C levels,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; ","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly increased,Flaxseed supplementation significantly decreased serum TC and non-HDL-C levels and increased HDL-C levels (Table II) compared with those in the unsupplemented DM group.,4280954
1206,4280954,"TC, non-HDL-C and TG levels","high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,"The addition of vitamin E to the flaxseed-rich diet significantly decreased TC, non-HDL-C and TG levels but did not improved the HDL-C level in diabetic hamsters.",4280954
1207,4280954,the aortic cholesterol content,"high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food","received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",Significantly decreased,Flaxseed or/and vitamin E supplementation of the diet significantly decreased the aortic cholesterol content in the hamsters with DM (Table II).,4280954
1208,4526336,proportion of words out of the total number of words,mild cognitive impairment (MCI),healthy,Significantly increased,The average proportion of words spoken by participants across the 3 assessment time points was different between the groups (p=0.01) with 68.3% (SD 9.3) among those with MCI and 60.0% (SD 9.3) among cognitively intact.,4526336
1209,4306068,The proportion of patients who received analgesics,pain score display group,not displayed in the control.,No significant difference,The proportion of patients who received analgesics when pain score was displayed was 6.5% more than when pain score was not displayed. This difference was however not statistically significant.,4306068
1210,4306068,The mean timing to analgesic administration,pain score display group,not displayed in the control.,No significant difference,"The mean timing (in minutes) to analgesic administration for the displayed and non-displayed groups were 81.3?±?41.2 (95% C.I 65.9, 96.7) and 88.7?±?45.4 (95% C.I 69.0, 108.3), respectively (p?=?0.538). The distribution of timing of analgesics according to the severity of pain is as shown in Table 3.",4306068
1211,5397544,Thromboelastography R-time,Low-molecular-weight heparin before and after the surgery,Low-molecular-weight heparin only before the surgery,No significant difference,There was no significant difference in thromboelastography R-time between the groups before low-molecular-weight heparin injection,5397544
1212,5397544,Alpha-angle values,Low-molecular-weight heparin before and after the surgery,Low-molecular-weight heparin only before the surgery,No significant difference,There were no significant changes in ?-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups,5397544
1213,5397544,Maximum amplitude values,Low-molecular-weight heparin before and after the surgery,Low-molecular-weight heparin only before the surgery,No significant difference,There were no significant changes in ?-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups,5397544
1214,3743198,Admission rate,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly decreased,"The admission rate decreased by 8.3% in the intervention group (adjusted odds ratio 0.31, 95% confidence interval 0.13-0.70, p=0.005).",3743198
1215,3743198,Medical costs,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly decreased,"In the multivariate linear regression analysis of medical costs, membership in the intervention group was associated with decreased costs (coefficient -712000 KRW, 95% CI -1341000 to -83000 KRW, p=0.027)",3743198
1216,3743198,Rate of certain diagnosis,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,No significant difference,"There was an increasing trend in the rate of certain diagnosis in the intervention group, but it was not statistically significant.",3743198
1217,3743198,Postural blood pressure measurement,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly increased,"Postural blood pressure measurement was more frequently performed in the intervention group than the control group (97.6% vs. 87.9%, p=0.003).",3743198
1218,3743198,Cardiac enzymes and electroencephalography testing,Educational program and ED protocol for syncope evaluation,No standardized guidelines or educational programs,Significantly decreased,"the use of cardiac enzymes and electroencephalography were lower in the intervention group than the control group, respectively (42.9% vs. 56.0%, p=0.041; 2.3% vs. 8.6%, p=0.029).",3743198
1219,5741263,Stroke duration,Amplitude training,Placebo,Significantly increased,"the current results showed increases in stroke duration and normalized jerk after amplitude training, which were absent in the placebo group",5741263
1220,5741263,Writing velocity,Amplitude training,Placebo,No significant difference,velocity remained unchanged throughout the study.,5741263
1221,5741263,Normalized jerk,Amplitude training,Placebo,Significantly increased,"A significant Time x Group interaction was found for the normalized jerk in the large-amplitude condition (F = 8.928, p &lt; 0.001) (Fig 1C). Further analysis revealed a higher normalized jerk in the EXP group compared to PLB group post-training (p = 0.027).",5741263
1222,3917123,Total score of fatigue,Routine unit care ,Placebo,No significant difference,"Post-hoc Duncan test showed that in the study group, total score of fatigue and score of fatigue in emotional, cognitive, and behavioral dimensions were significantly less than in the two groups of placebo and control after intervention (P &lt; 0.05), but there was no significant difference between the control and placebo groups (P &gt; 0.05).",3917123
1223,3917123,Fatigue score in the sensory dimension,Acupressure,Placebo,Significantly decreased,"Mean score of fatigue in the sensory dimension in the study group was significantly less than in the placebo group (P &lt; 0.05),",3917123
1224,3917123,Total score of fatigue,Accupressure,Placebo and routine unit care,Significantly decreased,"Post-hoc Duncan test showed that in the study group, total score of fatigue and score of fatigue in emotional, cognitive, and behavioral dimensions were significantly less than in the two groups of placebo and control after intervention (P &lt; 0.05), but there was no significant difference between the control and placebo groups (P &gt; 0.05).",3917123
1225,3917123,Fatigue score in the sensory dimension,Routine unit care,Placebo,Significantly increased,"Mean score of fatigue in the sensory dimension in the study group was significantly less than in the placebo group (P &lt; 0.05), and in the placebo group, it was significantly less that in the control group (P &lt; 0.05).",3917123
1226,4996255,"the number of steps to use, time taken to use and ease of use",Ellipta™ DPI,HandiHaler®,Significantly increased,"In the combined analyses from the two Phase IIIa active comparator studies, patients declared a preference for the Ellipta™ DPI compared with the HandiHaler® in relation to the number of steps to use (59% vs 17%), time taken to use (62% vs 14%) and ease of use (63% vs 15%), although 22%–24% of all patients declared no preference for either inhaler (Table 4).",4996255
1227,3452313,headache relief for attacks occurring inside and outside the menstrual period (migraine attacks),sumatriptan  for 2 months,placebo  for 2 months,Significantly increased,"For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% vs. 33%, p=0.007) and outside (79% vs. 31%, p&lt;0.001) the menstrual period.",3452313
1228,5966469,increase of fluency in the double loops tasks,the combined and in the pure handwriting group,the spelling training and the reading groups,Significantly increased,"One of the exceptions mentioned above was a marked increase of fluency in the double loops tasks observed in the combined and in the pure handwriting group from pre-test to post-test, which outperformed the spelling training and the reading groups as indicated by the significant interaction term intervention*time (F(3,171) = 2.7, p &lt; 0.05, ?p2 = 0.05).",5966469
1229,2694465,"forced vital capacity (FVC), FEV1/FVC and PaO2/FiO2 ratio",400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,No significant difference,"Both groups experienced reduced FVC postoperatively (3.24 L to 1.38 L in control group; 2.72 L to 1.18 L in morphine FEV1 (p=0.085), group), with no significant decreases observed between groups. The two groups also exhibited similar results for FEV1/FVC (p=0.68) and PaO2/FiO2 ratio (p=0.08).",2694465
1230,2694465,pain intensity,400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,Significantly decreased,"The morphine group reported less pain intensity (evaluated using a visual numeric scale), especially when coughing (18 hours postoperatively: control group= 4.73 and morphine group= 1.80, p=0.001).",2694465
1231,2694465,Cumulative morphine consumption,400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,Significantly decreased,"umulative morphine consumption was reduced after 18 hours in the morphine group (control group= 20.14 and morphine group= 14.20 mg, p=0.037).",2694465
1232,2694465,The plasma morphine concentration,400 ?g of intrathecal morphine followed by general anesthesia,general anesthesia,Significantly decreased,"Plasma morphine levels were zero at the end of surgery in both groups. However, plasma levels were significantly reduced in the morphine group during the postoperative period 24 hours after the operation (control group= 15.87 ± 18.05 ng mL?1 and morphine group 4.08 ± 5.28 ng mL?1, p=0.029),",2694465
1233,5506592,the proportion of households who purchased anti-mosquito products in the last month,education and mobilisation activities,baseline,Significantly decreased,"In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (difference ? 0.05, 95% CIca ?0.100 to ?0.010).",5506592
1234,5506592,"The mean expenditure on the products,",education and mobilisation activities,baseline,Significantly decreased,"The mean expenditure on the products, among those households who bought them, was USD6.43; 30.4% in the intervention clusters and 36.7% in the control clusters spent more than this (difference ? 0.06, 95% CIca ?0.12 to ?0.01).",5506592
1235,5228611,mean HIV treatment satisfaction total scores at weeks 24 and 48,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly increased,"Although both arms showed improved patient-reported outcome scores, participants in the E/C/F/TAF plus DRV group reported statistically significantly higher mean HIV treatment satisfaction total scores at weeks 24 and 48 (Fig. 5) and answered questions specific to the flexibility or convenience of and the patient's satisfaction with the treatment more favorably.",5228611
1236,5228611,days with missed doses,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly decreased,"Based on the visual analog scale adherence questionnaire, participants on E/C/F/TAF plus DRV consistently reported fewer days with missed doses, whereas those on their baseline regimen reported a higher number of days with missed doses as the study progressed: more participants in the E/C/F/TAF plus DRV group reported &lt;2 days with missed doses in the 30 days before week 24 (90% vs. 74%) or 48 (86% vs. 59%) and no days with missed doses in the 4 days before weeks 24 (98% vs. 83%) or 48 (99% vs. 73%).",5228611
1237,5228611,eGFR,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,No significant difference,There were no differences between the 2 groups in median changes from baseline in eGFR (week 48: +7.4 mL/min vs. +3.9 mL/min; P = 0.18).,5228611
1238,5228611,quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio),elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly decreased,Participants in the E/C/F/TAF plus DRV group had statistically significant declines in both measures of quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) at week 48 vs. increases in the baseline regimen group (Fig. 4).,5228611
1239,5228611,rate of any adverse events,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,Significantly increased,Participants in the E/C/F/TAF plus DRV group had a higher rate of any adverse events [92% (n = 82) vs. 78% (n = 36)].,5228611
1240,5228611,HIV-1 RNA &lt;50 copies per mililiter at week 24;,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily,stay on their baseline regimen,No significant difference,E/C/F/TAF plus DRV was noninferior to baseline regimens for the primary outcome (HIV-1 RNA &lt;50 copies per mililiter at week 24; FDA-snapshot algorithm) using the full analysis set (96.6% vs. 91.3%; difference 5.3%; 95.001% CI: ?3.4% to 17.4%) (Fig. 3).,5228611
1241,3051215,"mean changes in body weight, BMI, and waist circumference",anti-inflammatory agent (Diacerein treatment group),placebo,No significant difference,"The treatment group had a tendency towards more reduction in anthropometry as compared to the placebo group, in body weight reduction (- 7.0 kg vs. - 4.6 kg), body mass index (- 2.51 kg/m2 vs. - 1.59 kg/m2), and waist circumference (- 7.3 cm vs. - 4.4 cm). These reductions were not statistically significant.",3051215
1242,3051215,"hsCRP, and adiponectin",anti-inflammatory agent (Diacerein treatment group),placebo,No significant difference,"We also evaluated the changes in inflammatory markers between the two groups. Again, no statistical differences were apparent. Although there were no differences between the two groups, hsCRP, and adiponectin showed more favorable change in the treatment group than in the placebo group. Other inflammatory markers were not shown as expected, but TNF-? was decreased in both groups after intervention (Table 3).",3051215
1243,3466198,The median vaginal and cervical pH,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,Significantly decreased,"The median pH at the cervix, lateral vaginal wall, posterior fornix and CVL was significantly lower 2 hours after application of Acidform compared to the placebo group (p&lt;0.01)",3466198
1244,3466198,at least one local adverse event,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,Significantly increased,Eleven of 17 (65%) women who received Acidform had at least 1 AE compared with 2 of 18 (11%) who received HEC placebo gel (p?=?0.002).,3466198
1245,3466198,"CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein,",Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,No significant difference,"No significant drug effect was observed for the other cytokines, chemokines and host protective factors. However, there was a trend towards a reduction in CVL concentrations of IgG (p?=?0.06), IgA (p?=?0.05) and IL-8 (p?=?0.08) in women who applied Acidform gel.",3466198
1246,3466198,detectable L. crispatus or L. jensenii,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,No significant difference,There were no significant changes in the number of women with detectable L. crispatus or L. jensenii or in the concentrations of bacteria recovered by PCR in the Acidform or HEC group following 14 days of twice daily gel use (Table 4).,3466198
1247,3466198,G. vaginalis,Acidform twice daily for 14 consecutive days,hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days,No significant difference,"However, there was a trend towards a decrease in the concentration of G. vaginalis following repeated application of Acidform from a median of 1.3×106 to 3.6×104 DNA copies/swab (p?=?0.083).",3466198
1248,3056193,Hamilton Rating Scale for Depression (HAM-D) and the Montgomery-Asberg Rating Scale (MADRS),placeboxetine (PB) hydrochloride extended release capsules,sertraline hydrochloride,No significant difference,"Similar results were obtained with the MADRS assessments [Figure 2]. There was no difference between groups at baseline, there was significant improvement in each group at the end of weeks 2 (P&lt;0.01) and 6 (P&lt;0.001), and there were no significant differences between groups at any follow up visit.",3056193
1249,5225191,"medication-attributed, antidepressant-specific side effect score",amitriptyline,placebo pill,Significantly increased,"We found that the amitriptyline group’s medication-attributed, antidepressant-specific side effect score was significantly higher after the acquisition phase (p ? .001; g = 1.75; CI 1.02–2.49) and after the evocation night (p = .008; g = 0.88; CI 0.22–1.54) than the placebo group’s (see Table 2 and Fig. 3b).",5225191
1250,5225191,GASE-AD (antidepressant-specific side effects),amitriptyline,placebo pill,Significantly increased,the amitriptyline group reported significantly more side effects (see Table 2 and Fig. 3a).,5225191
1251,5225191,GASE-generic (generic side effects),amitriptyline,placebo pill,No significant difference,"We observed no differences between the groups in either the GASE-generic or GASE-generic-MA (multivariate analyses: group effect F (2, 36) = 1.89, p = .166; time effect F (4, 34) = 2.83, p = .040; group × time interaction effect F (4, 34) = 2.19, p = .091; univariate analyses regarding GASE-generic-MA: time effect F (0.60, 22.20) = 5.43, p = .027).",5225191
1252,3172326,visual analogue scale (VAS).,received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision,0.5 mg/kg of normal saline was injected,Significantly decreased,"VAS scores are presented in Table 2. For all of the evaluated times, the VAS score was significantly lower in the ketamine group than that of the control group.",3172326
1253,3172326,The interval time for the first analgesic request,received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision,0.5 mg/kg of normal saline was injected,Significantly increased,The interval time for the first analgesic request was 23.1 ± 6.7 minutes in the ketamine group and 18.1 ± 7.3 minutes in the control group (P = 0.02).,3172326
1254,3172326,The total number of pethidine injections in first 24 hours postoperatively,received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision,0.5 mg/kg of normal saline was injected,Significantly decreased,The total number of pethidine injections in first 24 hours postoperatively was 0.6 ± 0.6 in the ketamine group and 2.0 ± 0.8 in the control group (P = 0.032).,3172326
1255,4864053,mean decrease in [11C]Ro15?4513 BP,"MSD, 100 mg l?dopa plus 25 mg carbidopa",placebo (starch),Significantly increased,"r. For a composite gray matter region, a one?sample t?test showed that l?dopa was associated with an 11% mean decrease in [11C]Ro15?4513 BP (t = ?2.29, 9 degrees of freedom, P = 0.048). There was a highly significant effect of regions (linear mixed model, P = 0.000049).",4864053
1256,4864053,The BP of the GABA ligand,"MSD, 100 mg l?dopa plus 25 mg carbidopa",placebo (starch),Significantly decreased,"The BP of the GABA ligand decreased significantly with l?dopa in the medial prefrontal/anterior cingulate and right insula regions (by 18%, t = ?3.63 P = 0.0054, and 18%, t = 3.85 P = 0039, respectively), with no significant effect in the other regions.",4864053
1257,4488484,support for training first responders to use naloxone,Several message exposures,no-exposure control group,Significantly increased,"Factual information alone led to higher support for training first responders to use naloxone (77.4% versus 63.2% in the no-exposure control group),",4488484
1258,4488484,providing naloxone to friends and family members of people using opioids,Several message exposures,no-exposure control group,Significantly increased,"providing naloxone to friends and family members of people using opioids (45.5% versus 24.4% in the no-exposure control group),",4488484
1259,4488484,passing laws to protect people who administer naloxone,Several message exposures,no-exposure control group,Significantly increased,passing laws to protect people who administer naloxone (58.0% versus 41.6% in the no-exposure control group).,4488484
1260,4488484,"support all policies: providing naloxone to friends and family members, training first responders to use naloxone, passing laws to protect people if they administer naloxone, and passing laws to protect people if they call for medical help for an overdose ",receiving the combination of the sympathetic narrative and factual information,factual information alon,Significantly increased,"Participants receiving the combination of the sympathetic narrative and factual information, compared to factual information alone, were more likely to support all policies: providing naloxone to friends and family members (OR: 2.0 [95% CI: 1.4 to 2.9]), training first responders to use naloxone (OR: 2.0 [95% CI: 1.2 to 3.4]), passing laws to protect people if they administer naloxone (OR: 1.5 [95% CI: 1.04 to 2.2]), and passing laws to protect people if they call for medical help for an overdose (OR: 1.7 [95% CI: 1.2 to 2.5]).",4488484
1261,5414544,The rate of HBsAg positivity,Zimbabwe,Uganda,Significantly increased,"The rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratio?=?1.54, P?&lt;?0.001) despite a similar prevalence of antibody to HBV core antigen (56.3 vs. 52.4%) in the two settings.",5414544
1262,5414544,HBsAg positivity,male,female,Significantly increased,"Men were significantly more likely to test positive than women [adjusted odds ratio (aOR) 1.39, 95% confidence interval (CI) 1.19–1.61], although this difference was more marked in Zimbabwe (aOR 1.85, 95% CI 1.41–2.42) than Uganda (aOR 1.22, 95% CI 1.02–1.46) (P?=?0.005, test for interaction).",5414544
1263,3517421,breakdown recurrence,"two culling strategies on breakdown prolongation and recurrence, during and after culling",control,No significant difference,"There is no notable impact of culling treatment in the buffer zones, but there is a decrease in the odds of recurrence in the proactively culled core areas during the culling period, for both the 24 month (OR: 0.82; 95% CI [0.64–1.0]), and 36 month (OR: 0.69; 95% CI [0.54–0.86]) follow-up periods.",3517421
1264,3933059,"Systolic blood pressure (SBP), diastolic blood pressure (DBP)",Pomegranate juice (PJ),baseline,Significantly decreased,"Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (P = 0.013) and DBP (P = 0.010), amounting to an approximate reduction by 7% and 6%, respectively.",3933059
1265,3933059,flow-mediated dilation (FMD),Pomegranate juice (PJ),baseline,No significant difference,"However, percentage changes in FMD (20%) was not found to be statistically significant (P = 0.172).",3933059
1266,3933059,"C-reactive protein (CRP), intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), E-selectin and interleukin-6 (IL-6)",Pomegranate juice (PJ),baseline,No significant difference,"there was no significant difference in the circulating concentrations of inflammatory biomarkers namely hsCRP (P = 0.263), ICAM-1 (P = 0.248), VCAM-1 (P = 0.657), E-selectin (P = 0.182), and IL-6 (P = 0.763) following consumption of PJ.",3933059
1267,4709985,would have liked more information on acupuncture,tertiary education,other educations,Significantly increased,"The role of educational status was examined in response these questions and we found women with tertiary education would have liked more information on acupuncture (p?&lt;?0.009), no other associations were found.T",4709985
1268,3655855,Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations,1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks,safflower oil placebo for 4 weeks,Significantly increased,Figure 1 shows the effect of O3 dosing for four weeks on plasma phospholipid EPA and DHA. Plasma levels increased significantly (p?&lt;?0.001).,3655855
1269,3655855,"central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP ",1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks,safflower oil placebo for 4 weeks,No significant difference,"The effects of supplementation on components of the metabolic syndrome, plasma lipids, vascular measures, and cytokines are shown in Table 3. The daily treatment dose of 1.7 g of O3 for four weeks had no effect on any of these measures compared to the safflower placebo. Not shown are BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10, all of which also showed no effect.",3655855
1270,4401879,"energy, protein, and fat and zinc intake",30mg/day zinc gluconate for eight consecutive weeks,placebo for eight consecutive weeks,Significantly increased,"Supplementation with 30mg of zinc significantly increased energy, protein, and fat and zinc intake in zinc group (P &lt; 0.05). However, no change was observed in the placebo group (P &gt;0.05).",4401879
1271,4401879,"fasting blood sugar, insulin and homeostatic model assessment of insulin resistance",30mg/day zinc gluconate for eight consecutive weeks,placebo for eight consecutive weeks,No significant difference,"According to the results shown in this table, serum zinc increased (P =0.012) significantly, but there were no significant statistical changes in FBS, serum insulin levels and HOMA-IR (P ? 0.05).",4401879
1272,4880652,"the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores",fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,No significant difference,"When the modified Aldrete scores at 60 minutes, systolic pressures at 0 minutes, oxygen saturation at 10, 15, 20 minutes, diastolic blood pressure at 10, 15, 20 minutes, heart rates, and visual analogue scores were compared, there was no significant difference between groups (p&gt;0.05).",4880652
1273,4880652,"systolic blood pressures at 5, 10, 15, and 20 minutes",fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,Significantly decreased,"n the fentanyl group, systolic blood pressures at 5, 10, 15, and 20 minutes were significantly lower (p&lt;0.05) than in the paracetamol group;",4880652
1274,4880652,Diastolic blood pressures at 5 minutes,fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,Significantly decreased,Diastolic blood pressures at 5 minutes were significantly lower (p&lt;0.05) in the fentanyl group;,4880652
1275,4880652,SpO2 at 5 minutes,fentanyl (1 µg/kg) and propofol ,paracetamol (20 mg/kg) and propofol,Significantly decreased,"In the fentanyl group, SpO2 at 5 minutes was significantly lower (p&lt;0.05) than in the paracetamol group,",4880652
1276,3585965,Mean (± standard error of the mean) plasma GLPG0259 concentrations a,single ascending doses (1.5–150 mg)  of GLPG0259,multiple oral doses (20 and 50 mg once daily) of GLPG0259,No significant difference,"Although no statistical analysis was performed on t1/2,?z, no noticeable difference in this parameter was observed, with a mean value of about 26.0 hours (range 25.5–26.4 hours).",3585965
1277,3585965,the rate and extent of absorption of GLPG0259,GLPG0259 and methotrexate,GLPG0259 ,No significant difference,"Regarding GLPG0259, co-administration of methotrexate 7.5 mg did not significantly alter the rate and extent of absorption of GLPG0259, with point estimates for Cmax and AUC24h of 102.67% and 102.11%, respectively.",3585965
1278,3585965,the rate of absorption of methotrexate,GLPG0259 and methotrexate,GLPG0259 ,No significant difference,"When methotrexate was co-administered with GLPG0259 50 mg, the rate of absorption of methotrexate was slightly but not statistically significantly decreased, with a point estimate for Cmax of 89.63% (figure 3, table IV).",3585965
1279,5928476,bulk-fill composite resins’ bond strengths,SureFil SDR or EverX Posterior bulk-fill composite resins’ bond,ProRoot MTA or Biodentine calcium silicate cements,Significantly increased,The mean and standard deviation values of the tested materials obtained from the push-out bond strength test are presented in Table 2. SDR (4.10 ± 0.88) and EXP (3.86 ± 0.72) bulk-fill composite resins’ bond strengths were significantly higher than those of ProRoot MTA (2.29 ± 0.43) and BD (3.20 ± 0.49) calcium silicate cements (P&lt;0.05).,5928476
1280,5928476,bulk-fill composite resin values and calcium silicate cement values,SureFil SDR or EverX Posterior bulk-fill composite resins’ bond,ProRoot MTA or Biodentine calcium silicate cements,No significant difference,"However, there were no significant differences between bulk-fill composite resin values and calcium silicate cement values (P&gt;0.05).",5928476
1281,4132637,The incidence of the primary composite endpoint,ticagrelor,clopidogrel,Significantly decreased,"The incidence of the primary composite endpoint was reduced with ticagrelor vs. clopidogrel (10.0 vs. 12.3%; HR 0.83; 95% CI = 0.74–0.93; P = 0.0013) (see Supplementary material online, Figure S1A).",4132637
1282,4132637,Cardiovascular death,ticagrelor,clopidogrel,Significantly decreased,"Cardiovascular death occurred less often in the ticagrelor group than in the clopidogrel group (3.7 vs. 4.9%; HR 0.77; 95% CI = 0.64–0.93; P = 0.0070),",4132637
1283,4132637,myocardial infarction,ticagrelor,clopidogrel,Significantly decreased,"myocardial infarction was also less common with ticagrelor vs. clopidogrel (6.6 vs. 7.7%; HR 0.86; 95% CI = 0.74–0.99; P = 0.0419),",4132637
1284,4132637,stroke incidence,ticagrelor,clopidogrel,No significant difference,whereas stroke incidence did not differ significantly between treatment arms (1.3 vs. 1.4%; HR 0.95; 95% CI 0.69–1.33; P = 0.79).,4132637
1285,4132637,All-cause death,ticagrelor,clopidogrel,Significantly decreased,"All-cause death was reduced in those treated with ticagrelor vs. clopidogrel (4.3 vs. 5.8%; HR 0.76; 95% CI = 0.64–0.90; P = 0.0020) (see Supplementary material online, Figure S1B).",4132637
1286,4132637,major bleeding,ticagrelor,clopidogrel,No significant difference,"With ticagrelor when compared with clopidogrel, there was no significant difference in PLATO major bleeding (13.4 vs. 12.6%; HR 1.07; 95% CI = 0.95–1.19; P = 0.26),",4132637
1287,4132637,non-CABG-related major bleeding,ticagrelor,clopidogrel,Significantly increased,"higher rate of non-CABG-related major bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI = 1.05–1.56; P = 0.0139) (see Supplementary material online, Figure S2A and B).",4132637
1288,4132637,the rate of life-threatening or fatal bleeding or the rate of intracranial bleeding,ticagrelor,clopidogrel,No significant difference,"There was no significant difference in the rate of life-threatening or fatal bleeding (6.6 vs. 6.5%; HR 1.05; 95% CI = 0.90–1.22, P = 0.56), nor any significant difference in the rate of intracranial bleeding with ticagrelor compared with clopidogrel (0.3 vs. 0.2%; HR 2.01; 95% CI = 0.81–4.99; P = 0.13).",4132637
1289,4132637,The composite of major or minor bleeding (by PLATO criteria),ticagrelor,clopidogrel,Significantly increased,"The composite of major or minor bleeding (by PLATO criteria) occurred more often in the ticagrelor group (18.2 vs. 16.3%; HR 1.14; 95% CI = 1.03–1.25, P = 0.0078).",4132637
1290,4132637,major or minor bleeding (by TIMI criteria),ticagrelor,clopidogrel,No significant difference,"hen assessed by TIMI criteria, there was no significant difference in major or minor bleeding (13.2 vs. 12.3%; HR 1.08; 95% CI = 0.97–1.21; P = 0.16).",4132637
1291,5551214,the Aberrant Behaviour Checklist-Community Edition (ABC-C),horse riding intervention,control group,Significantly decreased,"There was a significant interaction effect between pre- to post-test change in Hyperactivity scores and the participant’s condition (F(1, 22) = 8.084, p = 0.009, r = 0.518). This signifies a large effect size, as it is above Cohen’s benchmark of 0.5. Whilst the control group had the same mean Hyperactivity scores at pre- and post-test (21), the intervention group’s mean score was significantly lower at post-test (22.3) than at pre-test (26.3) (Figure 2)",5551214
1292,5551214,"Childhood Autism Rating Scale, Second Edition (CARS2)",horse riding intervention,control group,Significantly decreased,"Whilst the control group had the same mean CARS2 scores at pre-test and post-test (42.61), the intervention group’s mean score was significantly lower at post-test (40.05) than at pre-test (40.95) (Figure 1).",5551214
1293,3636800,the total quantitative feedback score,completing 6 days of assessment (four sets of questions per day) with a native smartphone application,completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation,No significant difference,No significant difference was observed for the total quantitative feedback score when comparing the two delivery modalities.,3636800
1294,3636800,numbers of entries,completing 6 days of assessment (four sets of questions per day) with a native smartphone application,completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation,Significantly increased,"When controlling for order effect, participants completed significantly greater numbers of entries on the native smartphone application when compared to SMS text-only implementation (Tables 3 and 4).",3636800
1295,3636800,proportion of data points,completing 6 days of assessment (four sets of questions per day) with a native smartphone application,completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation,Significantly increased,"A greater proportion of data points were completed with the native smartphone application in comparison to the SMS text-only implementation (? = -.25, SE=.11, P=.02), which also took significantly less time to complete (? =.78, SE= .09, P&lt;.001).",3636800
1296,3901329,The prostate volumes,"an experimental arm with an extreme hypo-fractionated regimen (7?×?6.1 Gy?=?42.7 Gy given every other weekday, and always including two weekends without RT)"," conventional fractionation (39?×?2.0 Gy?=?78.0 Gy given once a day, five days per week) ",Significantly increased,"The prostate volumes measured on the treatment-planning CT averaged 23% larger than those delineated on the baseline MRI (MRIbaseline). The difference was statistically significant, p?=?0.0001.",3901329
1297,5951568,Overall scores for anxiety,provided with written information about the electrodiagnostic testing,control,Significantly decreased,Overall scores for anxiety in the NCS cohort were found to be significantly lower (p = 0.04) in the intervention group (14.53±2.44mm) than in the non-intervention group (21.28±2.86mm; Fig 2).,5951568
1298,5951568,Overall pain scores,provided with written information about the electrodiagnostic testing,control,No significant difference,Overall pain scores between the intervention (20.91±2.33mm) and non-intervention group (25.30±2.44mm) in the NCS cohort did not differ significantly (p = 0.15).,5951568
1299,5951568,the perceived pain  or anxiety levels,provided with written information about the electrodiagnostic testing,control,No significant difference,No significant differences in the perceived pain (p = 0.34) or anxiety (p = 0.65) levels were demonstrated for the intervention and non-intervention groups in the subgroup of patients that underwent needle EMG testing.,5951568
1300,5951568,levels of pain,provided with written information about the electrodiagnostic testing,control,Significantly decreased,Those who received information had significantly lower levels of pain (13.75±2.71mm) compared to those that did not (54.63±13.37mm) (Figs 4 and 5).,5951568
1301,3924124,CD4/8,"2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks",received only general health guidance.,Significantly increased,"Significant (P &lt; 0.05) interaction was observed for the secondary outcome measure CD4/8, which was used to represent participants' immunological function. Related to this result, significant (P &lt; 0.05) interaction was found between groups for CD4+ and CD8+.",3924124
1302,3924124,Rates of intervention attendance for the high and low attendance groups,"2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks",received only general health guidance.,Significantly increased,"Rates of intervention attendance for the high and low attendance groups were 57.0 ± 22.3% and 8.3 ± 9.4%, respectively, and were significantly different (P &lt; 0.001). Participants who performed their individualized programs attended the classroom more frequently.",3924124
1303,5451423,"Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf",empagliflozin after administration to German subjects,empagliflozin after administration to Egyptian volunteers,No significant difference,"*Studied groups from pharmacokinetic studies conducted in white German subjects using 25?mg EG13, 15, 20, 38 showed no significant difference at P?&gt;?0.05, with P?=?0.283 for Cmax and P?=?0.064 for AUC0-inf.",5451423
1304,5451423,"Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf",empagliflozin after administration to Japanese and Chinese subjects,empagliflozin after administration to Egyptian volunteers,No significant difference,"*Studied groups from pharmacokinetic studies conducted in Japanese11 and Chinese9 subjects using 25?mg empagliflozin showed no significant difference at P?&gt;?0.05, with P?=?0.651 for Cmax and P?=?0.891 for AUC0-inf.",5451423
1305,3596913,progression-free survival and overall survival,"receive FU 500 mg/m2 IV bolus weekly ×6 weeks plus leucovorin 500?mg/m2 IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85?mg/m2 IV on weeks 1, 3, and 5 of each 8-week (FLOX) ","receive weekly intravenous infusions of oxaliplatin 40?mg/m2, 5-FU 500 mg/m2, and leucovorin 250?mg/m2 (3 weeks on, 1 week off)",No significant difference,"There was no statistical significance in progression-free survival between the 2 regimens (P value by log rank test = .4619), and so was the situation in overall survival (P-value by log rank test = .5248).",3596913
1306,5789132,The mean pain score using FRS scale,receive the injection with diabetic needle, receive the injection with conventional syringe,Significantly decreased,"The mean pain score using FRS scale for 26 gauge conventional syringe was found to be 3.25, whereas mean pain score for 30 gauge insulin syringe was found to be 1.35 (Table 1). The mean difference found was statistically significant (p = 0.05).",5789132
1307,5789132,The mean SEM score,receive the injection with diabetic needle, receive the injection with conventional syringe,Significantly decreased,he mean SEM score in patients receiving LA with conventional syringe was found to be 2.47 and for patients receiving LA with insulin syringe was 1.48. The mean difference was statistically significant.,5789132
1308,5789132,The mean pain score and mean SEM scores in female patients,receive the injection with diabetic needle, receive the injection with conventional syringe,Significantly decreased,The mean pain score in female patients using conventional syringe was 3.40 and score using insulin syringe was 1.40 (Table 3). The difference was statistically significant. The mean SEM scores in female patients receiving LA with conventional and insulin syringe were 2.59 and 1.55 respectively. The difference was statistically significant.,5789132
1309,3258678,Clinical Dementia Rating – Sum of Boxes (CDR-SB),78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID,78-week treatment with placebo,No significant difference,The adjusted model for CDR-SB revealed no significant treatment effect (G × V interaction: P = 0.505).,3258678
1310,3258678,hippocampus volume (HV) change,78-week treatment with tramiprosate 150 mg BID,78-week treatment with placebo,Significantly decreased,"Compared to Placebo, the 100 mg BID group showed no volume change difference (P = 0.782), while a trend toward greater HV decrease was observed in the 150 mg BID group (P = 0.056).",3258678
1311,3258678,adverse effects,78-week treatment with tramiprosate 100 mg ,78-week treatment with placebo,No significant difference,"owever, the incidence of these AEs in the 100 mg BID group was not statistically different from placebo.",3258678
1312,3258678,Alzheimer Disease Assessment Scale – cognitive subscale (ADAS-cog),78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID,78-week treatment with placebo,No significant difference,The ADAS-cog adjusted model revealed a statistical trend for treatment effect in favour of the two tramiprosate groups (G × V interaction: P = 0.098) while post-hoc planned contrasts showed lower changes from Baseline relative to placebo in the 100 mg BID group at Week 26 (P = 0.065) and Week 52 (P = 0.090).,3258678
1313,5873424,total sleep time,paracetamol/buprenorphine,placebo tablets,Significantly increased,"In addition, TST improved significantly for the active treatment group compared with the placebo group (see Table 3).",5873424
1314,5873424,"sleep efficiency (SE), sleep onset latency (SOL), early morning awakening (EMA)",paracetamol/buprenorphine,placebo tablets,Significantly increased,"In the intervention group (paracetamol/buprenorphine), SE (70%?72%), SOL (32?24 min), and EMA (50?40 min) improved compared with the control group (SE, 70%?67%; SOL, 47?60 min; EMA, 31?35 min). Treatment effects were significant (P &lt; .01, P &lt; .05, and P &lt; .05, respectively).",5873424
1315,4124480,total weight lifted,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly increased,Patients who participated in the CBE arm lifted significantly more weight at the end of the exercise program compared with the beginning as shown in Figure 3: 3432 versus 1775 kilograms (P?&lt;?0.001).,4124480
1316,4124480,TDI focal score,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly increased,"TDI focal score, shown in Figure 5, increased by 5.1 in the CBE group versus a decrease of 0.2 in the control group, indicating less breathlessness (P?&lt;?0.001).",4124480
1317,4124480,Mean treadmill endurance times,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly increased,Mean treadmill endurance times for the two groups at baseline and after 12 weeks. Mean changes were a decrease of 59 seconds for the control group compared with an increase of 134 seconds for those completing the community-based exercise program (P?=?0.041).,4124480
1318,4124480,Mean SGRQ scores,12-weeks of progressive endurance and strength training at a local health club,continuation of unsupervised habitual physical activity,Significantly decreased,Mean SGRQ scores for the two groups at baseline and after 12 weeks. Mean changes were a decrease of 0.7 for the control group and a decrease of 4.6 for those completing the community-based exercise program (P?=?0.611). Decreased scores represent improvement in quality of life where a change of 4.0 is considered clinically meaningful.,4124480
1319,5494586,glucose incremental peaks,"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)",50?g OGTT  (A),Significantly decreased,"the repeated measures ANOVA with Greenhouse-Geisser correction resulted significant (p &lt; 0.001) and the Tukey-Kramer post hoc test revealed that B1 (36.2?±?3.8?mg/dL), B2 (19.6?±?2.9?mg/dL), and B3 (27.3?±?4.0?mg/dL) had significantly smaller glucose incremental peaks than A (55.9?±?6.1?mg/dL) with p values associated to such post hoc comparisons that were p = 0.04, p &lt; 0.001, and p = 0.002, respectively.",5494586
1320,5494586, insulin excursions ,"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)",50?g OGTT  (A),Significantly decreased,"All three commercial breakfasts showed somewhat smaller insulin excursions with respect to the one elicited by glucose administration (Figure 2(a), 2(b), and 2(c)). As for the comparison among the insulinemic AUC values (Figure 2(d)), the repeated measures ANOVA was significant (p &lt; 0.001) (without requiring any correction for the sphericity condition) and the Tukey-Kramer post hoc test showed that both B1 and B2 had smaller insulin AUCs than A (p = 0.002 and p = 0.016, resp.).",5494586
1321,5494586,the 2-hour plasma ghrelin,"3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream)",50?g OGTT  (A),No significant difference,"After glucose/breakfast ingestion, the 2-hour plasma ghrelin attained the lowest level in B3 (332.1?±?30.2?pg/mL), but the decrement with respect to A (420.6?±?44.2?pg/mL) did not achieve the statistical significance (Figure 3(c)).",5494586
1322,5494586,P300 latency incremental values,"B3: milk, apple, bread, and hazelnut chocolate cream",50?g OGTT  (A),Significantly decreased,"The repeated measures ANOVA with Greenhouse-Geisser correction was significant (p &lt; 0.01) and the Tukey-Kramer post hoc test showed that the only significant difference among means was the one between breakfast B3 and glucose (?33.6?±?5.9?ms versus 9.7?±?6.6?ms, p &lt; 0.01).",5494586
1323,5236513,lower abdominal pain/discomfort scores at week 8,Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856,placebo,No significant difference,"At W8, lower abdominal pain/discomfort scores were reported in the Active group compared to Placebo but the difference did not achieve statistical significance (Active group: 2.14 ± 1.292 a.u., Placebo group: 2.31 ± 1.355 a.u., P = 0.1052).",5236513
1324,5236513,Bristol Stool Scale (BSS) score,Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856,placebo,Significantly increased,"There was a statistically significant increase in the Bristol Stool Scale (BSS) score between W0 and W8 in the Active group (2.41 ± 0.817 a.u. vs 3.13 ± 1.197 a.u., P &lt; 0.0001, diff[95%CI] = 0.752 [0.391;1.114]) and in the Placebo group (2.24 ± 0.714 a.u. vs 2.58 ± 1.020 a.u., P = 0.0266, diff[95%CI] = 0.402 [0.032;0.771]) (Figure 3).",5236513
1325,5236513,stool consistency,Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856,placebo,Significantly increased,"At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as “normal” compared to Placebo (respectively 3.13 ± 1.197 a.u. vs 2.58 ± 1.020 a.u., P = 0.0003).",5236513
1326,3478519,"total fat, FM%, and percentage of trunk fat",assigned to the high-protein diet who carried the AA genotype of FTO rs1558902,assigned to the high-protein diet without this genotype,Significantly decreased,"When assigned to the high-protein diet, participants who carried the AA genotype had greater loss in total fat, FM%, and percentage of trunk fat than those without this genotype.",3478519
1327,3478519,"total fat, FM%, and percentage of trunk fat",assigned to the dietary fat components who carried the AA genotype of FTO rs1558902,assigned to the dietary fat components without this genotype,No significant difference,We did not find significant genetic effects and interactions on changes in fat distribution in subgroups treated by different dietary fat components (all P &gt; 0.05; Supplementary Table 2 and Supplementary Fig. 2).Similar results were found in the white participants (data not shown).,3478519
1328,4716419,Death and serious infections,enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,Significantly decreased,"The percentage of serious fatal and non-fatal infections was, however, higher in the CYC group (15.63% vs 3.7%, the per cent difference adjusted for baseline proteinuria 13.35 (95% CI 0.3 to 26.4), p=0.04).",4716419
1329,4716419,The early discontinuation rates,enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,Significantly decreased,"Of note, the adjusted rate of discontinuation within 6?months was significantly higher in the CYC group (per cent difference 16.90, 95% CI 1.3 to 32.4, p=0.03; adjusted for baseline proteinuria and eGFR).",4716419
1330,4716419,complete and partial remission rates and times to remission,enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,No significant difference,"At the 12th month, both arms were comparable in terms of complete and partial remission rates (68% CYC and 71% EC-MPS) and times to remission (96?days CYC and 97?days EC-MPS).",4716419
1331,4716419,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment)",enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months, intravenous cyclophosphamide (CYC) 0.5–1?g/m2 monthly,No significant difference,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) were 46.9% and 37% in CYC and EC-MPS (risk difference=9.84; p=0.44).",4716419
1332,3917204,"Probing depth (PD), Gingival recession (GR),  Clinical attachment level (CAL)",received treatment with rotary instruments,received scaling and root planing with hand instruments,No significant difference,"At deep pocket site (initial PD &gt; 6 mm), in the rotary instrument group, PD reduced from 7.2 ± 1.5 to 6.5 ± 1.8 and in the Gracey curette group, it reduced from 6.7 ± 0.9 to 5.4 ± 1.8. But while comparing these two groups, the results were statistically nonsignificant. Similarly, other clinical parameters like GR and CAL gave statistically nonsignificant results [Table 3].",3917204
1333,3917204,Clinical improvement in multi-rooted teeth ,received treatment with rotary instruments,received scaling and root planing with hand instruments,No significant difference,"In the rotary instrument group, 256 multi-rooted teeth and in the Gracey curette group, 302 multi-rooted teeth were treated. Clinical improvement was noticed in both moderately deep pocket sites and deep pocket areas. But comparison of groups showed them to be statistically nonsignificant [Tables 4 and 5].",3917204
1334,5673730,newborns weight,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,When fetal outcomes were evaluated the babies of Group-B were significantly more in weight as compared to Group-A (p=0.01).,5673730
1335,5673730,numbers of babies were delivered after 38 weeks of pregnancy,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021).,5673730
1336,5673730,HbA1C,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,There were two intrauterine deaths and significantly higher HbA1C at term in Group-B. (P=0.03).,5673730
1337,5673730,fasting blood sugar (FBS) at term ,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),No significant difference,FBS at term was non-significant (p=0.079),5673730
1338,5673730,number of cesarean sections due to feto-maternal disproportion,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,here was more number of cesarean sections due to feto-maternal disproportion in Group-B (28% vs.2%).,5673730
1339,5673730,glycemic control before and after the treatment,oral metformin 500 mg TDS (Group-A),insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B),Significantly decreased,Results analyzed for glycemic control before and after the treatment revealed that FBS was statistically less in Group-A (p=0.00) whereas for Group-B the value of FBS and HbA1C was statistically high. (p=0.002 &amp; 0.04 respectively).,5673730
1340,4012222,Global performance status and STS,lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks.,baseline,No significant difference,"Global performance status and STS appeared somewhat better, but these changes did not achieve statistical significance (Fisher’s exact test p =?0.15 comparing categories of PS; mean reduction in STS?=??1.2s, P?=?0.3).",4012222
1341,5320660,peptide YY [PYY],muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),Significantly increased,"At baseline, total PYY concentrations were significantly higher 120 min following the consumption of study muffins in the HAM-RS2 group than control group (P?=?0.043).",5320660
1342,5320660,"glucose, AUC leptin, and postprandial 120-min leptin",muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),Significantly decreased,"However, a significant within-group decrease in both AUC glucose (P?=?0.028) and AUC leptin (P?=?0.022) was observed from baseline to week 6 in the HAM-RS2 group.",5320660
1343,5320660,Mean overall satiety score,muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),No significant difference,Mean overall satiety score did not differ within or between groups (P?=?0.230).,5320660
1344,5320660,The mean score for the question “how full do you feel?”,muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),Significantly increased,The mean score for the question “how full do you feel?” in the HAM-RS2 group increased from baseline to the end of the study and approached significance (P?=?0.058) (data not shown).,5320660
1345,5320660,body composition,muffins enriched with 30 g HAM-RS2,muffins enriched with 0 g HAM-RS2 (control),No significant difference,Consuming muffins with HAM-RS2 did not significantly change body composition.,5320660
1346,5628593,Maximal voluntary isometric contraction,30-Hz whole-body vibration training,50-Hz whole-body vibration training,Significantly increased,"In the 30-Hz group, there was a significant increase in the maximal voluntary isometric contraction (p=0.039)",5628593
1347,5628593,Concentric peak torque of knee extensors,30-Hz whole-body vibration training,50-Hz whole-body vibration training,Significantly increased,"a statistically significant increase has occurred in the concentric peak torque of knee extensors in the 30-Hz (+13.6%; p&lt;0.001) group, while not in the 50-Hz (+2.1%; p=0.605) group. When the groups were compared, there was a significant (p=0.018) difference between the two groups in terms of improvements in the concentric peak torque.",5628593
1348,5628593,Eccentric peak torque of knee extensors,30-Hz whole-body vibration training,50-Hz whole-body vibration training,No significant difference,"In addition, the eccentric peak torque of knee extensors was increased significantly in both groups (p&lt;0.05); however, there was no significant difference between the two groups (p=0.873).",5628593
1349,5628593,Attendance rates,30-Hz whole-body vibration training,50-Hz whole-body vibration training,No significant difference,No significant difference existed between the two groups in the attendance rates (p=0.286).,5628593
1350,5820389,Number of absence days due to sickness at 6 months,Inpatient program,Outpatient program,No significant difference,"The median number of sickness absence days (work days) at 6&nbsp;months after inclusion was 58 (IQR 37â€“92) for the inpatient program and 51 (IQR 32â€“85) for the outpatient program. The difference was not statistically significant (Mannâ€“Whitney U test, pâ€‰=â€‰0.284).",5820389
1351,5820389,Sustainable return to work,Inpatient program,Outpatient program,No significant difference,"In the outpatient program 57% of the participants achieved sustainable return to work (median time 7&nbsp;months), in the inpatient program 49% (log rank, pâ€‰=â€‰0.167). The hazard ratio for sustainable return to work was 0.74 (95% CI 0.48â€“1.32, pâ€‰=â€‰0.165), in favor of the outpatient program.",5820389
1352,5820389,Number of absence days due to sickness at 12 months,Inpatient program,Outpatient program,No significant difference,"For the 12&nbsp;months follow-up, the median number of sickness absence days was 114 (IQR 46â€“172) for the inpatient program and 96 (IQR 35â€“175) for the outpatient program (Fig.&nbsp;2). The difference was not statistically significant (Mannâ€“Whitney U test, pâ€‰=â€‰0.403).",5820389
1353,3179725,Patient adherence,Active chest wall oscillation treatment,Sham chest wall oscillation treatment,No significant difference,Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70).,3179725
1354,3179725,Patient satisfaction,Active chest wall oscillation treatment,Sham chest wall oscillation treatment,No significant difference,"Satisfaction with study treatment was also high, even in the sham HFCWO group (active vs. sham HFCWO: comfortable, 88% vs. 92%, p = 0.67; feel better, 80% vs. 85%, p = 0.73).",3179725
1355,3179725,Dyspnea improvement,Active chest wall oscillation treatment,Sham chest wall oscillation treatment,Significantly increased,"After four treatments, a higher proportion of patients in the active treatment group had a clinically significant improvement in dyspnea (70.8% vs. 42.3%, p = 0.04).",3179725
1356,3179725,"Secondary outcomes including spontaneously expectorated sputum volume, and forced expired volume in 1 second",Active chest wall oscillation treatment,Sham chest wall oscillation treatment,No significant difference,There were no significant differences in other secondary outcomes.,3179725
1357,3403961,ECBI Intensity scale after treatment,Parentâ€“Child Interaction Therapy,Non-Clinical Group,No significant difference,"When the clinical group mothers were compared with the non-clinical group mothers on the ECBI Intensity scale at post treatment, no significant differences were found between the groups.",3403961
1358,3403961,ECBI Problem Scale after treatment,Parentâ€“Child Interaction Therapy,Non-Clinical Group,Significantly increased,"mothers in the clinical group continued to view their childâ€™s behaviour as significantly more problematic (ECBI Problem Scale; t (81)â€‰=â€‰2.21, pâ€‰&lt;â€‰.05) than mothers in the non-clinical comparison group.",3403961
1359,3842830,Daily OFF time,Istradefylline 20 mg or 40 mg,Placebo,Significantly decreased,"The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (âˆ’0.99 hours, Pâ€‰=â€‰.003) and istradefylline 40 mg/day (âˆ’0.96 hours, Pâ€‰=â€‰.003) groups compared with the placebo group (âˆ’0.23 hours).",3842830
1360,3842830,Secondary efficacy variables,Istradefylline 20 mg or 40 mg,Placebo,No significant difference,No differences were observed among the groups for other secondary efficacy variables.,3842830
1361,3842830,Daily OFF time,Istradefylline 20 mg,Istradefylline 40 mg,No significant difference,"The changes from baseline at the end point for daily OFF time for placebo, istradefylline 20 mg/day, and istradefylline 40 mg/day were âˆ’0.23, âˆ’0.99 (Pâ€‰=â€‰.003), and âˆ’0.96 (Pâ€‰=â€‰.003) hours, respectively. The differences from the placebo were significant, but there were no difference between the 2 groups.",3842830
1362,3842830,Daily ON time with problematic dyskinesia,Istradefylline 20 mg,Istradefylline 40 mg,No significant difference,Neither istradefylline 20 mg/day nor istradefylline 40 mg/day increased daily ON time with troublesome dyskinesia.,3842830
1363,4365564,Major neurological complications,CharitÃ© artificial disc,ALIF with BAK cages,No significant difference,"The rate of major neurological complications was similar between the 2 groups (investigational = 4.4%, control = 4.0%)",4365564
1364,4365564,Complications related to approach method,CharitÃ© artificial disc,ALIF with BAK cages,No significant difference,"The rate of approach-related complications in all 304 patients was 9.9% (30/304) and was similar between the 2 groups, with 9.8% (20/205) in the investigational group and 10.1% (10/99) in the control group",4365564
1365,4365564,Rate of superficial wound infection,CharitÃ© artificial disc,ALIF with BAK cages,No significant difference,"The rate of superficial wound infection was 3 times higher in the investigational group (6.3%) compared with the control group (2.0%), but there was no significant difference between the groups (P = .103)",4365564
1366,5311860,Effective use of syndromic alerts after 1 year,Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,No significant difference,"Despite efforts to create standardized protocols and engage public health agencies in the process, no significant differences in the effective use of syndromic alerts were observed beyond year 1.",5311860
1367,5311860,Generated alerts,Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,No significant difference,No difference was observed between study generated alerts and those generated by their systems.,5311860
1368,5311860,Alert response during the first year,Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,Significantly decreased,The effect of the intervention was more pronounced in year 1 with large LPHAs in the intervention group showing fewer responses to the alerts than control LPHAs.,5311860
1369,5311860,"All responses, excluding â€˜watchful waitingâ€™",Standardized aberrant event detection algorithm and response protocol,Pre-existing syndromic surveillance infrastructure and processes,No significant difference,"Using a direct test for statistical interaction, only the outcome of â€œall responses other than â€˜watchful waitingâ€™â€? had no statistical interaction to the year of the study (pâ€‰=â€‰0.86).",5311860
1370,5285426,Urological function scores in females,Robotic surgery,Laparoscopic surgery,No significant difference,"In females, there was no difference between the two groups in any of the components of urological or sexual function.",5285426
1371,5285426,Baseline rectal cancer diagnosis,Robotic surgery,Laparoscopic surgery,Significantly decreased,patients in the robotic group had lower rectal cancers (p&nbsp;=&nbsp;0.032),5285426
1372,5285426,Male sexual function scores,Robotic surgery,Laparoscopic surgery,Significantly increased,Mean scores deteriorated across all component of MSF in the laparoscopic group but none in the robotic group. Statistical comparison of the mean change of MSF scores from baseline revealed favourable outcomes for the robotic group across all four components of MSF as shown in Table 4. Composite MSF score change was also better in the robotic group,5285426
1373,5285426,Sexual function scores in females,Robotic surgery,Laparoscopic surgery,No significant difference,"Overall, there was no statistical difference between the mean change of scores from baseline between the two groups in any of the FSF components or the FSF composite scores.",5285426
1374,3628658,Hospital stay,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1375,3628658,Loss of blood during surgery,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1376,3628658,Incision lenght,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1377,3628658,Surgery time,Lateral decubitus position,Supine position,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.",3628658
1378,3628658,Harris hip values and union time of fractures,Lateral decubitus position,Supine position,No significant difference,"After treatment for 12 weeks, the Harris hip score and average union time of fractures were not statistically different between the two groups.",3628658
1379,4659198,Defecation frequency after 3 days,Phototherapy plus massage,Phototherapy only,Significantly increased,"On the third day, the massage group showed significantly higher defecation frequency (pâ€‰=â€‰0.045)",4659198
1380,4659198,Bilirubin levels after 3 days,Phototherapy plus massage,Phototherapy only,Significantly decreased,"On the third day, the massage group showed significantly higher defecation frequency (pâ€‰=â€‰0.045) and significantly lower bilirubin levels (pâ€‰=â€‰0.03) compared with the control group",4659198
1381,4659198,Total food intake,Phototherapy plus massage,Phototherapy only,No significant difference,"For all participating neonates, food intake increased through hospitalization. In both groups, food intake was significantly higher on the second and third days of hospitalization than on the first day (pâ€‰&lt;â€‰0.001). However, no significant difference was observed between the groups during hospitalization",4659198
1382,4659198,Body weight,Phototherapy plus massage,Phototherapy only,No significant difference,"The body weights of all neonates increased through hospitalization, with the body weight being significantly higher on the third than on the first day of hospitalization (pâ€‰=â€‰0.03). However, there was no significant difference between the groups",4659198
1383,4659198,Baseline medical characteristics,Phototherapy plus massage,Phototherapy only,No significant difference,"Table&nbsp;1 shows the medical characteristics of participating neonates. We observed no significant differences between the two groups in terms of type of feeding, gestational age at birth, body weight at birth, body weight on the date of admission, phototherapy duration, or physical weight loss.",4659198
1384,3464379,Plateletâ€“monocyte conjugation,N-acetylcysteine,Placebo,Significantly decreased,Plateletâ€“monocyte conjugation was significantly inhibited in patients at 2 h after administration of NAC (conjugated monocytes reduced from 53.1â€‰Â±â€‰4.5 to 42.5â€‰Â±â€‰3.9% of monocyte population: pâ€‰=â€‰0.011; Fig.&nbsp;2a); no significant effect was seen in the equivalent results from the placebo arm of the study (pâ€‰&gt;â€‰0.05; Fig.&nbsp;2b).,3464379
1385,3464379,Adverse events,N-acetylcysteine,Placebo,No significant difference,There were no adverse events.,3464379
1386,3464379,Microparticles count,N-acetylcysteine,Placebo,Significantly decreased,"There was a significant increase in microparticle count at 2&nbsp;h in the placebo arm of the study (pâ€‰=â€‰0.047 by paired Studentâ€™s t test) but a trend towards a reduction (pâ€‰=â€‰0.09) in the NAC arm (nâ€‰=â€‰14). Over a 7 day dosing period (c), there was a significant inhibition of microparticle count between NAC and placebo (black bars, NAC; white bars, placebo: pâ€‰=â€‰0.016 for NAC vs placebo; nâ€‰=â€‰13 by repeated measures two-way ANOVA)",3464379
1387,3464379,Plasma PAI-1,N-acetylcysteine,Placebo,No significant difference,There was no significant effect of NAC or placebo on plasma PAI-1 antigen or activity at either 2&nbsp;h after the first dose or after 7&nbsp;days of oral dosing (pâ€‰&gt;â€‰0.05).,3464379
1388,3464379,Intraplatelet tGSH,N-acetylcysteine,Placebo,No significant difference,Intraplatelet tGSH was not significantly altered in either the NAC or placebo arms of the study at +2&nbsp;h,3464379
1389, 4599543 ,clotting time,received fibrinogen concentrate,received saline solution (placebo),Significantly decreased,"After dosing, there was a significant (P=0.001) shortening of clotting time at the EXTEM in the treatment arm and no changes in the control arm.", 4599543 
1390, 4599543 ,clot firmness,received fibrinogen concentrate,received saline solution (placebo),Significantly increased,"Patients in the treatment arm demonstrated a significant increase in clot firmness both at EXTEM and FIBTEM, whereas patients in the control arm did not.", 4599543 
1391, 4599543 ,levels of fibrinogen,received fibrinogen concentrate,received saline solution (placebo),Significantly increased,"At the arrival in the ICU, patients in the treatment arm had significantly higher levels of fibrinogen, as measured by the central laboratory.", 4599543 
1392, 4599543 ,free from any allogeneic blood product transfusions,received fibrinogen concentrate,received saline solution (placebo),Significantly increased,"During hospital stay, 39 (67.2%) patients in the treatment arm were free from any allogeneic blood product transfusions, a significantly (P=0.012) higher rate than those in the control arm (44.8%).", 4599543 
1393, 4599543 ,postoperative bleeding,received fibrinogen concentrate,received saline solution (placebo),Significantly decreased,"Among the secondary endpoints, postoperative bleeding, as recorded from chest drains during the first 12 postoperative hours, was significantly lower in the treatment arm, and the total amount of PRCs, FFP, and PLT used during hospital stay was significantly lower.", 4599543 
1394, 5724392 ,transcranial Doppler (TCD) flow velocities,hydroxyurea,transfusions,No significant difference,"The final model-based TCD velocities (mean Â± standard error) on the Standard Arm versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã— 10âˆ’16 and a post-hoc superiority p=0.023. The planned per-protocol analysis excluding study participants who exited the study early showed almost identical findings, with difference = 5.06 (0.56, 9.57), non-inferiority p=1.05 Ã— 10âˆ’15 and a post-hoc superiority p=0.015. An age-adjusted analysis gave almost identical findings (not shown).", 5724392 
1395, 5724392 ,Iron burden,phlebotomy (Alternative Arm) ,chelation (Standard Arm),Significantly decreased,"Iron burden decreased more in the Alternative Arm, with ferritin difference âˆ’1047 ng/mL (âˆ’1524, âˆ’570), p&lt;0.001 and liver iron difference âˆ’4.3 mg Fe/gm dry weight (âˆ’6.1, âˆ’2.5), p=0.001.", 5724392 
1396, 5228669 ,"intraoperative estimated blood loss, postoperative drainage, total blood loss",receiving a loading dose of 30â€Šmg/kg Tranexamic acid over 15â€Šminutes before skin incision followed by a maintenance infusion of TA (2â€Šmg/kg/h) were continued until skin closure in the TA group.,Equivalent normal saline was administered in the placebo group.,Significantly decreased,"However, intraoperative estimated blood loss (170â€ŠÂ±â€Š153â€ŠmL vs 255â€ŠÂ±â€Š188â€ŠmL, Pâ€Š=â€Š0.016), postoperative drainage (145â€ŠÂ±â€Š84â€ŠmL vs 281â€ŠÂ±â€Š165â€ŠmL, Pâ€Šâ‰¤â€Š0.001), and total blood loss (315â€ŠÂ±â€Š205â€ŠmL vs 536â€ŠÂ±â€Š261â€ŠmL, Pâ€Š&lt;â€Š0.001) were significantly different between the TA and placebo groups (Fig. 2).", 5228669 
1397, 3456942 ,"response rate (RR), disease control rate (DCR), progression-free survival (PFS)",oxaliplatin (FOLFOX) plus bevacizumab ,irinotecan (FOLFIRI) plus bevacizumab ,Significantly increased,"In the first-line setting, 47 patients treated with mFOLFOX6 plus bevacizumab achieved RR of 61.7 %, DCR of 89.4 %, and median PFS of 13.1 months (95 % CI, 8.7â€“17.5 months). Thirty-one patients went on to receive a second-line therapy with FOLFIRI plus bevacizumab and achieved RR of 27.6 %, DCR of 62.1 %, and median PFS of 7.3 months (95 % CI, 5.0â€“9.6 months). Median 2nd PFS was 18.0 months (95 % CI, 13.7â€“22.3 months).", 3456942 
1398, 5766333 ,The percentage of patients who showed restlessness ,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),No significant difference,"The percentage of patients who showed restlessness was lower in the Combination group than in the PF group; however, there was no statistically significant difference between the two groups (6.9â€Š% vs. 24.1â€Š%, P â€Š=â€Š0.144).", 5766333 
1399, 5766333 ,The satisfaction scores,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly increased,"The satisfaction scores of both the endoscopists and the sedation providers were significantly higher in the Combination group than in the PF group (88 [6â€Šâ€“â€Š100] mm vs. 69 [31â€Šâ€“â€Š96] mm, P â€Š=â€Š0.003, and 95 [24â€Šâ€“â€Š100] mm vs. 67 [15â€Šâ€“â€Š93] mm, P â€Š&lt;â€Š0.001, respectively, median [range]).", 5766333 
1400, 5766333 ,incidence of hypoxemia,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),No significant difference,"Although the minimum percutaneous oxygen saturation level was statistically higher in the Combination group than in the PF group (96 [79â€Šâ€“â€Š99]% vs. 95 [68â€Šâ€“â€Š98]%, P â€Š=â€Š0.029, median [range]), there were no significant differences in the incidence of hypoxemia (defined as percutaneous oxygen saturation level â‰¤â€Š94â€Š%) between the two groups (24.1â€Š% vs. 34.5â€Š%, P â€Š=â€Š0.565).", 5766333 
1401, 5766333 ,the minimum pulse rate,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly decreased,"On the other hand, the minimum pulse rate was significantly lower in the Combination group than in the PF group (47 [34â€Šâ€“â€Š61] bpm vs. 59 [36â€Šâ€“â€Š72] bpm, P â€Š&lt;â€Š0.001, median [range]),", 5766333 
1402, 5766333 ,the incidence of bradycardia,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly increased,"and the incidence of bradycardia (defined as pulse rate â‰¤â€Š45â€Šbpm) was significantly higher in the Combination group than in the PF group (37.9â€Š% vs. 10.3â€Š%, P â€Š=â€Š0.029).", 5766333 
1403, 5766333 ,The maintenance dose of PF,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly decreased,"The maintenance dose of PF was less in the Combination group than in the PF group (2 [2â€Šâ€“â€Š4] mg/kg/h vs. 5 [3â€Šâ€“â€Š7] mg/kg/h, P â€Š&lt;â€Š0.001,", 5766333 
1404, 5766333 ,the number of times a rescue PF injection,combination of propofol (PF) and dexmedetomidine (DEX) (Combination group),PF alone (PF group),Significantly decreased,"nd the number of times a rescue PF injection was needed was also fewer in the Combination group than in the PF group (2 [0â€Šâ€“â€Š16] times vs. 6 [3â€Šâ€“â€Š13] times, P â€Š&lt;â€Š0.001, median [range]).", 5766333 
1405, 3106384 ,the heart rate and mean blood pressure 10 seconds after insertion,Proseal laryngeal mask airway (PLMA),endotracheal tube (ETT),Significantly decreased,"However, statistically significant (P&lt;0.05) increase in the heart rate and mean blood pressure in PLMA group was seen only 10 seconds after insertion [Figure 2].", 3106384 
1406, 3106384 ,oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2),Proseal laryngeal mask airway (PLMA),endotracheal tube (ETT),No significant difference,There were no statistically significant differences in oxygen saturation (SpO2) or end-tidal carbon dioxide (EtCO2) between the two groups before or during peritoneal insufflation., 3106384 
1407, 3106384 ,The PAP till 6 minutes after pneumoperitoneum was attained,Proseal laryngeal mask airway (PLMA),endotracheal tube (ETT),Significantly increased,"The PAP in group P showed a statistically significant (P&lt;0.05) increase in value after insertion till 6 minutes after pneumoperitoneum was attained, and thereafter it was insignificant.", 3106384 
1408, 5578640 ,fentanyl dose after 1 month and 3 months,vitamin D 4000 IE/day,untreated (control),Significantly decreased,"The change in fentanyl dose between the groups was analyzed by linear regression with bias corrected and accelerated bootstrap and revealed a statistically significant difference already after 1 month; 46 Î¼g/h (95% CI 24â€“78 Î¼g/h), which increased even further at three months; 91 Î¼g/h (95% CI 56â€“140 Î¼g/h) (Tables 2 and 3, Fig 2A).", 5578640 
1409, 5578640 ,ESAS QoL-score after three months,vitamin D 4000 IE/day,untreated (control),No significant difference,"A small improvement in the ESAS QoL-score (i.e. decrease in ESAS-score) among the vitamin D treated patients was observed after one month, eliminating the difference between the two groups; -1.4 (95% CI -2.6-(-0.21) (Tables 2 and 3, Fig 2B). After three months no further significant changes in either group were seen.", 5578640 
1410, 5578640 ,infections after 3 months,vitamin D 4000 IE/day,untreated (control),Significantly decreased,"After 3 months of vitamin D supplementation a statistically significant mean difference between the groups with regards to infections could be observed, with lower values in the vitamin D treated group; -26% (95% CI -41%â€“(-12%)) (Tables 2 and 3, Fig 2C).", 5578640 
1411, 5578640 ,25-OHD,vitamin D 4000 IE/day,untreated (control),Significantly increased,Follow-up monitoring of 25-OHD was performed after 3 months in 23 patients and showed a mean value of 73 nmol/L (SD 31) which was a significant increase from baseline as shown in Fig 3 (p&lt;0.0001)., 5578640 
1412, 5578640 ,The ESAS QoL-score after 1 month,vitamin D 4000 IE/day,untreated (control),Significantly increased,The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21)., 5578640 
1413, 4092608 ,patients reached the target INR in the first hour after ending cardiopulmonary bypass (CPB),prothrombin complex concentrates (PCC),fresh frozen plasma,Significantly increased,"More patients in this group reached the target INR in the first hour after ending CPB (T7, P &lt; 0.007).", 4092608 
1414, 4092608 ,received an additional dose of PPSB,prothrombin complex concentrates (PCC),fresh frozen plasma,Significantly decreased,In the FFP group 16/20 (80%) patients received an additional dose of PPSB vs 6/20 (30%) in the PCC group., 4092608 
1415, 4092608 ,factor II and factor X,prothrombin complex concentrates (PCC),fresh frozen plasma,Significantly increased,We found a significant difference between groups in factor II (P = 0.023) and factor X (P = 0.008) levels over time., 4092608 
1416, 5456350 ,wanted to receive a DEKA Arm,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,Significantly increased,"At end of Part A, 22 (69%) of the 32 participants who completed in-laboratory training wanted to receive a DEKA Arm and 5 (16%) might want one. At end of Part B, 14 (88%) of 16 prosthesis users who completed the home trial preferred the overall function of the DEKA Arm, 13 (81%) preferred DEKA hand function and 14 (88%) preferred DEKA wrist function to their own prosthesis.", 5456350 
1417, 5456350 ,scores of the DEKA Usability subscales,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,No significant difference,There were no statistically significant differences in scores of the DEKA Usability subscales for participants who completed Parts A and B and those who completed only Part A (Table 5)., 5456350 
1418, 5456350 ,The Overall subscale,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,Significantly increased,The Overall subscale was rated significantly (p = 0.0165) higher by completers of Part B (mn 5.8) than non-completers (mn 5.0)., 5456350 
1419, 5456350 ,rated the DEKA function and the external battery life,completers of in-laboratory (Part A) and home trial (Part B),completers of in-laboratory (Part A) only,Significantly increased,"Participants who completed Part B rated the DEKA function and the external battery life (mn 5.8, 5.8, 5.5) higher than those who did not complete Part B (mn 5.0; 4.7; 4.5, respectively).", 5456350 
1420, 2361654 ,colposcopy referrals (sensitivity?),primary hrHPV screening,cytological screening,Significantly increased,"Compared with the conventional arm, clearly more colposcopy referrals were made in the hrHPV screening arm (RR 1.51, CI 95% 1.03â€“2.22). As a result of performed colposcopies, a total of 52 histologically confirmed precancerous lesions were detected within the study population: 33 in the hrHPV screening arm and 19 in the conventional arm.", 2361654 
1421, 2361654 ,Specificity,primary hrHPV screening,cytological screening,Significantly decreased,"Specificity of the primary screening with sole hrHPV test (91.5â€“92.1%) was much lower than that with the cytology triage (98.7â€“99.3%), which was not quite as specific as screening with conventional cytology (99.2â€“99.6%).", 2361654 
1422, 3814588 ,"cognitive, habitual behavioral, affective",problem based learning intervention or critical reading intervention,"no intervention (control group, which continued clinical practice as normal)",No significant difference,"In all three dimensions there were significant differences within the groups in the pre- versus post-intervention scores, yet no significant differences were observed between groups. No interaction between pre- and post-intervention differences was detected in any of the groups for any dimension (Table 4). A post-hoc power analysis revealed that the sample size was insufficient to detect statistical differences in each of the groups for the effect size given by the mean scores between each group after the interventions.", 3814588 
1423, 5330006 ,Values of total antioxidant capacity (TAC),receiving 1200 mg of cranberry extract for 6 weeks,placebo group,Significantly increased,"At trial II, cranberry-supplemented athletes presented with significantly higher resting, post-exercise and post-recovery levels of TAC than the controls.", 5330006 
1424, 5330006 ,interleukin 6 levels during exercise tests,receiving 1200 mg of cranberry extract for 6 weeks,placebo group,No significant difference,"Supplementation with cranberry extract did not exert a significant effect on IL-6 concentration (main effect, pâ€‰=â€‰0.051).Fig. 2", 5330006 
1425, 5330006 ,tumor necrosis factor alpha levels during exercise tests,receiving 1200 mg of cranberry extract for 6 weeks,placebo group,No significant difference,"Based on the results of ANOVA, cranberry supplementation did not exert a statistically significant effect on TNF-alpha levels (main effect, pâ€‰=â€‰0.118).", 5330006 
1426, 5330006 ,serum iron,receiving 1200 mg of cranberry extract for 6 weeks,placebo group,No significant difference,"Supplementation with cranberry extract did not exert a significant effect on serum iron (main effect, pâ€‰=â€‰0.516).", 5330006 
1427, 5553001 ,had seen a social worker at preassessment,"Internet-based guided self-help program, including weekly support from a therapist via encrypted email",wait-list control condition,Significantly decreased,Significantly more parents in the intervention group had seen a social worker at preassessment., 5553001 
1428, 5553001 ,PTSD-Checklist-Civilian version (PCL-C) difference ,"Internet-based guided self-help program, including weekly support from a therapist via encrypted email",wait-list control condition,Significantly increased,". The model difference at postassessment was 9.16 points on the PCL-C in favor of the intervention group, representing a large effects size. At follow-up, the model difference was 8.07 points on the PCL-C in favor of the intervention group, representing a medium to large effect size.", 5553001 
1429, 5553001 ,the Beck Depression Inventory-II (BDI-II) difference ,"Internet-based guided self-help program, including weekly support from a therapist via encrypted email",wait-list control condition,Significantly increased,"The model difference at postassessment was 3.91 points on the BDI-II in favor of the intervention group, representing a medium effect size. The model difference at follow-up was 9.41 points on the BDI-II, representing a large effect size. For BAI, a linear model provided best fit to the data (see Multimedia Appendix 3). At preassessment, the intervention group reported a significantly higher level of symptoms; the model difference was 5.11 points on the BAI. The intervention group exhibited a significant decline over time, whereas the control group exhibited a significant increase in symptoms over time. At postassessment, there was no difference between the groups. However, at follow-up there was a difference of 6.99 points on the BAI in favor of the intervention group, representing a large effect size", 5553001 
1430, 5566825 ,total duration of illnesses,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,Significantly decreased,"Evaluation of total duration of illnesses related to infection and allergy showed that of the total duration of 3983 days of illness, there were 1369 (34.37%) illness days in CP group whereas it was 2614 (65.62%) days in the control group. This difference was observed statistically significant (P &lt; 0.01) and the proportionate difference was about 2 times (1.91) [Figure 3].", 5566825 
1431, 5566825 ,episodes of infection/allergy related to immunity,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,No significant difference,"A total of 540 participants had episodes of infection/allergy related to immunity. Of these, 254 participants (47.03%) participants were in CP group while 286 (52.96%) were in the control group. The difference observed was statistically not significant (P &gt; 0.05).", 5566825 
1432, 5566825 ,absent due to infection/allergy/immunity related illnesses,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,Significantly decreased,"There were a total of 281 participants who were absent due to infection/allergy/immunity related illnesses. Of these, 93 participants (33.09%) were in CP group while 188 (66.90%) were in the control group. This difference was found to be statistically significant (P &lt; 0.001) [Figure 5].", 5566825 
1433, 5566825 ,"energy, physical fitness, strength and stamina",receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,No significant difference,"Though no significant difference was observed between the groups at 3 and 6 months follow up, CP group showed a better improvement in energy levels, physical fitness, strength and stamina as compared to control group [Table 4].", 5566825 
1434, 5566825 ,CGI-I scale improvement,receive orally daily either CyavanaprÄ?Å›a (CP) (approx. 6 g) followed by a cup of milk (100 â€“ 200 ml),cup of milk only twice a day while continuing with their normal/routine diet.,Significantly increased,Assessment of participants on CGI-I scale showed that a higher percentage of participants (66.12%) showed improvement on this scale in CP Group as compared to control group (51.43%) [Table 7]., 5566825 
1435, 5336430 ,The percentage of patients with complete clinical clearance (CCC) 8 weeks after the end of treatment (primary endpoint),5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"The percentage of patients with CCC 8 weeks after the end of treatment (primary endpoint) was significantly higher in the 5-FU 0.5%/salicylic acid 10% arm compared with vehicle in both the ITT and per protocol (PP) populations [ITT LOCF: 49.5% vs. 18.2%; OR 3.9 (95% CI 1.7, 8.7) P = 0.0006 (Fig. 3a); PP LOCF: 55.1% vs. 19.6%; OR 5.1 (95% CI 2.1, 12.2) P = 0.0002].", 5336430 
1436, 5336430 ,differences between 5-FU 0.5%/salicylic acid 10% and vehicle during treatment,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,No significant difference,"During treatment, there were no significant differences between 5-FU 0.5%/salicylic acid 10% and vehicle (Fig. 3b); however, it should be noted that it can be difficult to assess lesion counts during treatment because of irritation at the site of administration.Fig. 3", 5336430 
1437, 5336430 ,"the proportion of patients who achieved PC of AK lesions eight weeks after the end of treatment,",5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"Eight weeks after the end of treatment, the proportion of patients who achieved PC of AK lesions was significantly greater in the 5-FU 0.5%/salicylic acid 10% arm than in the vehicle arm [69.5% vs. 34.6%; OR 4.9 (95% CI 2.3, 10.5) P &lt; 0.0001 (Fig. 4)].", 5336430 
1438, 5336430 ,The proportional reduction from baseline in the total number of AK lesions per patient ,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"The proportional reduction from baseline in the total number of AK lesions per patient was significantly greater with 5-FU 0.5%/salicylic acid 10% than with vehicle: 78.0% versus 46.9%, respectively; P &lt; 0.0001 (Fig. 5).", 5336430 
1439, 5336430 ,"overall treatment satisfaction and effectiveness domain mean scores at 8 weeks after the end of treatment,",5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"At 8 weeks after the end of treatment, 5-FU 0.5%/salicylic acid 10% was associated with significant improvements in overall treatment satisfaction and effectiveness domain mean scores in the TSQM compared with vehicle [69.2 vs. 56.1 (P = 0.0019); 70.8 vs. 59.2 (P = 0.0064), respectively].", 5336430 
1440, 5336430 ,the TSQM convenience and side effect domain scores,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,No significant difference,"No statistically significant differences were observed between the study arms for the TSQM convenience (70.7 and 71.2, respectively) and side effect (92.4 and 96.4, respectively) domain scores.", 5336430 
1441, 5336430 ,DLQI total score 8 weeks after the end of treatment,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"the improvement in DLQI total score switched in favor of 5-FU 0.5%/salicylic acid 10% 8 weeks after the end of treatment, although this was not statistically significant (P = 0.0725; Table 2; Supplementary Fig. S1).Table 2", 5336430 
1442, 5336430 ,Treatment-emergent adverse events,5-fluorouracil (5-FU) 0.5%/salicylic acid 10%,vehicle,Significantly increased,"Treatment-emergent adverse events, predominantly related to application- and administration-site reactions, were more common with 5-FU 0.5%/salicylic acid 10% than with vehicle (99.1% vs. 83.6%).", 5336430 
1443, 5610684 ,cortisol concentration from 20 to 45 min post-stressor onset,use their own Facebook profile,quietly read,Significantly increased,"However, compared to the Facebook use condition (Mdifference = â€“0.35, SD = 0.37), control participants (Mdifference = â€“0.51, SD = 0.38) showed a significantly greater decrease in cortisol concentration from 20 to 45 min post-stressor onset when controlling for gender and Facebook Intensity score2, F(1, 84) = 5.03, p = 0.03, 95% CI [0.21, 0.33], Î·2 = 0.06 (see Figures 2Aâ€“D).", 5610684 
1444, 5610684 ,"tension, anxiety, well-being",use their own Facebook profile,quietly read,No significant difference,"There were no significant condition differences for tension F(1, 91) = 1.56, p = 0.21, 95% CI [â€“0.29, 1.25], Î·2 = 0.02; anxiety F(1, 88) = 0.004, p = 0.95, 95% CI [â€“1.01, 0.95], Î·2 = 0.00; or well-being F(1, 91) = 0.33, p = 0.57, 95% CI [â€“0.49, 0.90], Î·2 = 0.004.", 5610684 
1445, 5610684 ,Subjective stress markers,use their own Facebook profile,quietly read,No significant difference,Subjective stress markers and cortisol for Facebook and Control conditions. Facebook and Control conditions showed no significant differences at any time point (p &lt; 0.05)., 5610684 
1446, 4859395 ,external elastic membrane (EEM) area and lumen area,nebivolol,atenolol,Significantly decreased,"On VHâ€?IVUS, nebivolol segments demonstrated significantly decreased EEM area (P=0.02) and lumen area (P=0.004) but similar changes in plaque components and number of TCFAs per vessel compared with atenolol (Table 2).", 4859395 
1447, 4859395 ,plaque components and number of TCFAs per vessel,nebivolol,atenolol,No significant difference,"On VHâ€?IVUS, nebivolol segments demonstrated significantly decreased EEM area (P=0.02) and lumen area (P=0.004) but similar changes in plaque components and number of TCFAs per vessel compared with atenolol (Table 2).", 4859395 
1448, 4859395 ,plaque area,nebivolol,atenolol,No significant difference,"Nebivolol also showed increased plaque area at followâ€?up (P&lt;0.001), whereas atenolol demonstrated plaque regression (P=0.047); however, the difference between the 2 arms was not significant (P=0.27).", 4859395 
1449, 4859395 ,constrictive remodeling,nebivolol,atenolol,Significantly increased,"With respect to arterial remodeling, static remodeling (remodeling index) was similar between the 2 groups, but serial remodeling was significantly different (P=0.002), with nebivolol segments demonstrating more constrictive remodeling (73% versus 46%)", 4859395 
1450, 4859395 ,excessive expansive remodeling,nebivolol,atenolol,Significantly decreased,"With respect to arterial remodeling, static remodeling (remodeling index) was similar between the 2 groups, but serial remodeling was significantly different (P=0.002), with nebivolol segments demonstrating more constrictive remodeling (73% versus 46%) and less excessive expansive remodeling (16% versus 39%) than atenolol (Figure 6).", 4859395 
1451, 4859395 ,Among lowâ€? wall shear stress (WSS) segments  Î”EEM area ,nebivolol,atenolol,Significantly decreased,"Among lowâ€?WSS segments (Table 4), those treated with nebivolol demonstrated decreased Î”EEM area compared with atenolol (P=0.02), consistent with a higher percentage of constrictive serial remodeling (83% versus 63%).", 4859395 
1452, 3406743 ,engaging in moderate physical activity,"enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance.",baseline,Significantly increased,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.", 3406743 
1453, 3406743 ,engaging in moderate physical activity,usual care (UCG),baseline,No significant difference,"The UCG did not change between baseline and follow-up; 75% of women in this group reported moderate physical activity at baseline, and 77% at follow-up.", 3406743 
1454, 3406743 ,engaging in vigorous physical activity,enhanced intervention (EIG),baseline,Significantly increased,"he EIG was approximately 3 times as likely to report engaging in vigorous physical activity at follow-up as at baseline; 13% of these women reported moderate activity at baseline, and 33% at follow-up.", 3406743 
1455, 3406743 ,engaging in vigorous physical activity,usual care (UCG),baseline,No significant difference,"Women in the UC group showed no change (16%, baseline vs 17%, follow-up).", 3406743 
1456, 3406743 ,readiness to engage in vigorous physical activity,enhanced intervention (EIG),baseline,Significantly increased,"The EIG was twice as likely to report being in the action/maintenance stage for vigorous physical activity at follow-up than at baseline; 47% of women in this group reported readiness to engage in vigorous physical activity at baseline, and 67% at follow-up.", 3406743 
1457, 3406743 ,readiness to engage in vigorous physical activity,usual care (UCG),baseline,No significant difference,"The EIG was twice as likely to report being in the action/maintenance stage for vigorous physical activity at follow-up than at baseline; 47% of women in this group reported readiness to engage in vigorous physical activity at baseline, and 67% at follow-up.", 3406743 
1458, 4600230 ,OSAUS scores of the clinical performance test ,simulation-based training followed by clinical training,clinical training only,Significantly increased,"OSAUS scores of the clinical performance test were significantly higher in the intervention than in the control group (mean, 59.1 Â± 9.3% vs 37.6 Â± 11.8%; P &lt; 0.001).", 4600230 
1459, 4600230 ,a pre-established pass/fail level of 50.0% in OSAUS score,simulation-based training followed by clinical training,clinical training only,Significantly increased,"A significantly higher number of participants from the intervention group passed a pre-established pass/fail level of 50.0% in OSAUS score compared with the control group (85.7% vs 8.3%, respectively; P &lt; 0.001).", 4600230 
1460, 4600230 ,"image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making",simulation-based training followed by clinical training,clinical training only,Significantly increased,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P &lt; 0.001), systematic examination (P = 0.001), interpretation of images (P &lt; 0.001), documentation of examination (P &lt; 0.001), and medical decision-making (P = 0.005)", 4600230 
1461, 4600230 ,knowledge of equipment ,simulation-based training followed by clinical training,clinical training only,No significant difference,but no difference was observed for knowledge of equipment (P = 0.095)., 4600230 
1462, 4600230 ,completed scans during the 2 months of clinical training,simulation-based training followed by clinical training,clinical training only,No significant difference,"During the 2 months of clinical training, participants in the intervention and control groups completed an average Â± SD of 58 Â± 41 and 63 Â± 47 scans, respectively (P = 0.67).", 4600230 
1463, 2837815 ,rotations or translations,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,At 2-year follow-up there were no statistically significant differences in rotations or translations between the SmartSet HV group and the Palacos R group., 2837815 
1464, 2837815 ,The mean distal translation,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,The mean distal translation observed was âˆ’0.15 mm for SmartSet HV and âˆ’0.16 mm for Palacos R., 2837815 
1465, 2837815 ,The mean rotation around the longitudinal axis,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,The mean rotation around the longitudinal axis was 0.9Â° for SmartSet HV and 1.2Â° for Palacos R., 2837815 
1466, 2837815 ,The Merle dâ€™Aubigne Postel score,SmartSet HV acrylic bone cements (without antibiotics),Palacos R acrylic bone cements (without antibiotics),No significant difference,The Merle dâ€™Aubigne Postel score was the maximum of 18 points for all patients in both groups., 2837815 
1467, 4367028 ,SBP and DBP,Trendelenburg (TBG) tilt &gt;30Â° ,Trendelenburg (TBG) tilt &lt;30Â°,No significant difference,Head down tilt was associated with a rising trend in SBP and DBP which was higher in TBG &gt;30Â° than TBG &lt;30Â° group however the results were not statistically significant [Table 4]., 4367028 
1468, 4367028 ,pulse rate,Trendelenburg (TBG) tilt &gt;30Â° ,Trendelenburg (TBG) tilt &lt;30Â°,No significant difference,"Interestingly, pulse rate decreased with head down tilt and fall was much higher in TBG &gt;30Â° than TBG &lt;30Â° group but without any statistical significance.", 4367028 
1469, 4367028 ,Bispectral index values,Trendelenburg (TBG) tilt &gt;30Â°,Trendelenburg (TBG) tilt &lt;30Â°,Significantly increased,"Bispectral index values also gradually increased with head down tilt and TBG &gt;30Â° group showed higher BIS value than TBG &lt;30Â° [Table 5 and Figure 1]. Although the BIS values among two groups were statistically significant, the patients from either group didnâ€™t complain of its awareness (probably due to their anesthetic state).", 4367028 
1470, 4367028 ,Nitroglycerine and fentanyl use,Trendelenburg (TBG) tilt &gt;30Â°,Trendelenburg (TBG) tilt &lt;30Â°,Significantly increased,Nitroglycerine and fentanyl use in TBG &gt;30Â° group was higher and statistically significant (P &lt; 0.05) when compared with TBG &lt;30Â° [Table 6]., 4367028 
1471, 4367028 ,PACU stay,Trendelenburg (TBG) tilt &gt;30Â°,Trendelenburg (TBG) tilt &lt;30Â°,Significantly increased,Again PACU stay was longer (P &lt; 0.05) in TBG &gt;30Â° group compared to TBG &lt;30Â° group [Table 6]., 4367028 
1472, 4222592 ,self-reported subjective feelings of satisfaction  for the AUC(0-5h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly increased,"Post-hoc testing revealed that compared to the C test meal, the AA test meal increased satisfaction by 23% (Pâ€‰=â€‰0.05) and decreased the desire to eat by 28% (Pâ€‰=â€‰0.04) for the AUC(0-5h).", 4222592 
1473, 4222592 ,desire to eat  for the AUC(0-5h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly decreased,"Post-hoc testing revealed that compared to the C test meal, the AA test meal increased satisfaction by 23% (Pâ€‰=â€‰0.05) and decreased the desire to eat by 28% (Pâ€‰=â€‰0.04) for the AUC(0-5h).", 4222592 
1474, 4222592 ,self-reported subjective feelings of satisfaction,consumed a standardized breakfast with Avocado Included (AI),consumed a standardized breakfast  [Control (C)avocado-free],No significant difference,"Additionally, the AI test meal showed a tendency towards increasing satisfaction by 22% Pâ€‰=â€‰0.07) as compared to the C test meal for the AUC(0-3h).", 4222592 
1475, 4222592 ,self-reported subjective feelings of satisfaction  for the AUC(0-3h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly increased,"For the AUC(0-3h), the AA test meal increased satisfaction by 26% (P=0.02)", 4222592 
1476, 4222592 ,the AUC(0-3h) for blood insulin,consumed a standardized breakfast with Avocado Included (AI),consumed a standardized breakfast with Avocado Added (AA) or consumed a standardized breakfast  [Control (C)avocado-free],Significantly decreased,"Compared to the AI meal, the AUC(0-3h) for blood insulin was higher in the C and AA meals (P=0.04 and P=0.05, respectively).", 4222592 
1477, 4222592 ,desire to eat for the AUC(0-3h),consumed a standardized breakfast with Avocado Added (AA),consumed a standardized breakfast  [Control (C)avocado-free],Significantly increased,decreased the desire to eat by 40% (P=0.01) as compared to the C test meal., 4222592 
1478, 4673066 ,performance on the diagnostic performance test,schema-based lecture,traditional,Significantly increased,"Schema-based instruction was associated with increased performance on the diagnostic performance test (64â€‰%â€‰Â±â€‰22 vs 44â€‰%â€‰Â±â€‰25, pâ€‰&lt;â€‰0.001).", 4673066 
1479, 4673066 ,intrinsic cognitive load,schema-based lecture,traditional,Significantly decreased,"Participants rated intrinsic cognitive load lower with the schema-based lecture (20 vs 24 points, mean difference =â€‰15â€‰%, standard error 3â€‰%, pâ€‰&lt;â€‰0.001).", 4673066 
1480, 4673066 ,extraneous or germane load,schema-based lecture,traditional,No significant difference,"There was no significant difference in reported extraneous (11 vs. 12 points, mean difference =â€‰3â€‰%, standard error =â€‰3â€‰%, pâ€‰=â€‰0.36) or germane (22 vs 21 points, mean difference =â€‰3â€‰%, standard error =â€‰4.5â€‰%, pâ€‰=â€‰0.42) load.", 4673066 
1481, 4673066 ,evaluation of the lecturers,schema-based lecture,traditional,No significant difference,"Fifty-nine (59â€‰%) participants evaluated the lecturers. Participants rated both lecturers similarly (traditional lecture: 4.98 vs schema-based lecture: 5.25, pâ€‰=â€‰0.114).", 4673066 
1482, 4881089 ,prevalence rates of reported musculoskeletal symptoms, ergonomic intervention,baseline,Significantly decreased,"The McNemar test indicated significant differences between prevalence rates of reported musculoskeletal symptoms in the arm (p = 0.004), upper back (p = 0.001), and lower back (p = 0.0001) regions before and after intervention. The prevalence rates of problems were significantly lower after intervention.", 4881089 
1483, 4881089 ,prevalence rates of reported musculoskeletal symptoms,control (did not receive ergonomic training),baseline,No significant difference,Table 3 shows musculoskeletal symptoms in the control subjects before and after intervention. McNemar test showed no significant difference in the prevalence rates of musculoskeletal symptoms in all regions before and after intervention., 4881089 
1484, 4881089 ,"mean scores in work pace, influence at work, meaning of work, predictability, rewards, role conflicts and social support from supervisor ", ergonomic intervention,baseline,Significantly increased,"he paired t-test showed significant differences in mean scores before and after intervention in: work pace (p = 0.002), influence at work (p = 0.005), meaning of work (p = 0.001), predictability (p = 0.001), rewards (p = 0.001), role conflicts (p = 0.001) and social support from supervisor (p = 0.001).", 4881089 
1485, 4881089 ,any of the scales of the Thai version of the COPSOQ questionnaire,control,baseline,No significant difference,Table 5 also shows that there was no significant difference in any of the scales of the Thai version of the COPSOQ questionnaire before and after intervention in the control group., 4881089 
1486, 5932317 ,week Ã— diameter Ã— application types in terms of LII ,copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ,nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch,No significant difference,No statistically significant three-way interaction was observed between week Ã— diameter Ã— application types in terms of LII (p &gt; 0.05)., 5932317 
1487, 5932317 ,The length of the arch perimeter between the canines and the length of the arch perimeter between the first molars,copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ,nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch,Significantly increased,The length of the arch perimeter between the canines and the length of the arch perimeter between the first molars were significantly higher in the CuNiTi group than in the NiTi group in terms of the main effect (application factor) (p &lt; 0.001)., 5932317 
1488, 5932317 ,The mean values obtained using 0.016-in archwire application,copper-nickel-titanium (CuNiTi) round archwires with increasing diameters applied sequentially to the mandibular arch ,nickel-titanium (NiTi) round archwires with increasing diameters applied sequentially to the mandibular arch,Significantly increased,"The mean values obtained using 0.016-in archwire application were significantly lower in the NiTi group than in the CuNiTi group in the second week (p &lt; 0.05); however, these were significantly higher in the fourth week. In the sixth week, the mean values obtained in the NiTi group were significantly lower than those obtained in the CuNiTi group (p &lt; 0.05).", 5932317 
1489, 5379843 ,calculus formation,use the Abhaibhubejhr or Total toothpastes,use the Cavity Protection toothpaste,Significantly decreased,"The subjects who used the Abhaibhubejhr and Total toothpastes for 12 weeks showed 20.51% and 38.46% less calculus formation, respectively than subjects who used the Cavity Protection toothpaste, which was statistically significant (P &lt; 0.05).", 5379843 
1490, 5379843 ,calculus formation,use the Total toothpastes,use the Abhaibhubejhr ,Significantly decreased,"In addition, subjects using the total toothpaste had 22.58% statistically significant less calculus formation than subjects using the Abhaibhubejhr toothpaste (P &lt; 0.05).", 5379843 
1491, 5021748 ,activated clotting time (ACT),the warfarin or dabigatran  ,the rivaroxaban or apixaban  ,Significantly increased,"The baseline ACTs in the control and dabigatran groups (151 Â± 17 and 156 Â± 15 s, respectively) were significantly longer than those in the rivaroxaban (135 Â± 12 s) and apixaban (132 Â± 17 s) groups (Fig. 2).", 5021748 
1492, 5021748 ,protamine usage for haemostasis,rivaroxaban or apixaban or dabigatran  ,control (warfarin),No significant difference,"No significant differences in protamine usage for haemostasis were found among the control and three NOAC groups (control, 13 Â± 20; dabigatran, 26 Â± 23; rivaroxaban, 25 Â± 25; apixaban, 28 Â± 28 mg).", 5021748 
1493, 5021748 ,heparin dosages required to produce an ACT 15 min after the initial bolus  that was identical to the control (110U/kg),rivaroxaban or apixaban or dabigatran  ,control (warfarin),Significantly increased,"The initial bolus heparin dosages required to produce an ACT 15 min after the initial bolus that was identical to the control (333 Â± 32 s) were 120 U/kg (318 Â± 29 s) and 130 U/kg (339 Â± 43 s) for dabigatran, 130 U/kg (314 Â± 31 s) for rivaroxaban and 130 U/kg (317 Â± 39 s) for apixaban. The NOAC groups required significantly larger doses of total heparin than the warfarin group.", 5021748 
1494, 4274342 ,The mean (SD) increase in endometrial thickness based on TVUS,ospemifene 60 mg/day,placebo,Significantly increased,"The mean (SD) increase in endometrial thickness based on TVUS was 0.51 (1.5) versus 0.06 (1.2) mm at 12 weeks, 0.56 (1.6) versus 0.05 (1.3) mm at 6 months, and 0.81 (1.5) versus 0.07 (1.2) mm at 12 months for participants in the ospemifene and placebo groups, respectively. The differences between participants receiving ospemifene and participants receiving placebo were statistically significant (P â‰¤ 0.001, Welchâ€™s test) at all three evaluations.", 4274342 
1495, 4274342 ,vaginal bleeding,ospemifene 60 mg/day,placebo,No significant difference,"We assessed for a possible association between endometrial thickness and vaginal bleeding, which demonstrated no statistically significant correlation (ospemifene 60 mg/day: Spearman Ï? = 0.0625, P = 0.2527; placebo: Spearman Ï? = 0.3152, P = 0.0847; Table 4).", 4274342 
1496, 4274342 ,endometrial cancer,ospemifene 60 mg/day,placebo,No significant difference,There were no cases of endometrial cancer observed with exposure of up to 52 weeks in the ospemifene clinical trials., 4274342 
1497, 4274342 ,pelvic organ prolapse,ospemifene 60 mg/day,placebo,No significant difference,There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups., 4274342 
1498, 3846239 ,The analgesic requirement,bupivacaine plus dexamethasone ,bupivacaine ,Significantly decreased,"The analgesic requirement was significantly lower in the B+D group compared with the B group (P=0.038), with 12 and 18 patients requiring post-surgical oral/intra muscular analgesics, respectively (Table 3).", 3846239 
1499, 3846239 ,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores",bupivacaine plus dexamethasone ,bupivacaine ,Significantly decreased,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores were significantly lower in the B+D group than in the B group(P&lt;0.0001, P=0.002, P=0.023, P&lt;0.0001 and P=0.011, respectively)", 3846239 
1500, 3846239 ,"At 24 h post surgery, VAS pain scores",bupivacaine plus dexamethasone ,bupivacaine ,No significant difference,but there was no statistically significant difference between the groups in VAS at 24 h after surgery P=0.221 (Table 2)., 3846239 
1501, 2627861 ,maternal blood lead concentrations,"ingest 1,200 mg dietary calcium",ingest placebo,Significantly decreased,"In the intent-to-treat analysis (n = 557), calcium supplementation was associated with an overall average reduction of 11% in maternal blood lead concentrations relative to placebo (p = 0.004) (Table 2).", 2627861 
1502, 2627861 ,maternal blood lead concentrations in the second/third trimester,"ingest 1,200 mg dietary calcium",ingest placebo,Significantly decreased,"This reduction was more evident in the second trimester (âˆ’14%, p &lt; 0.001) than in the third (âˆ’8%, p = 0.107) and was strongest in women who were most compliant (those who consumed â‰¥ 75% calcium pills; âˆ’24%, p &lt; 0.001), had baseline blood lead &gt; 5 Î¼g/dL (âˆ’17%, p &lt; 0.01), or reported use of lead-glazed ceramics and high bone lead (âˆ’31%, p &lt; 0.01).", 2627861 
1503, 5854362 ,anxiety and depressive symptoms , Cognitive Bias Modification for Interpretations (CBM-I) training,placebo training,No significant difference,"Our first and primary hypothesis, that CBM-I would result in reduced anxiety and depressive symptoms compared to Placebo, was not confirmed, as no significant Condition x Time interactions were observed for SCARED and CDI scores.", 5854362 
1504, 5850185 ,pDF strength at A1 and A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),unilateral TENS+TOT,Significantly increased,"he results suggest that for every 10 sessions of training, the Biâ€?TENS group demonstrated an additional 1.32â€?kg increase in pDF strength. Post hoc analyses revealed that the Biâ€?TENS group had greater improvement than the Uniâ€?TENS group in the pDF strength at A1 (mean difference, 2.62; P=0.036) and at A2 (mean difference, 3.23; P=0.034).", 5850185 
1505, 5850185 ,pDF strength at A1 and A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),baseline,Significantly increased,"When compared with baseline, the Biâ€?TENS group showed improvement in the pDF strength at A1 (mean difference, 2.67; P&lt;0.001) and at A2 (mean difference, 4.46; P&lt;0.001).", 5850185 
1506, 5850185 ,TUG completion time at A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),unilateral TENS+TOT,Significantly increased,"Post hoc analyses of the significant interaction effect reveal that the Biâ€?TENS group had greater improvement than the Uniâ€?TENS group in the TUG completion time at A2 (mean difference, âˆ’3.09; P=0.047).", 5850185 
1507, 5850185 ,the TUG completion time at A1 and A2,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),baseline,Significantly increased,"When compared with baseline, the Biâ€?TENS group showed improvement in the TUG completion time at A1 (mean difference, âˆ’2.01; P=0.001) and at A2 (mean difference, âˆ’3.76; P&lt;0.001).", 5850185 
1508, 5850185 ,paretic ankle dorsiflexion strength and the completion time for the Timed Up and Go test,bilareal Transcutaneous electrical nerve stimulation (TENS) and taskâ€?oriented training (TOT),unilateral TENS+TOT,Significantly increased,The subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (Î²=1.32; P=0.032) and in the completion time for the Timed Up and Go test (Î²=âˆ’1.54; P=0.004) than those in the unilateral TENS+TOT group., 5850185 
1509, 4134501 ,Mean pertuzumab Cmin at day 43,pertuzumab 840â€‰mg for cycle 1 and 420â€‰mg q3w for cycles 2â€“6 (Arm A),pertuzumab 840â€‰mg q3w for six cycles (Arm B),Significantly decreased,"the day 43 mean (s.d.) pertuzumab Cmin in Arms A and B was 40.0â€‰Î¼gâ€‰mlâˆ’1 (17.3) and 62.7â€‰Î¼gâ€‰mlâˆ’1 (29.1), respectively, and the geometric mean Cmin in Arms A and B was 36.8â€‰Î¼gâ€‰mlâˆ’1 and 56.4â€‰Î¼gâ€‰mlâˆ’1, respectively.", 4134501 
1510, 4134501 ,The safety profiles,pertuzumab 840â€‰mg for cycle 1 and 420â€‰mg q3w for cycles 2â€“6 (Arm A),pertuzumab 840â€‰mg q3w for six cycles (Arm B),No significant difference,"The total number of grade â©¾3 AEs was 78 in Arm A and 60 in Arm B and the most frequent grade â©¾3 AEs are shown in Table 3. Seventy-three percent and 67% of patients in Arms A and B, respectively, experienced at least one serious AE and the total number of all serious AEs was 35 in Arm A and 19 in Arm B.", 4134501 
1511, 4134501 ,Partial responses,pertuzumab 840â€‰mg for cycle 1 and 420â€‰mg q3w for cycles 2â€“6 (Arm A),pertuzumab 840â€‰mg q3w for six cycles (Arm B),Significantly increased,"At the end of cycle 6, a partial response was observed in 12 (86%) and 6 (55%) patients in Arms A and B, respectively, whereas 2 (14%) and 3 (27%) patients, respectively, had stable disease. Two patients in Arm B had progressive disease.", 4134501 
1512, 2361520 ,Median survival,receive immediate treatment,receive delayed treatment,No significant difference,"Median survival was 13.0 months in patients receiving immediate treatment and 11.0 months in the delayed-treatment group (hazard ratio, 1.08; 95% CI 0.79â€“1.47) (Figure 2). Adjustment for risk factors did not significantly change the hazard ratio (hazard ratio, 1.15; 95% CI 0.77â€“1.72).", 2361520 
1513, 2361520 ,progression-free survival,receive immediate treatment,receive delayed treatment,No significant difference,"There was no statistically significant difference in progression-free survival (time from randomisation until first evidence of progression after chemotherapy, 10.2 vs 10.8 months; hazard ratio, 1.08; 95% CI 0.71â€“1.64; P=0.73).", 2361520 
1514, 2361520 ,overall QoL,receive immediate treatment,receive delayed treatment,No significant difference,There was no statistically significant difference in overall QoL or any component domain between the two treatment strategies at baseline or at any subsequent time point., 2361520 
1515, 2361520 ,time to disease progression or survival,receive immediate treatment,receive delayed treatment,No significant difference,"Multivariate analysis was conducted with the Cox proportional-hazards model. Age, sex, liver metastases, ECOG performance status, baseline QoL scores, weight, disease-free interval &gt;12 months, stage at first presentation, and prior adjuvant chemotherapy did not statistically significantly influence time to disease progression or survival for immediate vs delayed treatment.", 2361520 
1516, 5593173 ,the creative foraging game (CFG) and the alternate uses test (AUT) scores,smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,Significantly increased,"Participants in the placebo group showed significantly higher originality than the control group, both in the CFG (MW U = 753, p = 0.036; Fig 2, left panel), and in the AUT (MW U = 278, p = 0.048, Fig 2, right panel). Effect size was medium (CFG: Cohenâ€™s D = 0.46; AUT: Cohenâ€™s D = 0.43).", 5593173 
1517, 5593173 ,Fluency and flexibility,smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,No significant difference,"In the CFG, we defined fluency as the number of shapes selected to the gallery during exploitation phases, finding no significant difference between control and placebo (MW U = 970, p = 0.73). In the AUT test, fluency showed a trend for being higher in the placebo group than in the control group (MW U = 286, p = 0.056, Cohenâ€™s D = 0.43) (Fig 3).", 5593173 
1518, 5593173 ,"the extent to which players found categories of shapes that were non-standard, naming it â€œout-of-the-boxnessâ€?, OB",smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,Significantly increased,"We find that the OB of the placebo group was significantly higher than the control with medium-to-large effect size (MW U = 683, p = 0.008; D = 0.6).", 5593173 
1519, 5593173 ,Torrance test (TTCT),smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions ,smelled and rated an odorant,No significant difference,"The placebo group showed higher originality than the control group both in the CFG (p&lt;0.04, effect size = 0.5) and in the AUT (p&lt;0.05, effect size = 0.4), but not in the Torrance test.", 5593173 
1520, 4107254 ,New oral anticoagulants administration,centers admitting â‰¥ 200 patients/year,centers admitting less than 200 patients/year,Significantly decreased,"New oral anticoagulants were more frequently (214/156 vs. 5/20) used in centers admitting less than 200 patients per year, which was statistically significant (p = 0.046).", 4107254 
1521, 4107254 ,interested in joining randomized trials evaluating any of the methods used in VTE prophylaxis,centers admitting â‰¥ 200 patients/year,centers admitting less than 200 patients/year,Significantly increased,"Centers admitting â‰¥ 200 per year were more interested in joining randomized trials evaluating any of the methods used in VTE prophylaxis (70.67 vs. 45; p = 0.039),", 4107254 
1522, 4107254 ,Dextrans administration,centers with stroke unit,centers without stroke unit,Significantly decreased,"Dextrans were less frequently used in centers with a stroke unit (6.6% vs. 13%, p = 0.05).", 4107254 
1523, 4107254 ,willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients,centers with stroke unit,centers without stroke unit,Significantly increased,"The centers with a stroke unit were also more willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients (95/132 vs. 20/38; p = 0.031), b", 4107254 
1524, 4518214 ,overall survival (OS) in patients with  locoregionally advanced nasopharyngeal carcinoma (NPC),chemoradiotherapy ,radiotherapy alone,Significantly increased,"The true study endpoint, 5-year OS, was 62% in the RT group and 72% in the CRT group (Plog-rankâ€‰=â€‰0.038; Fig. 1). The adjusted HR for CRT was 0.66 (95% CI, 0.44â€“0.97; PCoxâ€‰=â€‰0.036). This translates to a 34% relative reduction in deaths after CRT compared to RT.", 4518214 
1525, 4092926 ,goats body weight at slaughter,sunflower cake,soybean meal,No significant difference,The substitution of soybean meal by sunflower cake in the diet of goats did not affect (p&gt;0.05) body weight at slaughter (Table 3)., 4092926 
1526, 4092926 ,"Weights, carcass yields, rib eye area of goats",sunflower cake,soybean meal,No significant difference,Weights and carcass yields as well as rib eye area showed no differences (p&gt;0.05) with the substitution of soybean meal by sunflower cake., 4092926 
1527, 4092926 ,The commercial cuts and yields and goats,sunflower cake,soybean meal,No significant difference,The commercial cuts and yields were not influenced (p&gt;0.05) by the substitution of soybean meal by sunflower cake (Table 5)., 4092926 
